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iABSTRACT
In tropical Africa, fever is commonly associated with malaria. However, there are many other
illnesses presenting with fever. Non-malaria febrile illnesses (NMFIs) may be attributable to
multiple etiologic agents including viral, bacterial and parasitic infections in malaria-
endemic resource-poor countries. NMFIs pose challenges to peripheral health systems such
that  they are clinically under-diagnosed while malaria remains over-diagnosed.
Misdiagnoses of a febrile condition may lead to wrong prescription that delays treatment and
increases expenditure on health-care and also leads to increased morbidity and mortality. In
Sierra Leone, dealing with infections other than malaria remain a serious problem, starting
from diagnosis to providing care. Several factors make it difficult to test and treat for NMFIs.
Fewer febrile people report their fevers to healthcare centers and there are fewer resources
generally which include: fewer laboratories, insufficiently trained  laboratory technicians,
inadequate standardized infrastructure and unsuitable equipment, epileptic power supplies as
well as  poor cold-chain storage conditions for reagents among others.
The primary goal of this Ph.D. study was to investigate the prevalence/incidence of NMFIs
in Bo, Sierra Leone, using a tiered laboratory analyzes method. The specific objectives were
to: investigate the types and etiology of non-malarial febrile illnesses in Bo, Sierra Leone;
determine the prevalence/incidence of non-malarial pathogens causing febrile illnesses, and
investigate the distribution of NMFIs.
The study started with a baseline and syndromic survey of all households in the study
community (n=882 households with 5410 persons). A total cohort of 1403 persons was
recruited and followed for a period of one year. After obtaining informed-consent, bio-
samples were obtained from febrile subjects and used for laboratory analyses involving three
tiers.
The first tier (T1) included the use of rapid, lateral flow assays (RLFAs). T1 tests were:
chikungunya, malaria, typhoid fever, syphilis, HIV, hepatitis A, B and C, dengue fever,
leptospirosis, influenza A and B, RSV and Streptococcus aureus.  Subsequent tests at Tier 2
included  singleplex and multiplex PCR and bacterial culture;  with resequencing pathogen
microarray at Tier 3.
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From the initial survey 882 households with 5410 individuals and 76.6% reported having
malaria in a month prior to the study. About 1402 (25.9%) of persons in participating
households were reported to have had a fever within the past six months. The rate of fever
reported differed by age group and sex, with young children having the highest rate (p<0.001)
and females reporting more fevers than males (p<0.001).
Viral infections detected included; 46% chikungunya (95%CI 43.5-48.7), 24.2 human rhino
virus/enterovirus (95%CI: 17.4-32.6), 19.2% corona virus (95%CI: 13.1-27.1), 9.7% HIV
(95%CI: 8.2-11.4), 8.5% hepatitis B(HbSAg) (95%CI: 7.1-10.1),
8.7%HAV(IgG)(95%CI:7.3-10.3), 8.3% influenza B (95%CI:4.6-14.7 ), 5%
adenovirus(95%CI: 2.1-11.0), 4.7% hepatitis C(95%CI: 3.7-5.9), 2.8% dengue fever
(95%CI: 2.0-3.8), 1.7% parainfluenza virus and 1.7% influenza A(H1N1) (95%CI: 0.5-5.9),
0.8% cytomegalovirus (95%CI: 0.04-5.2) and 0.2 % human coxsackie virus A24 and
A22(95%CI: 0.07-0.6).
Bacterial infections detected included:  16.9% of Escherichia. coli (95%CI: 11.6-23.9);
12.6% of Klebsiella pneumonia (95%CI: 8.2-19.2); 12% of Citrobacter freundii (95%CI:
7.6-18.3); 8.5% of Enterobacter cloacae (95%CI: 4.9-14.2), 7.5% Haemophilus influenzae
(95%CI: 3.7-14.2), 5%Chlamydophila pneumonia (95%CI: 2.9-11.6), 4.7% Burkholderia
pseudomallei (95%CI: 3.7-5.9), 3.3% Moraxella catharrhalis (95%CI: 1.3-8.3), 2.8%
Kluyvera spp. and 2.8% Serratia plymuthica /marcescens (95%CI: 1.1-7.0), 2.5%
Mycoplasma pneumonia (95%CI:  0.9-7.1), 1.6% Treponema pallidum (95%CI:  1.1-2.5)
and 0.7% Enterobacter intermedium, 0.7 Enterobacter aerogenes and 0.7% Escherichia
hermannii (95%CI: 0.1-3.9) ), 1.1% Yersinia pestis(95%CI 0.7-1.8).
Helminths detected included: 19.3% Ascaris lumbricoides (95% CI: 14.2-25.8); 10.8%
hookworms (95% CI: 7.0-16.3); 6.3% Schistosoma mansoni (95% CI: 3.5-10.8); 1.1% had
Schistosoma haematobium; 1.2% Strongyloides stercoralis (95% CI: 0.3-4.1); and 2.8% had
Trichuris trichiura (95% CI: 1.2-6.5). It is worthy to note that these helminthes are
collectively neglected tropical diseases and also known as diseases of poverty.
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Though malaria remains endemic, the results provide evidence of several other pathogens in
circulation in Bo, Sierra Leone, one of which, Chikungunya, has a higher prevalence (46%)
than malaria (23%). Among the bacteria, Salmonella enterica serotype Typhi is of
importance as the population antibody levels has risen such that three-fifth of the study
population had up to 1:120 titers of both Anti-O and Anti-H antibodies. A new cut-off point
for the Widal test at about 1:160 or above is recommended to prevent over prescription of
antibiotics for cases not related to typhoid. This study demonstrates the need to prioritize
diagnosis and treatment of NMFIs in Sierra Leone.
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1CHAPTER ONE
INTRODUCTION
Fever and febrile illnesses account for a great burden of diseases in resource-poor countries.
This chapter introduces a thesis on the tiered laboratory analyzes for common infections to
characterize febrile morbidity not related to malaria in Sierra Leone. The section defines
fever and febrile illnesses and briefly overviews the burden of malaria and non-malarial
febrile illnesses in sub-Saharan Africa (SSA) in concert with diagnostic challenges within
SSA including over-diagnosis and misdiagnosis. The study country Sierra Leone is described
with administrative features, socio-demographic characteristics, health service utilization and
access to healthcare highlighted. The study objectives, hypothesis and research questions and
a generic method for the study are included. The final section describes the thesis structure.
1.1.0 Characteristics of Fever and Febrile Illnesses in Africa
Fever or pyrexia is usually a consequence of infection 1,2 and is a prominent clinical indicator
of  infectious disease processes in humans.3 It is also an adaptive compensatory defense
mechanism that activates the immune system; resulting in a decrease in pathogen growth rate
and an increase in host survival.4 Fever  which is a regulated increase in body temperature
above normal is distinct from hyperthermia5 that may result from physical exercises. The
increased metabolic heat production during exercise causes hyperthermia and is reversed by
the negative-feedback loop for thermoregulation unlike fever6, marked by a change in
thermal preference and relative independence from ambient temperature.7
Due to  variations in body temperature, no single value can be defined as fever8. However,
febrile temperatures start from 37.5 degrees Celsius or greater without the use of fever-
reducing medications9 and include: rectal temperature above 37.5ºC; single oral temperature
above 37.8ºC or repeated temperature of 37.2 ºC10; armpit temperature above 37.2ºC(for
2newborns), ear temperature above 38ºC11. Accepted values for fever from previous studies
are  summarized in the table below:
Table 1.1: Overview of Fever Temperatures
Definition of Fever Reference
>37.5 ˚C (oral) Watt & Jongsakul, 2003
37.8 ˚C (oral) Polat et al, 201412; Yoke et al 200913
≥38    ˚C (oral) Manock et al. 2009; Murdoch et al., 2004
>38 ˚C (axillary) Blacksell et al. 2007; Nga et al., 2006, Wagenaar et al., 2004
≥38    ˚C (unspecified) Ellis et al. 2006; Kasper et al., 2010
> 38.3 ˚C (oral) Leelarasamee et al. 2004;
> 38.3 ˚C(unspecified) Chrispal et al. 2010,
unspecified Joshi et al. 2008; Suttinont et al. 2006
Adapted from Baily14
Moreover, fever occurs at a cost to the body such that for every degree increase in body
temperature about 11-13% of oxygen is demanded, commensurate with the  increase in
metabolic processes15. Further increase in body temperature may have deleterious effects on
the neuronal system and sometimes results in fatality 5. Typically a variety of exogenous and
endogenous substances with pyrogenic and antipyretic properties initiate, characterize,
regulate and terminate febrile episodes.4,7 Pyrogens induce fever and are exogenous when
formed outside the host. Microbes, their secretions and materials such as lipopolysaccharides
(LPS) are exogenous pyrogens.3 Endogenous pyrogens, formed inside the host, include
cytokines such as interferon gamma, ciliary neurotrophic factor, tumor necrosis factor and
interleukins (IL) (Eg IL-6 and IL-1).4,3,16 IL-1 also promotes leukocytosis, activate
lymphocytes, and stimulates prostaglandin synthesis; and in concert with other cytokines,
reduce serum iron and zinc, heighten the production of acute phase proteins in hepatocytes,
and induces muscle proteolysis among other functions in many different tissue systems to
produce a range of metabolic and hematologic effects including fever, called “acute phase
response”16.
Due to increasing temperature during febrile illnesses, certain disease-causing organisms
3lose their disease-causing capability while enabling host defense mechanisms.17 At febrile
temperatures, IL-1 reduces iron and zinc in serum; iron is needed by bacteria to replicate
using iron-binding “siderophores” that are also temperature-sensitive and suppressed at
elevated temperatures5,18. In the same vein, viral replication is inhibited by destabilizing viral
polymerase promoter complexes that in turn inhibits the syntheses of certain proteins
required for the synthesis of viral particles in Influenza A and Polio5.
1.1.1 Burden of Malaria in Africa
In tropical Africa, fever is commonly associated with malaria that was known variously as
Roman fever,  marsh fever19 and whose name was derived from the Italian ‘Mal=bad,
Aria=air.’20 Malaria is caused by  Five species of the plasmodium parasite: P. falciparum,
P. vivax, P.ovale, P. malariae and P. knowlesi all of which are transmitted by the female
anopheles mosquito, which is the vector of the parasite.
Over 2.4 billion people are at risk of P. falciparum infection, which result in about 300 to
500 million clinical episodes and 1million deaths annually21. While about 2.9 billion persons
are at risk for P. vivax infection with up to 300 million clinical episodes per year21. A vast
proportion of malaria morbidity occurs in sub-Saharan Africa, SSA(Fig 1.1).
4FIG 1.1: MAP SHOWING SSA WITH HEAVIEST MALARIA BURDEN
51.1.2  Non-malaria Febrile Morbidity
The high morbidity of malaria in sub-Saharan Africa tends to eclipse other febrile illnesses
that are also common and co-exist with malaria. These fevers caused by endogenous and
exogenous pyrogens not related to malaria (non-malaria febrile morbidity) are common in
tropical and subtropical countries. They may be attributable to multiple etiologic agents
including viral, bacterial and parasitic infections in countries, which are resource-poor and
endemic for malaria22.
Typically several pathogens contribute to the non-malaria febrile morbidity in SSA. In a
study of the etiology of acute febrile episodes in children in Tanzania, Mahende et al.23
reported 46.8 %( 406/867) prevalence of upper respiratory tract infections, mainly of viral
etiology24; 15% pneumonia; 21.2% gastroenteritis, 8.3% malaria, 17.7% bacterial infections
and 1.2% HIV infection. In a related study, Crump et al.25 reported 1.6%(14/870) of malaria
as the cause of actual fever while  by contrast, bacterial, mycobacterial, and fungal
bloodstream infections accounted for 9.8%, 1.6%, and 2.9% febrile admissions, respectively.
As an addendum, Animut et al26 in Ethiopia, reported 7% pneumonia, 5.8% typhoid, 5.1%
typhus and 2.6% brucellosis as contributors to non-malarial febrile morbidity.
Several other studies in Africa reported a range of viral etiologic agents for non-malaria
febrile morbidity. Ouedraogo et al24 in Burkina Faso, reported  73%(153/203) of acute
respiratory children with at least one virus and detected 175 viruses: human
rhinoviruses(42.1%), enteroviruses(18.2%), respiratory syncytial virus(RSV)(12%),
influenza virus(6.2%) and also bacteria(30%). Other viral illnesses in the disease ecology
include: Crimean-Congo hemorrhagic fever(CCHF)27, O'nyong-nyong virus28 chikungunya
virus across Africa29, Lassa fever in West Africa30, dengue fever31 , viral hepatitiss32, HIV33,
Ebola34,35 and Maburg36 among others.
Further, neglected infections cause a high morbidity in SSA affecting over 200 million
persons within SSA. Prevalence reported include: 29% hookworms37, 25% schistosomiasis37,
25% ascariasis38, 24% trichuriasis38, 6-9% lymphatic filariasis37, 5% onchocerciasis39 and
63% active trachoma37 among others. The NTDs cause a great deal of disability exacerbating
poverty in these regions.
1.1.3 Diagnostic Challenges by Non-Malaria Febrile Illnesses in Resource-Poor
Malaria Endemic Regions.
NMFIs pose challenges40 to peripheral health systems in resource-poor countries, such that
they are clinically under-diagnosed while malaria remains over-diagnosed41,42,43.
Misdiagnoses of a febrile condition may lead to the wrong prescription that delays treatment
and increases expenditure on health-care and also leads to increased morbidity and mortality.
Misdiagnoses of malaria could mean failing clinically to suspect malaria as a cause of febrile
illness; leading to deaths in non-malaria endemic countries. 44, 45,46 In SSA misdiagnoses
occur from over suspicion of malaria for non-malarial febrile cases due to the low specificity
of predictors of malaria 47,48 which also overlap with several other febrile illnesses. 49, 50, 42
A typical example of misdiagnoses, consequent treatments, and their effects was illustrated
by the yellow fever outbreak in Uganda in 2010. The outbreak attributed to Ebola virus in
early  October 2010 was misdiagnosed as amoebic dysentery, alcohol poisoning, and Yersinia
pestis before being accurately diagnosed as yellow fever after three months.51Case fatality
rate was 25% (50/200) by the time of confirmation.51
1.1.4 Home-based and Presumptive Diagnoses of Febrile Illness
Additionally, for most SSA countries including Sierra Leone,  over 70% of febrile cases are
diagnosed at home in proxy of or prior to clinical or laboratory diagnoses.49 There is an
increased tendency for fatality and many people die each year without any clinical
investigation, but the deaths are attributable to infectious diseases.52 For example, Roth et
al53 working on the factors associated with mortality in febrile patients in Kenema, Sierra Leone
reported 53.4%(229/429) of mortality were of unknown causes. Such a trend has been the case for
decades in Africa,54,49 until the recent WHO policy of test-treat-and-track. The policy was a
consequence of substantial evidence that the intensity of malaria transmission in Africa is
declining55,56,57,58,59and rapid malaria parasitemia tests are well distributed in endemic
countries and easy to use.56 In addition, presumptive treatments are associated with an
7increased cost of drugs with potentially more risk from the medicines and a tendency for drug
resistance.49,57
1.1.5 Malaria Over-diagnosis
Notwithstanding, several instances of clinical or laboratory over-diagnoses of malaria have
been reported in the literature. In a study in Tanzania, East Africa, involving 4,474 febrile
patients; 54% were film negative for malaria, only one-third of these were treated with
antibiotics and the fatality rate of non-malarial cases was 12%42.
In North Africa, A-Elgayoum, et al.43 in a retrospective study of 3203 blood smears from 95
peripheral health facilities in Sudan, reported, 75.6% of over-diagnosis. A preceding study
by  Hume et al.49 assessed the household cost of malaria overdiagnosis in rural Mozambique,
South Africa and reported clinical over-diagnoses of 23% in children under 16years and 31%
in adults with malaria. Similar results have been reported in other studies in Africa. In
Malawi,49 23%  fatality of clinically diagnosed cerebral malaria occurred from NMFI; in
Kenya, 39% of co-morbid malaria patients died of non-malarial causes60 and  in another
study, cerebrospinal fluid of 9% of 49 children with cerebral malaria revealed Herpes
Simplex Type 1 infection61.
In Sierra Leone, West Africa(Fig 1.2), a study conducted in Bo,  in 2005, reported 18% over-
diagnoses of malaria.62 Another study in the same area on pediatrics between 2004 to 2006
reported  35% of over-diagnoses of malaria63. Similarly, Evans et al64 in Ghana, reported
40% bacteremic cases, clinically diagnosed as severe malaria, with a case fatality rate of
39%.
8Fig. 1.2 Map of Africa Showing West Africa and Sierra Leone Inset
1.1.6 Problems Associated with Testing and Treating Febrile Illnesses in SSA
Moreover, the proliferation of rapid diagnostic tests for malaria in SSA have made it
accessible to test-and-treat and to exclude NMFI from clinically diagnosed malaria cases65.
However, several factors make it difficult also to test and treat NMFIs. Clinical laboratory
services are among  the most neglected areas in SSA, having inadequately trained staff, fewer
9resources, fewer standardized infrastructure and inadequate equipment66. Reagents, if
available, may not be adequately stored due to epileptic power supplies67. Moreover,
restocking supplies locally is almost impossible for many ice-dependent consumables. The
cost also remains a significant issue to test for NMFIs, caused by several pathogens, requiring
sometimes multiplex molecular diagnostics. Such diagnostics are mostly not affordable even
at a cost recovery price, as patients in these countries mostly leave under 2USD a day in
many SSA countries. Global health care donations to SSA could solve this problem, but more
attention is paid to disease prevention and treatment than to diagnostics52. Differential
diagnoses of febrile illnesses remain eminent, but resource-poverty prevents the consistent
application of this method. Moreover, in many poor countries of the world, febrile illnesses
cause more problems in remote areas with less equipped laboratories and fewer experienced
technicians65. The quality control, sensitivity and specificity of tests under these conditions
are questionable and their use in the treatment still prone to high fatality rates52.
Simpler, cost-effective tests with precision for different etiologic agents of febrile illnesses;
requiring fewer skills for use and usable even in remote settings can salvage the situation.
However, there are also several cheap tests with either very low sensitivity or low specificity
making it had to depend on their results alone during the first time of use. Higher throughput
assays that are expensive for distributed use may be essential for confirming discordant
results of lower class tests or for guiding in assay selection.
1.2.0 SIERRA LEONE COUNTRY PROFILE
This Phd study was carried out in the Republic of Sierra Leone, which is on the West Coast
of Africa bordering on Guinea on its north and Liberia on the south and the Atlantic Ocean
on the West (Fig 1.2).
1.2.1 Administrative, Demographic, Socioeconomic and Health Profile of
Sierra Leone
Sierra Leone is divided into four main administrative regions: Western Area, Eastern
Province, Northern Province, and Southern Province. Western Area is subdivided into two
administrative districts (Western Urban and Western Rural), the South has four subdivisions
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(Bo, Bonthe, Moyamba and Pujehun districts) the East has three (Kenema, Kono and
Kailahun) the North has five(Bombali, Tonkolili, Kambia, Port Loko and Koinadugu
Districts). Each district is further divided into chiefdoms comprised of towns and villages.
Each administrative unit has a unit head that oversees the administration of that unit.
The overall population of the country was 5,997, 000 million inhabitants in 2011, with a
median age of 18 and growth rate of 3.3 % 68. Estimating from the 2011 figures the population
in 2012 was 6,194,901. About 43% of the population are under 15 years of age, 828,114
under-five years of age, 1,661,845 are between 5 and 14 years of age and 4% over 60 years.
A map of the Sierra Leone population is presented in Fig 1.3A. The population density was
86.7 per square kilometers.  Further, urban centers account for 39.2% of the population, and
the rural areas account for 60.8%, (Fig.1.3B). The crude birth rate of about 37.8/1000
population. The total fertility rate is 4.7 children per woman. The overall death rate is
20.6/1000 population, but in infants, the mortality rate is estimated at 103.5/ 1000 live births
whereas the under-fives mortality rate is 202/100069. Maternal mortality is very high at
1600/100,000 live births. Malnutrition in the country ranges from 4 to 9 % (Fig 1.3C). Based
on the  Human Development Report 70Sierra Leone is the 9th  least developed country, with
a human development index (HDI) of 0.359 ; almost one-third the value of the first  country
in the world, Norway, which  has a HDI of 0.955. The GDP in 2011 was 2.973 billion US
Dollars with a 6% annual growth rate 71.
Due partly to resource poverty(Fig 1.3D) exacerbated by the 11 years civil war that took
place in the country from 1991 to 2002, details of the socio-economic profile of Sierra Leone
are gloomy. The country had a crude birth rate of 37.8 per 1000; neonatal  mortality rate of
49 per 1000, infant mortality rate of 119 per 1000  and under-five death rate of  185 per 1000
in 2011; making Sierra Leone one of the worst countries in the world to be a child under-five
years of age 68.
The literacy rate is 42% of adults aged 15 years and above. The gross national income per
capita is 840 international purchasing power parity, USD (PPP.int. $) and 36 per 100 cellular
subscribers. The out of pocket expenditure as a percentage of private expenditure on health
was 91.4% in 2010 and 0.2% private prepaid plans as a percentage of private expenditure on
health. The per capita total expenditure on health in 2010 was 171(PPP int. $) and the per
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capita Government spending on health in 2010 was 26(PPP in $). About 20.8% of the gross
domestic product, (GDP) was expended on health in 2010. The Government spends 15.3%
of the total expenditure on health in the country, and private expenditure on health was
84.7%.
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Fig 1.3: Population, Poverty and Malnutrition Maps of Sierra Leone
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Health Service Utilization in Sierra Leone is useful  for antenatal care. About  75%  get
prenatal care in over four visits per year. At least 61% have births attended by skilled health
personnel, and 80% of 1-year olds get measles immunization, and  there  is 87% smear-
positive TB treatment success72, which was 79% in the year 2000, but TB detection rate is
52%73.
However, there were 0.2 physicians and 1.7 nurses per 10,000 population in 2010 when SSA
regional averages were 2.5 and 9.1 respectively. The Death of children under five is
attributable to malaria(23%), pneumonia(17%), diarrhea( 12%) and other diseases (16%)68.
For the general populace, the causation of death in the country is mainly due to
communicable diseases(85%) while   non-communicable diseases  account for 10%.74 There
is a high risk of high blood pressure, 41.9% for males and 40.5% for females and also a high
likelihood of tobacco use. Under 20% of the population has access to sanitation and a little
over 50% have access to clean water 74.
Access to healthcare is hindered further by long distances people have to cover to visit a
healthcare center within the country. A map of the locations of healthcare centers with a
background of the population density is presented below (Fig. 1.4).
Malaria remains endemic in Sierra Leone. In 2011, Sierra Leone  reported more cases  of
malaria, 638 859 cases, to the WHO than any other country in the World. There were 810
cases of HIV/AIDS per 100,000 population and 1,372 tuberculosis per 100,000 population68.
There are also possibilities of multiple comorbidities with malaria, and little has been
reported about co-morbidities of malaria with non-malarial febrile illnesses. In peripheral
health centers in Sierra Leone, it is hard to determine, other causes of infections if malaria is
not a cause of an infection.
14
Fig 1.4: Health Service Distribution Overlaid on Population Density
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1.3 OVERVIEW OF FEBRILE ILLNESSES IN SIERRA LEONE
Several febrile illnesses have been reported in Sierra Leone, but predominant among them is
malaria. Winkler et al75 reported 74%( 423/591) malaria prevalence in children in Northern
Sierra Leone and a related study76 in the same area also reported  73% prevalence of malaria.
However, Nnedu et al62 reported an 18% over-diagnoses of malaria in southern Sierra Leone
and another study in the same area on pediatrics between 2004 to 2006 reported  35% of
over-diagnoses of malaria63.
Roth and colleagues53 recently reported 53%  undifferentiated febrile illnesses in Kenema,
Eastern Sierra Leone. Schoep et al77 reported between 60-70% lassa-like, undifferentiated
febrile illnesses.
Reported prevalence of  NMFIs include 5.1% pneumonia53, 4.9% Lassa fever53, 41.7%
hookworms76, 8.3% S. mansoni infections76, 1.7% A. lumbricoides76 and 2.2% T. trichiura76,
4.3% Dengue77, 4% Chikungunya77, 2.8% West Nile Virus77, 2.5 % yellow fever77, 2% Rift
valley fever virus77, 8.6% Ebola77 and 3.6% Maburg77. Other diseases implicated in the
febrile ecology in Sierra Leone include Typhoid fever, 78 acute respiratory infections,79
Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis E 80,33,81, HIV82, tuberculosis83, lymphatic
filariasis84,85 onchocerciasis86, schistosomiasis87, Lassa fever88 and yellow fever89.
1.4 THE PRESENT STUDY
1.4.1 Aim of the Study
The primary objective of this Ph.D. study was to investigate the prevalence/incidence of non-
malarial febrile infections in Bo, Sierra Leone, using a tiered laboratory analyzes method.
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1.4.2 Specific Objectives
The specific objectives were to:
Investigate the types and etiology of non-malarial febrile illnesses in Bo, Sierra Leone.
Determine the prevalence/incidence of non-malarial pathogens causing febrile illnesses.
Investigate the distribution of non-malarial febrile illnesses using, a cross-sectional
qualitative survey combined with a spatiotemporal febrile syndromic surveillance system
involving Ushahidi.
1.4.3 Hypothesis
Malaria accounts for less than 50% of the febrile morbidity presented to peripheral health
facilities in Sierra Leone.
1.4.4 Primary Research Questions
What Pathogens are common causes of non-malarial febrile illnesses in Bo?
What is the prevalence/incidence of non-malarial, febrile illnesses in Bo?
Can syndromic surveillance of non-malarial febrile illnesses in Bo be correlated with the
clinical diagnosis?
1.4.5 Plan of the Study
The study was designed for one year, July 2012 to June 2013. A baseline syndromic survey
prefaced the laboratory analyzes and determined the recruitment of subjects. Subjects
recruited were followed for one year. A subsequent data collection and analyzes was also
done in 2014. Subjects were  recruited from the catchment population of Mercy Hospital
described previously.90, in brief, Mercy Hospital is a private hospital on the northern edge of
Bo, Sierra Leone (Fig 1.5 and Fig 1.6).
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Fig 1.5: Map of Sierra Leone with Bo District and Bo Town Insets
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Fig 1.6: Map of Bo Town
In this Ph.D. research, a tiered laboratory analyzes of bio samples for pathogens at different
cadres and costs of analyzes were used, with simpler, cheaper and readily accessible assays
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at the lowest tier and broad-spectrum, decision-quality, throughput assays at the final tier, to
facilitate: (a) a detection of uncommon pathogens, (b) informing about Tier1 and Tier Two
assay selections and (c) discovering new or emerging pathogens.
Biosamples of the subjects  recruited, who reported with fever, were analyzed using lateral
flow immunoassays (malaria, widal, Salmonella typhi IgG/IgM, Chikungunya, IgM),
Dengue (NS1, IgG/IgM), Leptospirosis, HBV(HBsAg),HCV,HAV, Syphilis, HIV 1 /2,
Yersinia pestis, Bhukhoderia pseudomallei, Lassa fever, Ebola Virus Disease. Other tests
carried out were culture and molecular tests at a tier (Tier 2 and 3). The tests done by the
rapid tests were uploaded to a cloud database. Also, syndromes were recorded on the
Ushahidi website created for this study at www.mhrlsl.com/ushahidi.
1.5 Overview of Research Methods
A baseline and syndromic survey were carried out of all households in the study community.
Fig 1.7: Survey Instrumentation
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A cohort of 1403 persons were recruited from the catchment population of Mercy Hospital
and followed for a period of one year. Biosamples were obtained from consented, febrile
subjects and used for laboratory analyses involving three tiers. The first tier included use of
rapid, lateral flow assays RLFAs) for chikungunya, malaria, typhoid fever, syphilis, HIV,
hepatitis A,B and C, dengue fever, leptospirosis, influenza A and B, RSV, Strep A and
TB(using LFIs from SD Bioline). Widal agglutination tests were done with the febrile antigen
kit (to assess the antibody levels of Salmonella enterica typhi.
Fig 1.8: TLA Flow Chart for Blood Samples
Urinalyses and blood chemistry analyses were done using the iStat 300 analyzer for blood
chemistry analyses and the urine dipstick, Multistix® 10SG (Siemens Healthcare Diagnostics
Inc. Tarrytown, NY, USA) for urinalyses. Urinalyses also entailed centrifugation and
microscopic smear with the Bayer Atlas of Urine Sediments (Siemens Healthcare
Diagnostics Inc. Tarrytown, NY, USA). Stool samples were assessed microscopically for
parasites including helminths.
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Fig 1.9: TLA Flow Chart for Urine, Stool and Nasal or Throat Swabs
Subsequent tests included microbial culture using blood, urine or stool samples. Blood
culture was done using the Oxoid SIGNAL (Oxoid Ltd., Basingstoke, United Kingdom)
blood culture system. Urine and stool samples were grown on agar media (Hardy
Diagnostics, Santa Maria, CA) or CHROMagar™ plates (CHROMagar, Paris, Fr.) which are
powder based media with agar, peptone and yeast extracts and chromogenic mix for
differentiation or group identification. The other types of media used were: Brain Heart
Infusion (BHI) Agar, Tryptic Soy Agar (TSA), MacConkey agar, Hektoen enteric (HE) agar,
Salmonella Shigella Agar (SS) (Hardy Diagnostics, Santa Maria, CA). API20E,
CHROMagar plates and PCR were used for identifying colonies from culture media.
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Advanced molecular tests done included: the resequencing pathogen microarray system
RPM-TEI v. 1.0 and RPM Flu v3.1 described previously by Leski et al91,51. Additionally,
the multiplexed PCR in vitro diagnostic system, FilmArray (BioFire Defense, Salt Lake City,
UT, USA)  that is also a lab-in-a-pouch system that performs a mesoscale fluid manipulation
(working volume of 0.001 to 0.2ml ) in a disposal, self-contained, thin-film plastic92 pouch93,
was used with panels(http://filmarray.com/the-panels/)  that detect respiratory pathogens,
blood culture identification panels detecting pathogens associated with sepsis and  biothreat
pathogens
(http://www.biofiredx.com/pdfs/FilmArray/Infosheet,%20FilmArray%20Biothreat-
0039.pdf)  such as Ebola zaire and Yersinia pestis. Culture isolates were identiﬁed genetically
after PCR ampliﬁcation and sequencing of a 16S rDNA amplicon that spanned the V3 and
V4 variable regions and the rpoB or gyrA gene previously described94,95,96. Additionally,
antimicrobial determinant microarray was used.
A local area network was created using a Eugenius Router and a FileMaker server 12 was
established to synchronize patient metadata per visit. A crowd sourcing and crowd mapping
site was created using Ushahidi and Bluehost at ww.mhrlsl.com/GIA/ushahidi for daily
incidence of diseases which were geolocated. A cloud database was set up for Tier 1 tests
using a Deki Readers (Fio Corporation, Canada).
1.6 STRUCTURE OF THESIS
The thesis is comprised of eight chapters.
Chapter 1 is the General Introduction and Aim of the Study. The chapter introduces fever,
febrile illnesses and non-malaria febrile illnesses in resource-poor countries. It describes the
diagnostic problems in resource-poor countries and also describes the study location and
what this PhD study is about.
Chapter 2 is based on the survey that prefaced the laboratory data collection and analyses.
The title is: Common Infections in Sierra Leone: Presumptive Self-diagnosis of malaria and
other febrile illnesses in Sierra Leone.
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Chapter 3 is titled-Common Infections in Sierra Leone: Viral Hepatitis.
Chapter 4 is titled-Common Infections in Sierra Leone: Respiratory Infections.
Chapter 5 is titled-Common Infections in Sierra Leone: Re-emergence of Chikungunya in
Bo, Sierra Leone.
The Chapter is titled-Common Infections in Sierra Leone-HIV Infections.
Chapter 7 is titled-Common Infections in Sierra Leone-Undifferentiated Febrile Illnesses.
Chapter 8 is the General Summary, Conclusion, and Recommendations.
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2.1 ABSTRACT
Background: The objective of this study was to evaluate the prevalence of self-diagnosis of
malaria and other febrile illnesses in Bo, Sierra Leone.
Methods: All households in two neighboring sections of Bo were invited to participate in a
cross-sectional survey.
Results: A total of 882 households (an 85% participation rate) that were home to 5410
individuals participated in the study. Of the 910 individuals reported to have had what the
household considered to be malaria in the past month, only 41% were diagnosed by a
healthcare professional or a laboratory test. Of the 1402 individuals reported to have had any
type of febrile illness within the past six months, only 34% had sought a clinical or laboratory
diagnosis. Self-diagnosis of influenza, yellow fever, typhoid, and pneumonia was also
common.
Conclusion: Self-diagnosis and presumptive treatment with antimalarial drugs and other
antibiotic medications that are readily available without a prescription may compromise
health outcomes for febrile adults and children.
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2.2 BACKGROUND
The overuse or inappropriate use of antimalarial medications and antibiotics is a growing
concern in many parts of the world, including Sierra Leone, a post-conflict country in West
Africa.  In Sierra Leone, these drugs are dispensed by government-run clinics and hospitals,
private healthcare facilities, licensed pharmacies, and through the informal sectors1. Because
medications are readily available without a prescription, people with self-diagnosed
infections can access treatments without first seeking a formal clinical consultation and/or
laboratory-confirmed diagnosis.  A survey conducted in April 2009 in several parts of Sierra
Leone—including the city of Bo, the focus of this paper—found that 50.8% of anti-malarial
drugs were dispensed without a prescription 1.
Easy access to antimalarial drugs and other antibiotic agents may compromise patient health
outcomes.  If the medications purchased for an infection are inappropriate—such as
antibiotics taken for a viral infection or chloroquine taken for a chloroquine-resistant case of
malaria—or if medications are not taken in the appropriate dosage and for an appropriate
length of time, self-diagnosis and treatment may contribute to prolonged illness, more severe
morbidity, and an increased risk of mortality.  A study in Bo district in 2008 found that only
48.3% of malaria-positive patients at a hospital that offered free care completed the full
course of prescribed antimalarial treatment 2.  Given that low rate of adherence to prescribed
treatment regimens, it is likely that few patients who access over-the-counter antibiotics
complete a full course of an appropriate, government-recommended formulation.  The
antimalarial medications available over-the-counter are rarely the formulations
recommended by the national government and the World Health Organization (perhaps a
good sign that national health system drugs are not leaking into the private market), and the
2009 study found a very low level of knowledge about national and international antimalarial
policies and regulations among private-sector sellers of medication, compared to a high level
of knowledge among public-sector providers 1.
Furthermore, misuse of antimicrobial agents can contribute to the emergence of drug
resistance, which is a growing concern in Sierra Leone.  A 2002-2003 study found treatment
failure among more than half of pediatric malaria patients who tested positive by PCR for
malaria and treated with chloroquine3. Treatment failure was assessed by PCR after treatment
46
and was also frequently observed for sulphadoxine-pyrimethamine (SP) 3.  These results suggest
that drug-resistant malaria is already common in the study area.  Evidence of drug-resistant
bacterial infections has also been reported, including outbreaks of multidrug-resistant
Shigella dysenteriae in 1999-2000 4 and drug resistant Staphylococcus aureus among
children during a 2008-2009 study in Freetown 5.  Sierra Leone has one of the highest rates of
multidrug-resistant tuberculosis (MDR-TB) in sub-Saharan Africa 6.
Over-diagnosis of malaria, in particular, may be common.  Even clinicians can find it difficult
to diagnose malaria accurately solely based on symptoms.  A study in the Bo district in 2005
found that 82% of children suspected by clinical officers to have malaria based on physical
symptoms such as fever, splenomegaly, and vomiting tested positive for parasitemia by a
Paracheck-pf ® rapid diagnostic test (RDT) and 18% did not 7. Between 2004 and 2006 in the
same region of Sierra Leone, only 65% of the Paracheck® RDTs performed on pediatric
patients with clinically-suspected malaria were positive, suggesting that antimalarial
medication may have been significantly over-prescribed without the use of confirmatory
laboratory tests 8.  It is important to note that some children in highly-endemic areas test
negative for malaria at the beginning of a febrile illness, such as a case of pneumonia, but
then become malaria-positive later in their course of illness due to their weakened state.
(Additionally, many children test positive for malaria even when they are asymptomatic.)
Parents without clinical training might be more likely than healthcare professionals to
diagnose any febrile illness as malaria and to seek presumptive antimalarial treatment.  While
presumptive treatment may be helpful—and perhaps even lifesaving—when the child
actually does have malaria, a misdiagnosis may result in delayed treatment for the actual
cause of the fever, and the delay in seeking professional medical care may increase morbidity
and mortality 9.
The goal of this paper was to evaluate the prevalence of self-diagnosis of malaria and other
febrile illnesses in Bo, Sierra Leone’s second largest city.
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2.3 METHODS
2.3.1 Sampling Strategy.
All households within the Kulanda Town and Njai Town sections (neighborhoods) of the city
of Bo were eligible for participation.  The research laboratory has previously mapped all of
the buildings within these sections and conducted a household census, in 2010, to identify
which structures were residential ones 10.  The resulting geographic information system (GIS)
was used to create a map of all of the homes within the study community.  In June 2012,
members of the research team visited each household on the map, as well as 11 new
households (which were added to an updated map), to ask for their participation.  Of the 1038
households in these sections, 882 (85.0%) agreed to participate.  For each of these
households, one adult, usually the head of the household, was interviewed to gather
information about the whole household.
2.3.2 Data Collection.
Each interview began with questions about the household’s environmental characteristics,
such as building materials and access to utilities, and about household demographics, such
as the age and sex of each current resident.  Students at boarding school, adults working in
another town and not sleeping at the residence in Bo, and others who spent at least 6 months
of the past year living elsewhere were not considered to be current household members.
Then a series of questions were asked about febrile illnesses experienced by household
members.  These questions were developed in consultation with residents of the Kulanda
Town / Njai Town sections to ensure clarity, and asked about all household members of all
ages.  First, the household representative was asked whether anyone currently living in the
household had been ill with what the household considered to be malaria in the past one
month.  If malaria was reported to have occurred, follow-up questions asked where those
with malaria were diagnosed (such as at a hospital or clinic, at home by a nurse, or at home
by an untrained person—that is, self-diagnosis) and whether they were tested for malaria by
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a laboratory.  A second set of questions asked whether anyone currently living in the
household had a febrile illness earlier in 2012 (that is, in the 6 months prior to the interview).
Follow-up questions asked about the frequency and duration of febrile illnesses; symptoms
associated with these fevers (such as joint tenderness, headaches, altered behavior, and
jaundice); and whether the febrile person was examined by a clinician and/or had a laboratory
test to determine the cause of the fever.  A final set of yes/no questions asked whether the
household considered anyone currently living in the household to have ever had any of more
than a dozen listed communicable and non-communicable conditions, and whether those
diagnoses were made by a doctor or were self-diagnosed.
2.3.3 Data Management and Analysis.
Responses were entered by the interviewers directly into a Filemaker Pro 12 relational
database on a password-protected tablet computer.    Households were identified by a number
linked to a map stored at the research laboratory; these codes were random and not related to
the geographic coordinates of the map.  Data were analyzed using the statistical software
program SPSS (version 20).  Proportions, means, and standard deviations were used to
describe the variables.  Chi-squared tests were used to compare rates in independent
populations, such as different age groups.
2.3.4 Ethical Considerations.
Adults ages 18 and older were interviewed after providing informed consent, which was
documented with a signature or a thumbprint.  The consent form and study materials were
available in both English and Krio, the local language in Sierra Leone.  No compensation or
other incentive was offered.  To protect the confidentiality of information shared with the
research team, no names or addresses were entered into the database. The data entered into
each tablet computer were deleted daily after the data files on the tablets were downloaded
to a password-protected desktop computer in a locked and guarded research facility.  The
research protocol was approved by the Sierra Leone Ethics and Scientific Review Committee
and by Njala University (Sierra Leone), the Liverpool School of Tropical Medicine (UK),
the U.S. Naval Research Laboratory (USA), and George Mason University (USA).
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2.4 RESULTS
The 882 participating households contained 5410 individuals, with a mean household size of
6.1 persons. The households reported a somewhat diverse set of socio-environmental
characteristics. While 1186 (66.7%) of the 1778 beds reported to be located in the
participating homes were said to have bednets, 328 (37.2%) of households reported
having no bednets. In total, 877 (99.4%) of households reported seeing a rat in the house
in the past month, 860 (97.5%) reported seeing cockroaches in the house in the past month,
677 (76.8%) had a tile or concrete rather than dirt floor, 546 (61.9%) had a trash bin in the
home (of which 153 covered the bin), 353 (40.0%) had electricity, and 155 (17.6%) had a
drinking water source within 50 meters of the home.
In total, 675 (76.5%) of the 882 households reported at least one case of malaria (as defined
by the household) in the month prior to the survey, with a total of 910 (16.8%) of the 5410
individuals reported to have had malaria during that time period. However, 540 (59.3%) of
these 910 individuals were presumptively diagnosed by the ill person or a household member,
and only 370 (40.7%) were diagnosed following laboratory testing.
A total of 1402 (25.9%) of the individuals within participating households were reported to
have had any type of febrile illness (whether caused by malaria or another condition) within
the past six months. The rate of fever reported differed by age group and by sex, with
young children (those 0 to 4 years old) having the highest rate (p<0.001) and females
reporting more fevers than males (p<0.001) (Table 2.1). Only 33.9% of people with fever
were reported to have had laboratory tests to determine the cause of the fever. There were
significant differences in the likelihood of testing by age (p=0.011). Households with
indicators of higher socioeconomic status (SES), such as those with electricity in the home
or a drinking water source very near to the home, generally reported slightly lower rates of
febrile illness within the household (Table 2.2). Markers of household SES were not
significantly associated with reported testing rates.
Self-diagnosis of several other conditions was common (Table 2.3). All of the 234
individuals reported to have ever had influenza, as defined by the household, indicated a
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self-diagnosis. More than 96% of the 160 persons reported to have had what the household
considered to be yellow fever (which had been the focus of a recent vaccination campaign
[11]) reported self-diagnosis,  as did more than 60% of the 445 persons reported to have
had typhoid (which is a relatively common laboratory diagnosis in Bo, as per Widal
tests). More than half of the 317 people reported to have had what the household designated
as pneumonia were self-diagnosed. However, diagnosis of less common and more specific
conditions, such as  bacterial meningitis, hepatitis B, and hepatitis C, were nearly always
reported to have been diagnosed by a doctor and not self-diagnosed by the household.
Table 2.1: Prevalence of reported febrile illnesses and testing in the past 6
months, by age and sex
Table 2.1: Prevalence of reported febrile illnesses and testing in the past 6 months, by age and sex
Age
Group Total Females Males
p-value for Chi-
squared test of
difference by sex
(2-tailed)
n
n (%)
reported
to have
had fever
Of those
reported to
have had a
fever, n (%)
who had tests
to determine the
cause of
the fever
n
n (%)
reported
to have
had fever
Of those
reported
to have had
fever,
n (%)
tested
n
n (%)
reported
to have
had fever
Of those
reported
to have
had fever,
n (%)
tested
reported
fever
cases
testing for
cause among
those reported
to have had
fever
0-4 705
368
(52.2%) 136 (37.0%) 348
193
(55.5%)
72 (37.3%)
357
175
(49.0%)
64
(36.6%) 0.088 0.885
5-14 1527 423(27.7%) 128 (30.3%) 835
233
(27.9%)
77 (33.0%) 692 190(27.5%)
51
(26.8%) 0.847 0.169
15-29 1739
293
(16.8%) 99 (33.8%) 973
181
(18.6%)
53 (29.3%)
766
112
(14.6%)
46
(41.1%) 0.027 0.040
30-44 803 136(16.9%) 58 (42.6%) 423
86 (20.3%) 30 (34.9%) 380 50 (13.2%) 28(56.0%) 0.003 0.018
45-59 381
95 (24.9%)
36 (37.9%) 180
56 (31.1%) 19 (33.9%)
201
39 (19.4%) 17
(43.6%) 0.009 0.351
≥60 255 87 (34.1%) 19 (21.8%) 134 52 (38.8%) 12 (23.1%) 121 35 (28.9%) 7 (20.0%) 0.090 0.749
Total 5410
1402
(25.9%) 476 (34.0%) 2893
801
(27.7%)
263 (32.8%)
2517
601
(23.9%)
213
(35.4%) 0.001 0.309
1402 (25.9%) of household members reported fever, of whom 476 (34.0%) were tested to determine the cause of the fever. In total, 801 (27.7%) females and 601
(23.9%) males reported fever, and 263 (32.8%) of females and 213 (35.4%) of males with fever were tested. The rate of fevers reported was different by sex and
by age group, but there were not significant age and sex differences in testing.
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Table 2.2: Household environmental characteristics and reported febrile
illnesses in the household (HH)
Table 2.2: Household environmental characteristics and reported febrile illnesses in the household (HH)
Household
(HH) feature
(among 882
households)
1+ HH member reported to have
had malaria in the past month
Of those HHs with malaria,
1+ person with malaria reported
to have had malaria testing
1+ HH member reported to have
had any febrile illness in the past 6
months
Of those HHs reporting fever,
1+ person with fever reported
to have had a formal diagnosis
among
HHs
with this
feature
among
HHs
without
this
feature
p- value
among
HHs
with this
feature
among
HHs
without
this
feature
p- value
among
HHs
with this
feature
among
HHs
without
this
feature
p- value
among
HHs
with this
feature
among
HHs
without
this
feature
p- value
Fewer than
six
individuals
in the
household
(n=552,
62.8% of
HHs)
417
(75.3%)
258
(78.7%) 0.252
125
(30.0%)
102
(39.5%) 0.011
453
(81.8%)
269
(82.0%) 0.932
129
(28.5%)
172
(63.9%) <0.001
Households
with at least
one bednet
(n=691,
78.3%)
517
(74.8%)
158
(82.7%) 0.020
176
(34.0%)
51
(32.3%) 0.686
584
(84.5%)
138
(72.3%) <0.001
248
(42.5%)
53
(38.4%) 0.387
Having a tile
or concrete
floor rather
than a dirt
floor
(n=677,
76.8%)
508
(75.0%)
167
(81.5%) 0.055
177
(34.8%)
46
(27.5%) 0.081
539
(79.6%)
183
(89.3%) 0.001
217
(40.3%)
84
(45.9%) 0.183
Having a
trash bin in
the home
(n=546,
61.9%)
388
(71.1%)
287
(85.4%) <0.001
138
(35.6%)
85
(29.6%) 0.105
428
(78.4%)
294
(87.5%) 0.001
163
(38.1%)
138
(46.9%) 0.018
Having
electricity
(n=353,
40.0%)
264
(74.8%)
411
(77.7%) 0.320
90
(34.1%)
133
(32.4%) 0.641
271
(76.8%)
451
(85.3%) 0.002
112
(41.3%)
189
(41.9%) 0.880
Using a
drinking
water
source
within 50
meters of
the home
(n=155,
17.6%)
106
(68.4%)
569
(78.3%) 0.010
27
(25.5%)
196
(34.4%) 0.070
124
(80.0%)
598
(82.3%) 0.505
52
(41.9%)
249
(41.6%) 0.949
Malaria and febrile illnesses were significantly more likely to be reported by households without at least one bednet, those with a dirt floor, those without
a trash bin in the home, those without electricity, and those without a drinking water source near the home. Testing of at least one household
member was less likely to be reported by smaller households and those without a trash bin in the home.
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Table 2.3: Reports of family medical history, by source of diagnosis
Table 3.3: Reports of family medical history, by source of diagnosis
Condition
n (%) of households reporting that
someone currently living in
the household has
ever had this condition
Of households reporting this
condition, n (%) reporting that
the condition was
diagnosed by a doctor
Of households reporting this
condition, n (%) reporting that
the condition was
self-diagnosed
Influenza 234 (26.5%) 0 (0%) 234 (100%)
Lassa fever 5 (0.6%) 0 (0.0%) 5 (100%)
Yellow fever 160 (18.1%) 6 (3.8%) 154 (96.3%)
Common cold 774 (87.8%) 180 (23.3%) 594 (76.7%)
Asthma 79 (9.0%) 21 (26.6%) 58 (73.4%)
Typhoid fever 445 (50.5%) 177 (39.8%) 268 (60.2%)
Pneumonia 317 (35.9%) 151 (47.6%) 166 (52.4%)
Bacterial meningitis 10 (1.1%) 8 (80.0%) 2 (20.0%)
Hepatitis B 5 (0.6%) 5 (100%) 0 (0.0%)
Hepatitis C 1 (0.1%) 1 (100%) 0 (0.0%)
Tuberculosis 0 (0.0%) 0 (0.0%) 0 (0.0%)
Rift Valley fever 0 (0.0%) 0 (0.0%) 0 (0.0%)
Dengue fever 0 (0.0%) 0 (0.0%) 0 (0.0%)
Households reported a high rate of self-diagnosis for conditions such as influenza (100% of reported cases self-diagnosed), yellow fever
(96.3%
self-diagnosed), colds (76.7% self-diagnosed), typhoid fever (60.2% self-diagnosed), and pneumonia (52.4% self-diagnosed).
54
2.5 DISCUSSION
We found that the majority of febrile illnesses in Bo, Southern Province, Sierra Leone, are
self-diagnosed without clinical examination or laboratory testing, including the more than
half of suspected malaria cases that are treated presumptively without any clinical
diagnostics.  The fact that households with greater numbers of individuals were more likely
to report that at least one household member had been tested for a febrile illness supports the
validity of reports about diagnosis and testing rates, since a greater number of persons in the
household increases the probability of a severe illness occurring for at least one resident.  The
validity of the survey instrument is also supported by the low numbers of households
reporting uncommon diseases such as bacterial meningitis unless these conditions were
diagnosed by a doctor.
These results are similar to those from studies in other parts of West Africa which have found
that more than half of adults self-diagnose fevers and self-medicate for what they consider to
be malaria 12,13.  Of those who self-treat, only a small proportion know the correct dosage for
common antimalarial medications 12.
This high rate of self-treatment is concerning, since it is likely that a significant proportion
of these presumptive cases are treated inappropriately (as per the introduction to this paper).
Some people who would benefit from antibiotic and supportive therapy may not be receiving
adequate care, and many people who purchase medication for their self-diagnosed malaria or
other conditions may be taking drugs that are ineffective for their condition.  Febrile
individuals who self-treat may experience disease complications and increased treatment
costs resulting from delayed access to appropriate medications and other therapy 14.  Taking the
wrong medication, such as taking antimalarials for a fever caused by a different infectious
agent, generally means that the actual infection remains untreated for at least several days.
When tests are available at a reasonable cost, testing before treating may significantly reduce
the inappropriate use of antimicrobial medications.  For example, a cohort study of children
ages 1 to 10 years in Uganda found that only 32% of fevers were caused by malaria, and the
researchers concluded that a test-before-treating approach in that study population would
reduce the use of antiparasitic drugs by two-thirds 15.  The reduction of unnecessary treatment
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achieved by a test-then-treat approach will, by definition, be lower in higher-endemicity
areas, including parts of Sierra Leone, where a recent community-based study in the Bo area
found that 83% of febrile women and young children who were tested had malaria 16.  Even so,
testing may significantly reduce the number of people taking unnecessary medications.  The
17% of the 17,130 tested individuals who were malaria-negative in the Bo area study
represented nearly 3000 people who avoided the unnecessary use of antimalarial drugs 16.
Testing does not have to occur in a clinical setting.  In rural Sierra Leone, free malaria testing
by community health workers (CHWs) has increased access to diagnosis for thousands of
households 16.  Those who test positive for malaria are treated by the CHWs, and those with
negative malaria tests or complicated malaria cases are referred to a nearby hospital for
advanced care (although the follow-up rate for referrals from this program has been shown
to be very low).  In some places, testing and treatment by CHWs has been found to be
preferred over home treatment 17.  However, one potential challenge to testing programs is
convincing healthcare providers and patients not to prescribe or take antimicrobials after a
negative test result.  A study from Ghana found that more than half of patients who tested
negative for malaria were prescribed antimalarials anyway 18, and some studies from other parts
of Africa have found similar results 19.  Taking antimalarial medication “just in case” may be
seen as the best option when households do not have the resources to travel to and pay for
further clinical examination and testing.
Besides the direct benefits to patients, expanded use of testing before treatment may slow the
further development of drug resistance by reducing the proportion of the population
accessing pharmaceutical agents without prescriptions tailored to their actual diagnoses.
Patients who have seen a clinician and have a confirmed diagnosis may be more likely than
others to complete a full course of an appropriate antibiotic or antimalarial, especially if their
treating clinicians counsel them about the importance of compliance with prescribed
treatments (an occurrence dependent on those practitioners having the time and resources to
provide health education).  Community-based behavior change communication processes
may also help to promote healthy use of pharmaceuticals by households and communities,
but when these public health structures are not in place the burden of health education
typically falls on clinicians.
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2.6 LIMITATIONS.
This study had several limitations that require a conservative interpretation of the findings.
No laboratory tests were conducted to confirm the reported causative agents for participants’
febrile illnesses, so we do not know how often their self-diagnoses were accurate.
Additionally, participants were not asked about their use of antibiotic and antiparasitic drugs,
such as what medications they preferred to take when febrile or where they procured these
medications.  Because these questions were not part of the survey, we have limited
information about whether the self-treatment used by febrile participants was appropriate for
their illnesses.
2.7 CONCLUSIONS.
This study provides evidence that self-diagnosis and self-medication for malaria and other
febrile illnesses is common in Bo, Sierra Leone.  In order to better understand the
implications of self-diagnosis and presumptive treatment on patient health outcomes, we
recommend that further studies evaluate the types of infections common in this population to
see how well clinical laboratory results match self-diagnoses.  Future research should also
examine the pharmaceutical access and use habits of local residents to see whether
appropriate courses of medication are being taken by those with and without prescriptions
from a clinician.  Understanding the knowledge, attitudes and beliefs, and health practices
and behaviors of residents regarding diagnosis and treatment of fevers may contribute to
improved health services, policies, and practices.
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COMMON NON-MALARIAL FEBRILE ILLNESSES IN SIERRA LEONE:
VIRAL HEPATITIS A, B AND C INFECTIONS
3.1 ABSTRACT
Background
Viral hepatitis is a common and sometimes serious infectious disease. Globally, over 400
million people are chronically infected by the hepatitis B virus3; over 170 million people
affected by hepatitis C virus 4 and tens of millions affected by hepatitis A.5 Many developing
countries such as Sierra Leone, are characterized by significant health and hygiene challenges
that predispose to the transmission of hepatitis viruses.
Objectives
The goal of this research was to investigate the prevalence and distribution of viral hepatitis
in Bo, Sierra Leone.
Methods
A cohort of 1403 persons was followed for one year starting on July 7th, 2012 to July 7th,
2013. Blood samples were collected from febrile subjects and about 0.5-1.5mls of blood were
used in analyzes and 0.5-1ml for storage and/ further immunochromatographic test, (ICT) or
lateral flow assay (LFA) analysis as required. . About 5 -100µl of blood were used per ICT.
The following rapid tests were used: Hepatitis, HBsAg and Hepatitis Combo (HBsAg,
HBeAg, HBsAb HBeAb, HBcAb), HCV and HAV IgG/IgM (Standard Diagnostics, Seoul,
Korea). All tests were uploaded via a portable, battery-operated LF assay reader/imager
(Deki reader, Fio Corporation, Toronto, Canada) to a cloud database at www.fio.net.com for
a quality assessment.
Results
There was an average monthly attendance of 160.25 SD±10.63 for the twelve months of
cohort study, with a significant difference in monthly attendances (P<0.001). A monthly
average of 10.4±1.9SD for Hepatitis B; 5.5±2.5SD for Hepatitis C  and 8.9(±3.4SD) for Anti-
Hepatitis A were recorded. The prevalence of hepatitis B was 9.7% and hepatitis C, 4.7%
while seroprevalence of Hepatitis A was 8.7%. Two age groups, 15-29 years, and ≥ 45years
had higher rates of both HCV and HBV while more females were infected than males.
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Syndromically, 32% fever, 22% cough,  15% headache and  16% abdominal pain  were the
commonest syndromes of viral hepatitis among male subjects. In female subjects, fever
(32%), headache (18%), abdominal pain (18%), cough (15%) were the commonest
syndromes. However, these syndromes are not unique to viral hepatitis and may not be
precise.
The average specific gravity was 1.94±0.85SE. The normal range for specific gravity of urine
is 1.003-1.02017, this high average range is indicative of high urine concentration or
dehydration of subjects. About 50.04% (95% CI 47.21% -52.85%) were cloudy; 10.21 %(
95%CI 8.63-12.04%) had proteinuria and 57.7 %( 95%CI: 54.9%-60.45%) had traces of
protein in their urine. Though dark or cloudy urine could mean infections of other etiologies,
viral hepatitis has been associated with dark urine18 and protienuria19.
Conclusion
For every one person affected by hepatitis C in Bo, Sierra Leone, two individuals are affected
by Hepatitis B, with no risk of infection from Hepatitis A.  The lack of new cases of hepatitis
A within the cohort demonstrates a better environmental health within the catchment
population of Mercy Hospital. Notwithstanding, viral hepatitis remains a major contributor
to illnesses and death in resource-poor countries such as Sierra Leone. The treatment options
in Sierra Leone are fewer and hard-to-get for infected persons.
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3.2 INTRODUCTION
Viral hepatitis is a common and sometimes serious infectious disease marked by necrosis and
inflammation of the liver1 and contributes to a significant morbidity and mortality
worldwide2. Hepatitis A viruses are transmitted enterally and lead to usually self-limited
acute hepatitis. Viral Hepatitis B (HBV) and  Hepatitis C ( HCV) are transmitted by
parenteral routes and can result in chronic hepatitis, progressing to liver cirrhosis and
hepatocellular carcinoma 2.
Globally, over 400 million people are chronically infected by the hepatitis B virus3; over 170
million people affected by hepatitis C virus 4 and tens of millions affected by hepatitis A5.
Every year,  over 300,000 cases of liver cancer and similar numbers of  gastrointestinal
hemorrhage and ascites are due to hepatitis B3.  Over 100,000 cases of liver cancer per year,
with digestive hemorrhage and ascites episodes, are due to hepatitis C virus4 while hepatitis
A remains a major disease of poverty and endemic in resource-poor areas5.
Many developing countries such as Sierra Leone, are characterized by significant health and
hygiene challenges that predispose to the transmission of hepatitis viruses. There is late
detection of viral hepatitis for several reasons. Poverty, inadequate prevention and screening
services6, ignorance, lack of easy accessibility to healthcare centers and lack of trained
personnel and diagnostic facilities are major reasons. Additionally, un-affordability or lack
of expensive drugs, such as Lamivudine, and consultations with quacks and traditional
healers compound the problem.7 The  studies of viral hepatitis in Sierra Leone  have reported
seroprevalences ranging from 5 to 48%, with the most recent one on hepatitis B done in Bo,
Sierra Leone8. Infrequent studies have been done in the past  decade, but all the studies
document a high seroprevalence of hepatitis amongst different population groups in Sierra
Leone9 10
HBV is of a greater global importance than many other viral causes of human hepatitis11.
Knowledge of Hepatitis B as an important cause of morbidity and mortality led to a
worldwide effort to reduce transmission  through routine infant vaccination.12 Usually,  HBV
occurs early in life in poor countries.13 It is transmitted via  body fluids  vertically (i.e. from
mother-to-child), horizontally (i.e. child-to-child), sexually or through parenteral routes13,14.
Since all modes of transmission are possible in Africa, coupled with resource poverty and
weak healthcare systems, the risk of contracting HBV is higher in this region.
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There are vaccines against HBV, but Sierra Leone is yet to implement mass vaccinations that
target both children and adults. The health sector  is yet to couple vaccinations with routine
screenings for all viral hepatitis including HBV9 outside blood donors who are normally
healthy persons over 12 years of age.  There is a scarcity of data on the disease incidence or
prevalence locally.
The goal of this study was to investigate the seroprevalence and distribution of viral hepatitis
in Bo Sierra Leone.
3.3 METHODS
3.3.1 Sampling Strategy
The study was conducted at the Mercy Hospital in Bo Sierra Leone. Within the catchment
area of the study hospital, 100% of heads of households (about 1027) were interviewed.
These houses were identified using an existing digital, interactive map. Each dwelling house
was given a unique identifier (NF001 for the first house and NF1000 for the 1000th house).
The unique ID given to a house was used for a household (when a single family lives in a
house). For houses with multiple households, (families), alphabets A-Z were added to the
label (NF001A, NF001B, NF001C; for three households in one house). The interviews were
conducted using survey forms entered into FilemakerGo database on Apple Ipads.
A prospective cohort of 15% of households, about 1403 individuals, were randomly selected.
To randomly select cohort households, shape files of the catchment area with digitized
building footprints were displayed in a Quantum GIS (QGIS) window. Using the Random
Selection item of the research tool menu in QGIS, the number of houses were randomly
selected and saved as a separate layer. This layer was displayed, and the houses labeled
according to their unique code assigned to them ;( e.g. NFC001, NFC002, and so on). The
labeled map was then printed out, and the houses with their addresses attached to each code
were sampled.
A cohort of 1403 persons was followed for one year starting on July 7th, 2012 to July 7th,
2013. Additional non-cohort data was collected from January 2014 to July 2014 .
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3.3.2 Data Collection
3.3.2.1 Immunoassays
Blood samples were collected from febrile subjects and about 0.5-1.5mls of blood were used
in analyzes and 0.5-1ml for storage and/ further immunochromatographic test, (ICT) or
lateral flow assay (LFA) analysis as required. About 5 -100µl of blood were used per ICT.
The following rapid tests were used: Hepatitis, HBsAg and Hepatitis Combo (HBsAg,
HBeAg, HBsAb HBeAb, HBcAb), HCV and HAV IgG/IgM (Standard Diagnostics, Seoul,
Korea). All tests were uploaded via a portable, battery-operated LF assay reader/imager
(Deki reader, Fio Corporation, Toronto, Canada) to a cloud database at www.fio.net.com for
a quality assessment (Fig 3.1). The automated reader  has been used variously to confirm
rapid lateral assays with congruent results15,16.
3.3.2.2 Syndromic Data Collection
Syndromic data were synchronized with the surveillance system. The system was comprised
of a Filmmakers 12 Server hosted on a 19" MacBook Computer with a local area network
using a Cisco router and outpatient records digitized on the network (Fig 3.1).
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Figure 3.1: Syndromic Data Collection and Device-to-cloud system
3.3.2.3 Urinalyses
Urine samples collected  were analyzed for parameters such as color, appearance, specific
gravity, and contents, using the urine dipstick, Multistix® 10SG (Siemens Healthcare
Diagnostics Inc. Tarrytown, NY, USA). The samples were centrifuged, and microscopic
smear ensued alongside with the Bayer Atlas of Urine Sediments (Siemens Healthcare
Diagnostics Inc. Tarrytown, NY, USA).
3.3.3 Ethics
Ethical approval was sought in five institutions: the Liverpool School of Tropical Medicine
(LSTM), the Njala University Sierra Leone (NU), Sierra Leone Ethics and Scientific Review
Committee, George Mason University (GMU) and the US Naval Research Laboratory
(NRL). Study site, Mercy Hospital Research Laboratory,  has a joint research agreement that
ensures all protocols are reviewed by the George Mason University Review Board, Njala
University Institutional Review Board, and Naval Research Laboratory Ethics Board. The
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Sierra Leone Ethics and Scientific Review Committee of the Sierra Leone Ministry of Health
and Sanitation provided approval by the MOHS.
Informed Consent of participating subjects got first recorded at the community level during
the syndromic survey. All adult members of households involved in the longitudinal study
were asked to consent to participate and again asked about their willingness to donate a blood
sample when they present with illness. Further consent was obtained during the sample
collection for those subjects that visited the hospital when febrile.
3.4 RESULTS
There was an average monthly attendance of 160.25 SD±10.63 for the twelve months of
cohort study, with a significant difference in monthly attendances (P<0.001). The ages 5 to
14 years had an average of 25.83±7.85 attendances per month. Those within 15 to 29 years
had an average monthly attendance of 48.83±6.7. Ages  30 to 44 had 41.66±4.2 while the age
group ≥45 years had a monthly attendance of 43.91±6.7 (Table 3.1).
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Table 3.1 Monthly attendance by febrile subjects
5-14yrs 15-29yrs 30-44yrs ≥45yrs Male Female Total
Month
Jan 23 61 37 30 73 82 151
Feb 8 59 40 56 54 87 163
Mar 17 61 27 56 47 89 161
Apr 57 23 54 15 61 71 149
May 9 62 31 58 113 160 160
June 23 53 44 34 52 96 154
July 11 25 66 53 54 97 155
Aug 7 54 43 37 56 107 141
Sept 101 10 17 8 64 97 136
Oct 16 31 43 42 54 95 132
Nov 14 97 65 97 61 99 273
Dec 24 50 33 41 65 89 148
Mean±
SD
25.8±27.2 48.8±23.4 41.7±14.6 43.9±23.1 62.8±17.3 97.4±21.8 160.3±36.8
CI of
Mean
±17.3 ±14.8 ±9.3 ±14.7 ±11 ±13.8 ±23.4
Midian 16.5 53.5 41.5 41.5 58.5 95.5 152.5
Total
febrile
episodes
310 586 500 527 754 1169 1923
There was a monthly average of 10.4±1.9SD for Hepatitis B; 5.5±2.5SD for Hepatitis C (Fig
4.1) and 8.9(±3.4SD) for Anti-Hepatitis A. The prevalence of hepatitis B was 9.7% and
hepatitis C, 4.7% while seroprevalence of Hepatitis A was 8.7%. Two age groups, 15-29
years, and ≥ 45years had higher rates of both HCV and HBV while more females were
infected than males(P˂0.05) (Fig.3.2).
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Fig 3.2: Age and Sex Distribution of Viral Hepatitis in Bo, Sierra Leone
Ages
N
um
be
r o
f C
as
es
0
5
10
15
20
25
30
30-44 45+15-295-14
HBsAg Males
HBsAg Females
HCV Males
HCV Females
Syndromically, 32% fever, 22% cough, 15% headache and 16% abdominal pain were the
commonest syndromes of viral hepatitis among male subjects (Fig 3.3A). In female subjects,
fever (32%), headache (18%), abdominal pain (18%) cough (15%) were the commonest
syndromes (Fig3.3B). However, these syndromes are not unique to viral hepatitis and may
not be precise.
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Fig 3.3A Syndromes of Viral Hepatitis in Males in Bo, Sierra Leone
Fig 3.3B Syndromes of Viral Hepatitis in Females in Bo, Sierra Leone
Furthermore, in the follow-up seroprevalence study that was done in 2014, 175 febrile
subjects were recruited at Mercy Hospital. They had an average age of 31.4 years, and
80(44.7%) of them, females, were tested for hepatitis A, B, and C.  About 51.43% (95%CI:
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44.07-58.72%) were positive for hepatitis B envelope antibody (HbEab), 49.71 % (95%CI:
42.39 -57.04%) were positive for HBV core antibody (HbCAb) and only 1.71% (95%CI:
0.58-4.91%) and 1.14 %( 95%CI: 0.31-4.1%) were positive for HBV surface antigen
(HBsAg) and HBV surface antibody (HBsAB) respectively. Further, 1.14 %( 95%CI: 0.31-
4.1%) were positive for hepatitis C.
In addition, urinalyses were done on 1,215 urine samples obtained from subjects during the
cohort study. The average specific gravity was 1.94±0.85SE. The normal range for specific
gravity of urine is 1.003-1.02017, this high average range is indicative of high urine
concentration or dehydration of subjects. About 50.04% (95% CI 47.21% -52.85%) were
cloudy; 10.21 %( 95%CI 8.63-12.04%) had proteinuria and 57.7 %( 95%CI: 54.9%-60.45%)
had traces of protein in their urine. Though dark or cloudy urine could mean infections of
other etiologies, viral hepatitis has been associated with dark urine18 and protienuria19.
3.5 DISCUSSION
The results demonstrate a high incidence of viral hepatitis in the cohort population in Bo
Sierra Leone. About 100 out of every 1000 persons are affected per year while about 50 out
of every 1000 persons per year are affected by Hepatitis C.
The results are consistent with existing data for viral hepatitis, where HBV12,19 infects up to
8-15% and about 2-3% are affected globally by HCV13 and  HAV is reported to be in
transition in West Africa20.
However, HCV, believed to have originated from West Africa,21 remains a cause of
morbidity in Bo, Sierra Leone. The seroprevalence of HCV in Bo is higher than the global
seroprevalence which has increased in the past 15 years to 2.8% ( 95% UI: 2.6%-3.1%)22 but
consistent with the West African rates of 4.7 to 8.8%22.  There are currently lot of treatment
options for HCV in developed countries23–26, but poor countries such as Sierra Leone lack
adequate  therapeutics for HCV and the limited supplies are provided at exorbitant rates
which are unaffordable by many of the countries residents which live under 2USD a day.
Having co-infections may affect treatment outcome adversely thereby making HCV positive
cases at high risk of secondary diseases.
In the case of HBV, several studies in Sierra Leone have reported discordant prevalence on
the seroprevalence of HBsAg. In 2005, Wurie10 reported a seroprevalence of 6.3%(19/302)
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of HBsAg among Sierra Leonean pregnant women of middle and high socioeconomic status
and 11.2%(20/179) HBsAg in peri-urban and rural Sierra Leonean pregnant women
indicating a higher prevalence in poorer settlements within the same country.  In 2010,
Solayide27 reported a seroprevalence of 21.7%(43/198) of HBsAg in Freetown. In 2014,
Koroma and Kangbais reported a seroprevalence of 47.5 %( 1054/2218) in Bo Sierra Leone.
Our result of 9.7% seroprevalence of Hepatitis B is consistent with the findings of Wurie10
but contrary to the results of Koroma and Kangbai8, who reported  a 47.5% seroprevalence
of HBsAg among women in Bo Sierra Leone  from samples tested from May 2012 to June
2013 at the Bo Government Hospital. The study was done almost in parallel with this study
and from within the same township. However, their study was based on clinical records and
it is hard to tell if the records were entered correctly and included all persons that were tested
for HBsAg.
However, in a follow-up study that was done in 2014,  51% (90/175) of persons screened
had a history of Hepatitis B infection while only 1.41% were positive for Hepatitis C and
only 1.41%  tested positive for HBsAg. While new infections were low, the additionally data
demonstrated a high seroprevalence of viral hepatis B consistent with the data by Koroma
and Kangbai8.
The disease incidence during the one year cohort study seems to have been higher generally
in Bo, Sierra Leone especially in the cohort study communities which are generally poor,
having houses occupied by multiple families with an average of 6 per household and 18 per
house.28
3.6 CONCLUSION
For every one person affected by hepatitis C in Bo, Sierra Leone, two individuals are affected
by Hepatitis B, with no risk of infection from Hepatitis A.  This incidence recorded in the
period of July 2012 to June 2013, may differ from incidences recorded at other times in the
future. The lack of new cases of hepatitis A within the cohort demonstrates a better
environmental health within the catchment population of Mercy Hospital where this study
was carried out, as poor sanitation generally contributes to HAV transmission.
Notwithstanding, viral hepatitis remains a major contributor to illnesses and death in
resource-poor countries such as Sierra Leone, and the incidence of the disease seems to
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fluctuate with time and space. The treatment options in Sierra Leone are fewer and hard-to-
get for infected persons.
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COMMON FEBRILE INFECTIONS IN SIERRA LEONE: RESPIRATORY
INFECTIONS.
4.1 ABSTRACT
Background: Respiratory infections constitute an important non-malaria febrile condition4,
contributing to over 17% of  deaths of children under five6 and  has a significant proportion
of the 85% of deaths caused by communicable diseases in Sierra Leone
The aim of this study was to investigate respiratory pathogens using a tiered laboratory
analyzes approach in Bo Sierra Leone. Syndromes of respiratory infections within the
catchment of Mercy Hospital were  assessed.
Methods: This study was part of a cohort study that lasted for 12 months starting in July
2012 up to June 2013. A syndromic survey preceded the respiratory sample collection within
the catchment population of Mercy Hospital in Bo Sierra Leone. In addition, syndromic
surveillance was done using data synchronized by the monitoring system.Throat swabs and
nasal swabs were collected from cohort subjects and tested using three tiers of analyzes. Tier
1 involved the use of lateral flow immunoassays, tier2: multiplex PCR and tier 3:
resequencing pathogen microarray.
Results:
Syndromically, there were 38.62 % (821/2126; with 95% CI: 36.57-40.71%) respiratory
syndromes in Bo for the twelve month period between July 2012 and June 2013. Based on
syndromes, children between 6 and 14 years were 44.44% (104.00/234) prevalent (95%CI:
38.21-50.85); 32.6% (CI 28.64-36.83) for 15-29 year olds; 39.55 %( CI, 32.06-42.54) for
those between 30 to 44 years; and 37.15 %( CI, 32.06-42.54) for those that were either 45
years or above.
There were 10(8.3%) detections of Influenza B and 2(1.7%)  of pandemic flu H1N1, 29 cases
of Human Rhino virus/enterovirus(24.2%), 23 cases of Corona Virus (19.2%),  7 cases of
bacterial Chlamydophila pneumonia(5.8%), 6 cases of adenovirus(5%), 2 Parainfluenza
1(1.7%),3 bacterial Mycoplasma pneumonia(2.5%). Other detections were Streptococcus
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pneumonia, Haemophilus influenza, Moraxella catharrhalis, Klebsiella pneumonia, and
Cytomegalovirus.
Conclusion
The high syndromic prevalence of respiratory infections suggests that these type of infections
constitute a standard non-malarial condition in Bo Sierra Leone. Further, both viruses and bacteria
remain important etiologic agents of respiratory infections. Further studies are required to compare
the diagnostic capabilities of the multiplex PCR system and RPM, where discrepant results were
observed.
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4.2 INTRODUCTION
Apart from malaria, several common febrile illnesses in Sierra Leone contribute to disease
morbidity and mortality 1,2,3,4,5.  Respiratory infections constitute an important non-malaria
febrile condition4, contributing to over 17% of  deaths of children under five6 and  has a
significant proportion of the 85% of deaths caused by communicable diseases in Sierra Leone
7
. All infections of the respiratory tract are respiratory infections 8,9 with the upper respiratory
tract (URT) comprising the nose, paranasal sinuses, middle ear, nasopharynx, oropharynx
and laryngopharynx 10. Infections of the upper respiratory pathways include  the common
cold, pharyngitis, tonsillitis, pharyngotonsilitis, sinusitis, rhinosinusitis, epiglottitis, and
laryngotracheitis; which are usually benign, transitory and self-limited or intense diseases
9,11
.
The lower respiratory tract (LRT) on the other hand, is all the part of the respiratory pathway
that is below the vocal cords and includes the tracheae, bronchi, bronchioles and alveoli air
sacs. Infections of the lower respiratory tract  are called lower respiratory infections,
including; laryngotracheobronchitis with a syndrome called croup, bronchiolitis, pneumonia
and influenza infections, 10,12–16. Respiratory infections could also be  classified based on
their symptomatology into acute respiratory or mild respiratory infections, 8,9.
However,  there is scarcity  of data  on respiratory infections in Sierra Leone17.
Notwithstanding, the global report on respiratory infections is grim and acute respiratory
infections (ARI) are   eminent contributors to illnesses and death. ARIs have a worldwide
disease burden estimated at 112,900,000 disability adjusted life years and 3.5 million deaths,
mostly in resource-poor countries such as Sierra Leone 18, 19. Of the deaths caused by ARIs,
about 2 million are children under five years corresponding to about 19% of all deaths in this
age group20,21.
The causative agents of upper and lower respiratory tract infections encompass several
pathogens. The upper respiratory tract has normal flora consisting of Streptococcus
pneumonia, anaerobic and microaerophilic streptococci, Streptococcus milleri (found in
sinuses), Haemophilus influenzae and other Haemophilus sp. Diphtheroids, coagulase-
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negative staphylococci, S. aureus, Moraxella catarrhalis and Neisseria spp. Prevottela
melaninogenicus and other species 10.
Notwithstanding the cause of the illness, definitive diagnoses in resource poor settings for
respiratory infections is barely available. Clinicians use their experience and knowledge of
predictors or syndromes of respiratory infections to treat infected persons. It may not suffice
in an advanced era where pathogens change form, and there are molecular platforms to detect
the pathogens involved. Detecting  a pathogen as part of the etiologic agents in the respiratory
disease ecology of a resource-poor location, necessitates simpler and cheaper kits for testing
respiratory pathogens in austere environments.
4.3 GOAL
The aim of this study was to investigate respiratory pathogens using a tiered laboratory
analyzes approach in Bo Sierra Leone. Syndromes of respiratory infections within the
catchment of Mercy Hospital were  assessed.
4.4 METHODS
This study was part of a cohort study that lasted for 12 months starting in July 2012 up to
June 2013. A syndromic survey preceded the respiratory sample collection within the
catchment population of Mercy Hospital in Bo Sierra Leone. In addition, syndromic
surveillance was done using data synchronized by the monitoring system.
Throat swabs and nasal swabs were collected from cohort subjects and tested using three tiers
of analyzes.
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Fig. 4.1: Respiratory Sample Collection
First tier comprised of lateral flow immunoassays (LFIs) or immunochromatographic tests
(ICT). Second tier was by the FilmArray multiplex polymerase chain reaction (PCR), and
the final tier was resequencing pathogen microarray using RPM Flu Chip 3.1.
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4.4.1 Tier 1: Lateral Flow Immunoassays Method
The LFIs used were the multiplex Influenza A, Influenza B and Pandemic Flu (H1N1) tests;
Streptococcus aureus LFI and respiratory syncytial virus (RSV). Swabs collected were in
duplicate: two throat swabs and two nasal swabs per subject. One of the two sets of collected
swab samples were dipped and swirled each in a 1.5ml Eppendorf tube containing 400ul of
saline solution for molecular analyzes and the other used for rapid lateral flow
immunoassays.
SD BIOLINE Influenza Ag A/ B/ A (H1N1) Pandemic was used. The nasal swabs obtained
from subjects and immersed in the sample buffer provided with the kit as directed by package
insert. The test strip was then removed and inserted into the tube to sample and buffer and
result acquired at 15 minutes. Positive and negative controls included in the assays were also
done to assess the quality of the assay.
For Streptococcus aureus, only throat swabs were eligible for sample types as described in
the package insert of the SD Bioline test kit. The kit detects viable or nonviable organisms
directly from the throat swabs within 5-10mins with a sensitivity and specificity of 87.3%
and 95.8% respectively. After placing the throat swab   in a test tube provided with the kit,
three drops of Extraction Reagent A was added.  This was followed by three drops of
Extraction Reagent B  and swirled before inserting test strip and waiting for 5-10 minutes for
the result.
The SD Bioline RSV test kit was used for detecting antigens of respiratory syncytial virus.
The Kit has a sensitivity of 92.3% and a Specificity of 93.3%. To conduct a test, about 200-
250 µl of assay diluent was added to the provided test tube as directed by insert. The swab
was  dipped into diluent and swirled, after 10 minutes of waiting for it to settle down, test
strip was added and result obtained within 15 minutes.
4.2.2 TIER 2: MULTIPLEX PCR RESPIRATORY PANEL
The FilmArray system (Biofire Diagnostics, Salk Lake City,Utah, USA), is a multiplexed
PCR in vitro diagnostic system that is also a lab-in-a-pouch system (Fig 4.2) that performs a
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mesoscale (0.001 to 0.2ml working volume) sample fluid manipulation in a self-contained,
disposable thin-film plastic pouch22.
Fig 4.2: The FilmArray System
The FilmArray Respiratory Panel (FRP) assay carries out an automated, rapid, nested
multiplex PCR using two target controls; one RNA target from Schizosaccharomyces pombe
and a DNA target, which is included in the wells and controls for the second-stage PCR22. It
simultaneously detects any of 20 respiratory pathogens including 17 viruses and their
subtypes and three bacteria pathogens in a single respiratory specimen. The device can detect
pathogens based on both complete genome sequences and partial gene sequences. The list of
pathogens detected by the FDA approved respiratory panel include:
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Table 4.1: list of pathogens detected by the FDA approved respiratory panel
The FilmArray does nested multiplex PCR without amplicon contamination. The pouch is a
closed system and up to 120 second-stage PCRs can be performed in the pouch, enough for
multiple tests for several pathogens and still include controls for process validation.
Conserved sequences from specific gene segments of proteins or 5’ UTR regions were
selected as assay targets in the assay. Subsequent to injection of the sample into the pouch,
are: (1) sample lysis (2) nucleic acid purification (3) cDNA synthesis and outer multiplex
PCR (4) automated nested PCR and (5) amplicon melt analysis23.
The FRP pouch (Fig 4.3)  and its physical design   has been described extensively by Babady
et al. 22 It contains all of the freeze-dried reagents (primers, buffers, enzymes, LCGreen Plus
dye, etc.) required for nucleic acid extraction, nested RT-PCR, and high resolution melting24
and  is the site of biological processes that allow the device to manipulate quantification of
sample nucleic acids for screening of pathogen markers. Three pneumatic elements within
the instrument, including the pistons and the plungers in the top of the fitment control the
movement of liquid throughout in the pouch.
Influenza A FluA/H1 subtyping Coronavirus NL63
Influenza B FluA/H3 subtyping Coronavirus HKU1
Parainfluenza virus 1 FluA/H1-2009 subtyping Coronavirus OC43
Parainfluenza virus 2 Human Rhinovirus/ Enterovirus Human Metapneumovirus
Parainfluenza virus 3 BocavirusS Adenovirus
Parainfluenza virus 4 Coronavirus 229E Bordetella pertussis
Respiratory Syncytial
Virus
Chlamydophila pneumonia
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Figure 4.3:  An Annotated FilmArray Pouch
All of the biochemical reagents used for reservoirs and PCR arrays are freeze-dried into 12
wells of the fitment. From left to right:
Well 1: PCR Process control material (Schizosaccharomyces pombe cells)
Wells 2, 3, 4, 5: Sample Wash Buffer
Well 6: Nucleic acid elution buffer
Well 7: Reverse transcription/first stage PCR master mix
Well 8: Dilution buffer
Wells 9, 10: Second stage PCR master mix22
Well 11:  Empty
Well 12: Overflow reservoir for the second stage PCR mix22
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In the lysis chamber, through a process called bead beating, the FilmArray breaks apart any
cells or viruses in the sample. Ceramic beads, agitated in high speeds, break open cells and
viruses and release the nucleic acids. These acids bound to magnetic beads, which then
proceed into the purification chamber. A wash buffer eliminates any cellular or viral debris
while a magnetic field keeps the beads in place. In this stage, an elution buffer releases the
bound nucleic acids. A reverse transcription is then initiated to convert any target RNA
fragments into DNA. Afterward, a first-stage PCR with specific primer pairs are used to
amplify fragments, and the remaining products are then further amplified if possible during
the second-stage PCR step. The final products are aliquot and tagged with fluorescent
antibodies for detection (BioFire). As shown below, analysis of these products can give
identification for the following pathogens.
4.2.2.3 FilmArray Sample Processing Procedures
The Food and Drug Administration approved sample for the FilmArray, nasal swabs, were
used, and samples extracted by swirling tips of swabs into 0.1M saline solution. The
FilmArray test kit is provided with two vials, a red sample vial, and a blue hydration buffer
vial. The hydration solution in blue vial was first added to the pouch, using the buffer syringe
(blue) to rehydrate the freeze-dried reagents. Unprocessed sample was mixed directly with
the sample buffer in red vial.  The sample-buffer mix was injected into the pouch using the
sample buffer syringe. The prepared pouch was inserted into the FilmArray instrument,
barcode of pouch registered by the barcode reader and a run initiated. Results are available
in approximately 1 hour.
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Fig 4.4: FilmArray Sample Processing Steps
The instrument performs individual second-stage PCR reactions and perform high-resolution
melting analysis. The FA software algorithms automatically determines if the analytes are
detected in the specimen,24 based on the melting profile of the PCR products.
4.2.3 Resequencing pathogen microarray (RPM-FLU V.3.1)
The resequencing pathogen microarray (RPM) system (Fig 4.5) was used in this study. Flu
chip RPM-Flu v.3.1 was utilized in this study. A Resequencing Pathogen Microarray (RPM)
is highly multiplexed assay for detecting and differentiating similarly related etiologic agents
by using carefully overlapping probe sets to determine a target organism’s nucleotide25,26.
RPM has different chips with different targets on them, but the flu chip (Fig 4.6) can detect
over 30 viral and bacterial pathogens. Because it is a resequencing array, it can also detect
emerging pathogens or near neighbors of existing pathogens.
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Fig. 4.5: Rpm System in Bo Sierra Leone
Hybridization
ovens
Affymetrix
3000 7G Scanner
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with
Software
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GSEQ
Affymetrix
Fluidics
Stations
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Fig 4.6: RPM Chip Design
Source: Tessarae.LLC
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Fig 4.7: RPM Procedures (Lin et al26)
RPM technology operates a multistep process: (1) nucleic acid extraction of either DNA,
RNA, or both (2) sample amplification via whole genome amplification or multiplex PCR
(3) labeling (often preceded by fragmentation) (4) microarray hybridization (5) microarray
scanning.
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4.2.3.1 Specimen collection and processing
Sterile swabs were used to obtain a sample from throat and nostrils. The swabs were dipped
in 400ul of saline solution and 150ul of the solution spiked on Whatman protein-saver Fast
Technology for Analysis (FTA) cards. The FTA cards protect nucleic acid samples from
degradation by nucleases and other processes27. They are integrated with a weak base,
chelating agent, anionic surfactant or detergent, and uric acid (or a urate salt) imbedded into
a cellulose-based matrix. Moreover, they are proven for adequately storing DNA and RNA
samples at room temperature for weeks or years without noticeable degradation27.
As positive controls, live influenza strains H1N1 and H3N2 virus samples at different
concentrations (0.1 pg/μl and 0.01 pg/μl for each) were stored on FTA cards. FTA cards
inactivate all pathogens and do not need to be stored under BSL-2 conditions27.
4.2.3.2 Primer Design
Four independent multiplex primer mixes, separated to simplify primer design and enhance
multiplex optimization, were used to amplify targeted sequences on RPM-Flu v.3.1
microarrays. To accommodate the genetic variability of RNA-based and DNA-based viruses
and ensure amplification of even closely related strains, a software-script automated a primer
selection algorithm to select primers by unique primer regions. Each of the four multiplex
primer cocktails dedicated to the detection and amplification of a class of pathogens:
influenza, other viruses, bacteria, and entero/rhinovirus species.
4.2.3.3 Multiplex RT-PCR amplification
Following 2μl of cDNA reverse transcription (25ºC, 10 min; 50ºC, 50 min; 85ºC, 5 min), the
obtained cDNA was apportioned into four independent aliquots of equal volume for each
sample type. Four separate multiplex PCR reactions, as described above, were conducted
with specific primer cocktails to amplify all detectable targets. For this step, from the master
mix of each cocktail solution, 45μl were added to 4.9μl of the cDNA. Each prepared sample
solution was incubated in the thermal cycling protocol (24ºC, 10 min; 94ºC, 2 min; 16 cycles
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[94ºC, 30 sec; 45ºC, 30 sec; 72ºC, 90 sec]; 24 cycles [94ºC, 30 sec; 96ºC, 30 sec; 60ºC, 2
min]).
4.2.3.4 Microarray Hybridization and Analysis
PCR amplification products were recombined and purified using Qiagen purification
columns. Purified products were fragmented using DNase I and labeled with biotinylated
ddATP via terminal transferase. These mixes were incubated (37ºC, 30 min; 95ºC, 5 min).
RPM-Flu v.3.1 microarray chips were pre-heated in the oven with pre-hybridization buffer
solution for 12 minutes at 60 rpm. 96μl of hybridization solution added to 34.5 of the
fragmented and labeled PCR products.  Once loaded, the microarray chips were incubated at
95ºC for 5 minutes and then 49ºC for another 5 minutes.  Final hybridization of chips ran
overnight at 49ºC, 60 rpm.
On the molecular level, overlapping 25-nucleotide probe sets inside the chips shifted by one
base nucleotide are generated for the whole prototype sequence. Each probe set contains one
matching and three mismatched probes differing only by the middle nucleotide for each
resequenced base of the prototype sequence. The probes for each probe set occupy four
neighboring spots on the microarray. The differential hybridization to probes in each
configured to labeled fragments of the target allows the sequence  determination. The base
calls for detected target fragments are made by resequencing adapted software base on the
relative strength of hybridization to probes within each set. In this way, the resequencing
microarray detects related targets containing single nucleotide polymorphisms.
After hybridization, the samples were then removed from the microarray cartridges, and
hybridization buffer was reloaded into each chip.  The chips were washed and stained using
SAPE stain solution, antibody mixes, and array washing buffer at a GeneChip 450
microfluidics station.  A GeneChip 3000 scanner was used to scan and analyze the
microarrays.  Scan results, which included sequencing data based on microarray
hybridization patterns via fluorescence and in situ probe detection, were generated with
GeneChip software. Sequences, including notations of mismatched gene signatures and
single nucleotide polymorphisms indicative of mutations, were used to produce FASTA
92
output files. FASTA files were submitted for analysis to Tessarae using a proprietary
identification algorithm and BLAST search of the Genebank database.
RESULTS
4.3.1 Syndromic Distribution of Respiratory Infections
Syndromically, there were 38.62 % (821/2126; with 95% CI: 36.57-40.71%) respiratory
syndromes in Bo for the twelve month period between July 2012 and June 2013. There were
no significant differences by sex (P>0.05). Age wise, there were 41.22 % (277/672)
prevalence (95% CI, 37.56-44.98) for children under five years of age. Children between 6
and 14 years were 44.44% (104.00/234) prevalent (95%CI: 38.21-50.85); 32.6% (CI 28.64-
36.83) for 15-29 year olds; 39.55 %( CI, 32.06-42.54) for those between 30 to 44 years; and
37.15 %( CI, 32.06-42.54) for those that were either 45 years or above (Table 4.2). (Note that
this result includes 672 children that were not part of the cohort of 1403 and 51 recurrences
of respiratory syndromes)
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Table 4.2: Distribution of Respiratory Syndromes from the Catchment of Mercy Hospital in Bo, Sierra Leone.
Age Overall Males Females P-Value of
Chi
Squared
tests for
differences
by sex
N Respiratory
Syndromes
(RS)
% of
Syndromes
(%RS)
95%CI N RS % RS 95%CI N RS %RS 95%CI
0-5 672 277 41.2 37.6-45.0 262 109 41.6 35.8-47.7 410 168 41.0 36.3-45.8 0.9
6-14 234 104 44.4 38.2-50.9 109 48 44 0 35 1-53 4 125 56.0 44.8 36.4-53.5 09
15-29 500 163 32.6 28.6-36.8 180 63 35.0 28.4-42.2 320 100 31.3 26.4-36.5 0.4
30-44 397 157 39.6 34.9-44.4 186 74 39.8 33.0-47.0 211 83.0 39.3 33.0-46.1 0.9
≥45 323 120 37.2 32.1-42.5 164 65 39.6 32.5-47.3 1S9 55.0 34.6 27.6-42.3 0.3
Mean 425.2 164.2 38.9 34.1-43.3 180.2 71.8 40.0 33.0-47.1 245 92.4 38.2 31.9-43.9
±SD 169.04 67.74 4.0 54.9 22.8 3.3 118.1 46.3 5.3
Total 2126 821 38.6 36.6-40.7 901 359 39.8 36.7-43.1 1225 462 37.7 35.0-40.5 P>0.05
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4.3.2 Tiered Analyzes of Respiratory Samples
Of the respiratory syndromes encountered, 120 were tested. All were tested by rapid lateral
flow immunoassays and rapid automated PCR. 16 of the 120 samples, about 13% were
selected, and this set was tested using RPM-Flu v.3.1. From the RLFI, only the multiplex
influenza RFLI had detections. There were 10(8.3%) detections of Influenza B and 2(1.7%)
detections of pandemic flu H1N1 in Bo Sierra Leone. The other two, Streptococcus aureus
and RSV kits had no detections, and the higher tier tests did not also pick up RSV or Strep
A.
At Tier 2, the following pathogens were detected: 29 cases of Human Rhino
virus/enterovirus(24.2%), 23 cases of Corona Virus (19.2%),  7 cases of  bacterial
Chlamydophila pneumonia(5.8%), 6 cases of adenovirus(5%), 2 Parainfluenza 1(1.7%) and
3 bacterial Mycoplasma pneumonia(2.5%).
At Tier 3 six pathogens were detected using RPM-Flu v.3.1.  The detections were
Streptococcus pneumonia (76%) Haemophilus influenza (53%) Moraxella catharrhalis
(29%), Klebsiella pneumonia, Cytomegalovirus and Influenza A (6% each)
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Fig 4.6. Data summary. 17 of 120 nasopharyngeal swab samples analyzed on RPM Flu
v.3.1 to detect and identify possible infectious respiratory pathogens.
There was a 100% concordance between RSV rapid lateral flow immunoassay (SD Bioline,
Seoul, South Korea) and the FilmArray PCR diagnostic platform for 120 tests and the RPM
platform for 17 tests that were compared. The RSV kit tested negative for 120 samples
screened. The PCR also tested negative for the same 120 samples screened for RSV. In the
case of RPM, only 17 tests were accessed, and all were in agreement with the RSV kit. For
all tests, negative controls tested negative and positive controls tested positive.
Similarly, there was a 100% concordance between the Strep a rapid lateral flow
immunoassay (SD Bioline, Seoul, South Korea) and the FilmArray PCR diagnostic platform
and the RPM platform. The Strep a kit tested negative for 120 samples screened. The PCR
also tested negative for the same 120 samples screened for Strep a. In the case of RPM, only
17 tests were accessed, and all were in agreement with the Strep a kit.
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However, there was no concordance between the multiplex influenza kit which tests for
Influenza A (non-pandemic), Influenza A (H1N1), and Influenza B. The test did not agree
with the PCR tests and the RPM tests.
Further, between the Tier 2 and Tier 3 assays, there were discordant results. While the RPM-
Flu microarrays detected more bacterial pathogens, the multiplex PCR detected more viral
pathogens. These bacterial Streptococcus pneumoniae, Haemophilus influenzae, Moraxella
catarrhalis, and Klebsiella pneumonia were detections on the RPM Flu chip with
approximately 80% of the 17 samples tested by RPM testing positive for S. pneumoniae,
whereas 40% of samples were positive for H. influenzae. Specifically, on analyzing sample
TALRESP_001, while FilmArray detected Coronavirus OC43, the RPM-Flu v.3.1 detected
S. pneumoniae and H. influenzae. In other instances, such as TLA_RESP_006, where
FilmArray detected no pathogens present, RPM-Flu v.3.1 found targeted gene signatures for
S. pneumoniae, M. catarrhalis, and H. influenza.
FilmArray is not designed to be able to detect the same broadband spectrum that RPM-Flu
can detect. In fact, RPM detects and identifies even unknown strains of certain species based
on resequencing advantages, but through a much more time-consuming process. Cases that
are even further exacerbated by conditions like malaria can become even more severe or even
fatal.
4.3.3. DISCUSSION
The high detections of viral pathogens in this study are not surprising though such a broad-
spectrum etiology research has not been done previously in the study location. Most upper
respiratory infections are of viral etiology9.  In a study of viruses and bacteria in the etiology
of the common cold, different strains of rhinoviruses were found to be the primary cause of
the infection 28.  Further, it has been indicated previously that viruses such as coronavirus,
influenza virus, respiratory syncytial virus (RSV), parainfluenza virus, adenovirus, and
Metapneumovirus are contributing agents to common cold. 29
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It is important to understand detection of cytomegalovirus, which is one of the eight herpes
viruses that affects humans, with a likelihood to infect immunocompromised patients30. The
RPM also detected an Influenza A matrix gene that is generic and the strain of the Influenza
A pathogen is unknown. Surprisingly, serotypes for influenza A can be detected using
FilmArray. However, given that screening via FilmArray showed no presence of influenza
serotypes, this affirms the broader detection scope and higher resolution of the RPM system.
Influenza increases in clinical severity with increase in the age of the patient and persons
with other health disorders, causing an intermittent  seasonal morbidity and mortality
worldwide31. The global burden of influenza varies every year with higher burdens in seasons
when influenza A (H3N2) viruses predominate32, rather than influenza A (H1N1) and B
viruses33,34.
It was surprising that there was no detection of RSV though investigated at the three tiers
from the nasal and throat swabs. This poor performance of the tests for detecting RSV could
be due to the sample type used; nasal and throat swabs instead of nasal wash or
nasopharyngeal aspirate. Nasopharyngeal aspirate (NPA) or nasal wash specimens have been
reported 35,36,37, to be sufficient for sampling respiratory viruses though the use of NPAs is
not ideal for children. In a comparative specimen sampling, using NPAs, throat swabs, (TS)
and nasal swabs (NS) in the viral etiologies of acute respiratory infections; Do et al38,
reported that the overall diagnostic yield from NPAs was superior. In a related study, Sung
et al39 compared NPA and NS specimen collection methods to results from three different
assays: Immunofluorescence test (IF), viral culture (VC) and more importantly, PCR. Using
the Cohen Kappa test (95% Confidence Interval, 0.6-0.8 meaning high agreement) there was
a high concordance between NS and NPA for PCR tests involving Adenovirus, Influenza A,
Influenza B, Parainfluenza and RSV. Do et al. 38 recommended the combination of NS and
TS for generally sampling .
In the area of diagnosis, current methods employed to diagnose and detect respiratory
pathogens include various polymerase chain reaction (PCR) assays40,41,42 and antigen tests
using different fluorescence and enzyme-linked immunoassays 43. Though enzyme-linked
immunoassays are easy to use and suited for use especially in the field and in cases where
many samples are to be tested for pathogens, it was not available for this study.Rapid lateral
flow immunoassays were used.  They are however unreliable in the sense that: they
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sometimes fail to detect pathogens and they only indicate the presence or absence of a
pathogen but not the genetic sequence, concentration or other information that may be
relevant to clinicians or researchers. PCR, on the other hand, is currently used not only as a
confirmatory assay but also as a diagnostic test. It is economical in terms of time and
resources, but the several methods for real-time PCR assay design have very low sensitivities
for many clinical applications44, this is due mainly to the probe design and quality of primers.
Also, in resource-poor settings PCR is not applicable in many areas due to resource
limitations and low technical capabilities, but the rapid automated  PCR system  used in this
study, is easy to use, runs for a shorter period and reduces turn-over time. However, unlike
other PCR assays, the thermocycler processes one sample at a time and is not ideal for
handling bulk samples during outbreak situations and is also expensive to run, as each pouch
cost about 100 US dollars, making  120 pouches worth 12,000 US dollars, excluding value
of operator time.
Generally, there were detections of bacterial pathogens on both molecular platforms used,
with pathogens: Streptococcus pneumonia, Klebsiella pneumonia, Chlamydophila
pneumonia and Mycoplasma pneumonia, four bacterial causative agents  associated with
atypical and community-acquired pneumonia45,46; Haemophilus influenzae, which exist both
as a commensal in adults47,48 and as a serious source of morbidity in children, causing
meningitis, pneumonia and bacteremia47,48; Moraxella catarrhalis which is responsible for
certain bronchopulmonary infections in adults and  otitis media and sinusitis in children49,50
. These results  are consistent with other studies that have also indicated the role bacteria play
in infections of the nasal sinuses and pharynx leading to rhinosinusitis and pharyngitis,
epiglottitis and laryngotracheitis9. In addition pneumonia disease alone can kill over 1.6
million people each year, with vast a majority of its victims coming from the world’s poorest
countries such as Sierra Leone. 51. This study also indicates high bacterial activity in the
causation of respiratory infections in Bo, Sierra Leone.
Though computational methods, including gene resequencing, microarray scan analysis, and
comparisons against data found on GeneBank by alignment, do confirm the presence of
certain pathogens; biological methods used in this study can be a cause for the contrast in
detection and identification of emerging and infectious respiratory agents. The storage of the
nasopharyngeal swab samples is a possible source of discrepancy. The FTA cards, protein
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saver types, may have been better in stabilizing DNA and protein-rich samples and less
efficient in preserving RNA-based microorganisms, in this case respiratory viruses, that were
stored on to these cards. Additionally, spotting preparations for these samples may have
diluted them to a degree that lowered sensitivity. Sample storage may account for the absence
of RNA-based viruses during detection using RPM-Flu v.3.1. Nonetheless, when comparing
diagnostic capabilities, FilmArray is simpler and thus faster, but RPM-Flu carries greater
detection resolution and is capable of detecting and identifying a broader range of pathogens
while differentially separating apart notable strains and sequencing divergences for both
bacteria and viruses.
4.4 CONCLUSION
The high syndromic prevalence of respiratory infections suggests that these type of infections
constitute a standard non-malarial condition in Bo Sierra Leone. Further, both viruses and
bacteria remain important etiologic agents of respiratory infections. Further studies are
required to compare the diagnostic capabilities of the multiplex PCR system and RPM, where
discrepant results were observed.
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CHAPTER FIVE
COMMON FEBRILE ILLNESSES IN SIERRA LEONE:REEMERGENCE
OF CHIKUNGUNYA VIRUS IN BO, SIERRA LEONE
This chapter is from a published paper that was published in the Emerging Infectious
Disease ISSN: 1080-6059 Volume 19, Number 7—July 2013. It has been updated and
modified appropriately to form this chapter.
Rashid Ansumana, Kathryn H. Jacobsen, Tomasz A. Leski, Andrea L. Covington, Umaru Bangura,
Mary H. Hodges, Baochuan Lin, Alfred S. Bockarie, Joseph M. Lamin, Moses J. Bockarie, and
David A. Stenger
5.1 ABSTRACT
Background
Outbreaks of infection with chikungunya virus (CHIKV), an alphavirus that is transmitted
by bites of infected Aedes spp. mosquitoes, were frequent in sub-Saharan Africa and
southern and Southeast Asia during the 1950s–1970s, but the infection largely disappeared
in the 1980s; only sporadic cases were observed 1. The virus reemerged in the early 2000s.
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Objective
The main goal of the study was to investigate the incidence and/prevalence of non-malarial
febrile illnesses such as Chikungunya in Bo Sierra Leone and to determine the geographical
distribution of the infection using a crowdsourcing platform, ushahidi.
Methods
A tiered analysis approach was used. First, all specimens from febrile study participants
were tested for ≈12 infections with various pathogens, including CHIKV, by commercially
available test kits. Specimens that showed negative results in this first round of testing were
further tested by using cultures, multiplex PCR, and resequencing pathogen microarrays.
Results
Using person-time rate at 95% confidence interval (CI) per 1000 people per year, the
incidence of Chikungunya within the cohort was calculated to be 573.7. The prevalence was
46.04%; 95%CI: 43.45- 48.66% with ages ranging from 6 years to 85 years; 344(53.25%; 95%CI:
49.32-57.14%) were female patients. Of these 646 ChikV patients, 370 (57.3.0%) reported
arthralgia, 390 (60.4%) chills, and 355 (55.0%) headaches. Co-infections were common; 69
(10.68%; 95%CI 8.5-13.3%) were co-infected with malaria, 37 (5.7%; 95% CI: 4.2-7.8%) with
HIV, 36 (5.6%95% CI: 4.1-7.6%) with viral hepatitis and smaller numbers with tuberculosis,
typhoid, and syphilis. Twelve CHIKV-positive samples were also positive for dengue.
Conclusion
The results suggest that an outbreak of chikungunya virus occurred in Sierra Leone.
Because Mercy Hospital serves only a relatively small proportion of the residents of Bo, the
cases detected likely represent only a small fraction of the total cases that have occurred.
Further study will be required to document the extent of the outbreak.
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5.1. INTRODUCTION
Outbreaks of infection with chikungunya virus (CHIKV), an alphavirus that is transmitted
by bites of infected Aedes spp. mosquitoes, were frequent in sub-Saharan Africa and
southern and Southeast Asia during the 1950s–1970s, but the infection largely disappeared
in the 1980s; only sporadic cases were observed 1. The virus reemerged in the early 2000s;
major outbreaks were reported in Kenya, some island nations in the Indian Ocean, and
several countries in Asia.
The primary symptoms of CHIKV infection are high fever (>38.5°C [102°F]) and severe
pain in the distal joints of the extremities or the lumbar spine. A maculopapular rash,
sensorineural impairment, severe headache, and other nonspecific symptoms may also
occur. Symptoms usually resolve within 1–2 weeks after onset of fever, but for a sizeable
proportion of patients, arthralgia and arthritis become chronic and pain persists for years 2,3
A nationwide serosurvey in Sierra Leone in 1972 detected cases of CHIKV infection
throughout the country 4, but we are not aware of any cases reported since the mid-1970s.
Two recent developments made reemergence appear imminent. First, outbreaks of
reemerging CHIKV have been reported in neighboring Guinea 5 and in Senegal 6 Second,
recent yellow fever cases in Sierra Leone have shown that Aedes spp. mosquito–borne
infections are common7. Thus, it was not surprising when we conducted an infectious
disease surveillance study in July 2012 in the city of Bo, in Southern Province, Sierra
Leone, that we detected possible chikungunya virus infections.
The main goal of the study was to investigate the incidence and/prevalence of non-malarial
febrile illnesses such as Chikungunya in Bo Sierra Leone and to determine the geographical
distribution of the infection using a crowdsourcing platform, ushahidi.
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5.2 METHODS
On July 7, 2012, a one-year prospective cohort study at the Mercy Hospital Research
Laboratory (MHRL) in Bo, Sierra Leone, was initiated to identify the diversity of
pathogens causing febrile illness in the city. A tiered analysis approach was used. First, all
specimens from febrile study participants were tested for ≈12 infections with various
pathogens, including CHIKV, by commercially available test kits. Specimens that showed
negative results in this first round of testing were further tested by using cultures, multiplex
PCR, and resequencing pathogen microarrays. The research protocol was approved by
Njala University, George Mason University, the Liverpool School of Tropical Medicine,
the US Naval Research Laboratory, and the Sierra Leone Ethics and Scientific Review
Committee.
5.2.1 Tier 1 Analyses
During July 7, 2012–July 7,2013, a first-tier lateral flow immunoassay (LFI) tests of blood
samples were conducted from outpatients ≥5 years of age who had been clinically
examined at the hospital, were found to have febrile illness, and consented to having blood
drawn for laboratory testing. LFI test kits (SD Bioline; Standard Diagnostics, Inc., Seoul,
South Korea) were used for diagnosis of IgM against CHIKV; IgG and IgM against dengue
virus and hepatitis A virus; hepatitis B virus surface antigen, hepatitis C virus, HIV-1/2,
and antibodies against these viruses; and IgG and IgM against Leptospira spp., Salmonella
enterica Serovar typhi, and syphilis.
5.2.2 Tier 2 analyses
Tier 2 analyses were comprised of semi-nested PCR and 6 PCRs targeting different regions
of the viral genome, including alphavirus consensus PCR, flavivirus consensus PCR,
filovirus consensus PCR, arenavirus consensus PCR. For the semi-nested PCR the method
used was adapted from Rianthavorn8.
In the initial PCR, DVRChkF 50-ACCGGCGTC TACCCATTCATGT-30 (nt 10237–
10258)18 and CU3-CHIKR 50-TCGCTRCAGCACACRGCACC-30 (nt 10741–10760)
were used as forward primer and reverse primer, respectively. The Roche High-Fidelity
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Fast-Start PCR kit (Roche Diagnostics, Indianapolis, IN, USA) was used together with the
Applied Biosystems Gene Amp 9700 thermocycler (Perkin Elmer, Norwalk, CT. USA) and
the Bio-Rad MJ Mini Thermal cycler (Bio-Rad Laboratories, Hercules, CA). The cycling
conditions for reverse transcription were; 25°C  for 10 minutes;  50°C for 50 minutes, 85°C
for 5 minutes and 4°C forever. This was then followed by the first PCR with cycling
conditions: 95°C for 2 minutes for denaturation, followed by 40 amplification cycles 95°C
for 30 seconds for denaturation, 55°C for 30 seconds for primer annealing, 72°C for
extension and 95°C for 2 minutes for final extension. Then, the semi-nested PCR was
performed by using CU1CHIKF 50-GCATCAGCTAAGCTCCGCGTC-30 (nt 10378–
10398) as an inner forward primer. Gel Electrophoresis was done by the Flash gel DNA
System (Lonza Group Ltd Basel, Switzerland).
5.2.3 Tier 3 analyses
The resequencing pathogen microarray system RPM-TEI v. 1.0 described previously by
Leski et al9,10 was used in this study to rule out O’nyong-nyong and Dengue, viruses that
may cause symptoms similar to those caused by chikungunya virus. In addition the new
Resequencing Pathogen Microarray, the IVDC4-03, with tiles for Chikungunya was also
used.
Additionally, for all chikungunya genes on genebank, the evolutionary history was inferred
using the Minimum Evolution method11. The optimal tree with the sum of branch length =
0.39778494 is shown. The evolutionary distances were computed using the Maximum
Composite Likelihood method12 and are in the units of the number of base substitutions per
site. The ME tree was searched using the Close-Neighbor-Interchange (CNI) algorithm13 at
a search level of 1. The Neighbor-joining algorithm14 was used to generate the initial tree.
The analysis involved 129 nucleotide sequences. All positions containing gaps and missing
data were eliminated. There were a total of 11338 positions in the final dataset.
Evolutionary analyses were conducted in MEGA515.
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5.3 RESULTS
Using person-time rate at 95% confidence interval (CI) per 1000 people per year, the
incidence of Chikungunya within the cohort was calculated to be 573.7.
More than half of the cases tested during the first month of the surveillance program were positive
by LFI for CHIKV. Thus, we notified the Sierra Leone Ministry of Health and Sanitation of a
possible CHIKV outbreak. By June 30, 2013, 646(46.04%; 95%CI: 43.45- 48.66%) febrile patients
were positive by LFI for CHIKV (Figure 5.1). Ages of the 619 CHIKV IgM-positive patients
ranged from 6 years to 85 years; 344(53.25%; 95%CI: 49.32-57.14%) were female patients.
Of these 646 patients, 370 (57.3.0%) reported arthralgia, 390 (60.4%) chills, and 355
(55.0%) headaches. Co-infections were common; 69 (10.68%; 95%CI 8.5-13.3%) were co-
infected with malaria, 37 (5.7%; 95% CI: 4.2-7.8%) with HIV, 36 (5.6%95% CI: 4.1-7.6%)
with viral hepatitis and smaller numbers with tuberculosis, typhoid, and syphilis. Twelve
CHIKV-positive samples were also positive for dengue.
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Figure 5.1: Monthly number of IgM-positive chikungunya virus test results at
Mercy Hospital Research Laboratory, Bo, Sierra Leone, July 7, 2012–June 30,
2013
Most patients reported that they had sought medical care within several days after the onset
of their febrile illnesses. Levels of IgM against CHIKV are usually detectable by
immunochromatographic methods within a few days after infection and persist for ≈3–4
months 1,2 The LFI test kits for CHIKV were reported by the manufacturer to have a
sensitivity of 97.1% and a specificity of 91.1% compared with those of ELISA 16. An
independent evaluation found a sensitivity of 50.8% and a specificity of 89.2% for the kits;
sensitivity ranged from 40.9% 1–5 days after onset of illness to 65.4% 16–20 days after
onset 17.Specificity decreases after the first week 18,19.
On July 28, an Ushahidi-based website (www.ushahidi.com) to compile case reports was
launched. Details about the patients who were positive for CHIKV were uploaded to a
website (www.mhrlsl.com/GIA/ushahidi) and, if possible, were geolocated on an open
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street map (www.openstreetmap.org) that linked to a map of Bo created previously for
health research purposes 20. The map showed the geographical distribution of Chikungunya
within the city of Bo (Fig 5.2). However, because the sample was not population-based
because Mercy Hospital is 1 of several hospitals serving Bo, a city-wide attack rate could
not be determined.
Figure 5.2: Residence locations for IgM-positive cases of infection with
chikungunya virus, Bo, Sierra Leone, July, 2012–July 2013.
Results from the Semi-nested PCR is shown below (Fig 5.3). 8 out of 15 samples tested by
semi-nested PCR were positive and 2 of the 8 that were positive by Semi-nested PCR were
IgM negative for ChikV. However the 18 samples tested with the other 6 PCRs targeting
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different regions of the viral genome, including alphavirus consensus PCR, flavivirus
consensus PCR, filovirus consensus PCR, arenavirus consensus PCR yielded negative
results. The RPM TEI lacks tiles for chikungunya but results were negative for onyong
nyong and dengue which may produce similar symptoms as Chikungunya.
Fig 5.3: Results of Chikungunya Specific Seminested RT-PCR
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The negative results from the other PCRs could be possibly because of genetic sequence
variation from well-characterized strains or because of the timing of specimen collections.
Viral loads for humans with CHIKV infection decrease after the second day of symptoms,
and viral titers may be low after the fifth day 18,19. Because CHIKV nucleic acids are only
detectable in serum for a few days, reverse transcription PCR results are often discordant
with those of serologic (IgM and IgG) assays. Confirmation that an outbreak occurred is
dependent on isolation of the virus, followed by molecular characterization, full-genome
sequencing, and phylogenetic mapping. Due to funding limitations sequencing of the virus
was not done, but all genes on GeneBank for Chikungunya were extracted and a
phylogenetic tree drawn with Mega 5.1(Fig 5.4)
115
Figure 5.4: Evolutionary relationships of taxa
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5.4 CONCLUSIONS
The results suggest that an outbreak of chikungunya virus occurred in Sierra Leone. The
exact time of the reemergence of this virus cannot be pinpointed, but retrospective analyses
of outpatient charts suggested that, on the basis of syndromic criteria, the first cases
occurred in January 2012 and the outbreak peaked during the rainy season in 2012. Other
outbreaks reported in central and west Africa have also occurred during the rainy season,
which is typical for Aedes spp. mosquito–borne infections6,21,22 . Because Mercy Hospital
serves only a relatively small proportion of the residents of Bo, the cases detected likely
represent only a small fraction of the total cases that have occurred. Further study will be
required to confirm the laboratory results and, if further investigation is warranted, to
document the extent of the outbreak.
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CHAPTER SIX
COMMON FEBRILE ILLNESSES IN SIERRA LEONE: HIV INFECTION
6.1 ABSTRACT
Objective(s): The goal of this study was to investigate the prevalence and incidence of HIV
in a cohort of subjects within the catchment of Mercy Hospital in Bo Sierra Leone.
Design: A cohort of 1403 subjects were recruited randomly from the catchment population
of Mercy Hospital and followed for a period of one year with laboratory tests done when
subjects become febrile.
Methods: All subjects got  tested with an SD Bioline 4th Generation HIV Ag/Ab Combo
lateral flow immunoassay (Standard Diagnostics Inc. Kyonggi-do, Korea).  The test kit  is a
qualitative test for detecting HIV p24 antigen and antibodies  (IgG, IgM and IgA) specific
to HIV-1 including subtype-O and/or HIV-2 in human serum, plasma or whole blood. Other
tests for syphilis, malaria, HBsAg, HCV, HAV, were done. Patient blood chemistry tests
were done using CHEM8+ cartridges of the Abbott Point of Care Chemistry analyzer, I`-
STAT 300 (Abbott Laboratories. Abbott Park, IL USA).
Results: A person-time rate of 102.4 HIV cases at 95% CI per 1000 people per year were
determined in Bo Sierra Leone. The prevalence of HIV was 9.34 %( 100/1403); 61% were
females and 39% males. Of those that were having HIV, 10.69 %( 14/131) were co-infected
with Hepatitis B; 3.1 %( 4/131) were having syphilis; 1.5 %( 2/131) were having Hepatitis C
virus. Blood chemistry of 32 HIV- patients were assessed, 15(46.88%) had hemoglobin
values below 12g/dl with a median Hb value of 10.90g/dl and 6(18.75%) of hematocrit values
were critically low (≤27%PCV).
Conclusions: This study provides additional evidence that the HIV epidemic is a serious
problem in the city of Bo Sierra Leone. There is a need for more independent studies on the
prevalence of HIV in Sierra Leone and to improve the diet of those affected by HIV.
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6.2 INTRODUCTION
Human immune-deficiency virus (HIV) and the Acquired Immune Deficiency Syndrome
(AIDS) which results from HIV infection, remain among the most dreaded diseases
worldwide. Twenty-one countries  of the  world with the  highest rates of HIV are in sub-
Saharan Africa; eight of them have more than one million people living with HIV and overall,
HIV has infected more than 40 million Africans since the start of the epidemic; 22 million of
which have died. [1]. In 2012, there were 2.3 (1.9–2.7) million new HIV infections globally,
depicting a 33% decline in incident cases 3.4 (3.1–3.7) million in 2001 and there was a
concomitant decrease in AIDS deaths in 1.6 (1.4–1.9) million AIDS deaths in 2012,
compared to 2.3 (2.1–2.6) million deaths in 2005[2].
In Sierra Leone, since  1987 when the first cases of HIV/AIDS were identified in Bo and
Kenema Districts, there has been an increase in the number of persons living with HIV/AIDS
[3]. The country’s HIV epidemic is mixed, generalized and heterogeneous as the infection
cuts across all sectors and different strata of the population through
varied transmission dynamics[4]. National seroprevalence of  HIV peaked in 2005 and
stabilized in 2007 and adults with  HIV were estimated at 1.5% , and pregnant women
attending antenatal clinics were 3.2% prevalent[4]. However, there is no concordance
between the National HIV prevalence figures in Sierra Leone and independent research
studies carried out in the country.
In 2002, it was reported that about 7% of women receiving antenatal care in Freetown had
AIDS[5]. In the same year, country-wide, 45,000 persons were reported to be having HIV
and in 2005; 75,000 were with HIV[6]. The percentage increase in three years was 66.7%[3]
but reported national prevalence has been static since 2005. Students have done most studies
that have been done on HIV in Sierra Leone and they remain unpublished. However,
published data on HIV are not consistent with national figures.
In Bo, seroprevalence reported by the Ministry of Health and Sanitation(MOHS) in 2005 was
1.9%, and higher percentage of females were affected than males[7]. Bhoobun et al[8]
working on facilitators and barriers related to voluntary counseling and testing for HIV
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among young adults in Bo  reported that over two-thirds of  young adults have never been
tested for HIV and over two-thirds of those not tested previously were  willing to try in the
near future, but report fears about family/partner rejection, job loss, and other potential
consequences of testing and a strong desire for robust testing privacy. There are seemingly
more persons positive for HIV that are yet to be tested.
This study investigated the prevalence and/ incidence of HIV in a cohort of subjects within
the catchment of Mercy Hospital in Bo Sierra Leone.
6.3 METHODS
A cohort of 1403 subjects were recruited randomly from the catchment population of Mercy
Hospital and followed for a period of one year. The selections were prefaced by a syndromic
surveillance survey described previously[9].
All subjects were tested with  an SD Bioline 4th Generation HIV Ag/Ab Combo lateral flow
immunoassay (Standard Diagnostics Inc. Kyonggi-do, Korea) which is a rapid, qualitative
test for the detection of HIV p24 antigen and antibodies to  isotypes IgG, IgM and IgAspecific
to HIV-1 including subtype-O and/or HIV-2 simultaneously in human serum, plasma or
whole blood[10]. Positive HIV tests were redone with the SD Bioline Kit and the Alere
Determine™ HIV-1/2(Alere Medical Co Ltd. Matsudo-shi, Chiba, Japan). Other tests for
syphilis, malaria, HBsAg, HCV, HAV, were done. Patient blood chemistry tests were done
using the Abbott Point of Care Chemistry analyser, i-STAT 300 (Abbott Laboratories. Abbott
Park, IL USA), with the CHEM8+ cartridges.
6.4 RESULTS AND DISCUSSION
The prevalence of HIV in Bo was 9.7% % (95%CI: 8.2-11.4)( 136/1403). Of those that were
having HIV, 61% were females  and  10.3 %( 14/136) were coinfected with Hepatitis B; 3.0
%( 4/136) were having syphilis, 1.5 %( 2/136) were having Hepatitis C virus. A person-
time rate of 102.4 HIV at 95% CI per 1000 people per year was determined in Bo Sierra
Leone.
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Blood chemistry of 32 HIV-positive patients were assessed(Table 6.1), 15(46.9%) had
hemoglobin(Hb) values below the reference range of(12-17 g/dL);mean Hb values was
12.0(± 3.35SD ) and median value was 11.8g/dl; only 9(28.1%) of hematocrit values were
within the reference range(38-51 %PCV), 6(18.8%) were critically low(≤27%PCV) and the
average %PCV for critically low values was 21.7(±1.96). 11(34.4%) had glucose above the
reference range of (70-105mg/dl) and a mean of 143.5± 50.6mg/dL; 30(93.8%) had ionized
calcium (iCa) below the reference range of 1.2 -1.3mmol/L with a mean iCa of 1.1 mmol/L
but 2(6.3%) had critically low iCa (≤0.7 mmol/L). 5(15.6%) patients had creatinine values
above the critical value (≥2.0 mg/dL), and the average of the critically high values was
2.6(±0.7SD). For potassium ions, 2(6.3%) had critically high values (≥6.5 mmol/L) ; 2(6.3%)
also had critically high values (≥120 mmol/L) of Chloride ions and 1(3.1%) had critically
low value (≤15 mmol/L) of total carbon dioxide (TC02). All other values were within the
critical values with the following averages: urea nitrogen (BUN) was 13.4(±12.5) mg/dL;
sodium ion (Na) 134.84(±6.3) mmol/L; anionic gap (AnGap) was 14.7(±4.1) mmol/L.
This study demonstrates that the HIV epidemic remains a serious problem in Bo Sierra
Leone. The prevalence of 9.7% in this study is consistent with findings from other
independent studies carried out in Sierra Leone. In Kenema, one of the first cities where HIV
was  initially reported in Sierra Leone,  Kouyoumdjian[11] reported  HIV prevalence of
12.6% in women specifically accessing voluntary counselling and testing (VCT), and 6.7%
in men specifically accessing VCT from a sample of  2230 persons.
A study in Freetown[12], reported a prevalence of 14.89% HIV infection seen in a private clinic
in the year 2000 compared to 9.25% in the year 1999; and in 2006, another study[3] reported  a
prevalence of 11.4%(937/8,251) after monitoring VCT and women reporting for antenatal
care in 7 hospitals in Freetown.
Further, blood chemistry of HIV positive patients were mostly healthy with few values
beyond their critical values necessitating the need to improve the diet of the patients.
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TABLE 6.1: BLOOD CHEMISTRY ANALYSES OF HIV INFECTED PERSONS
Subject Parameter Hb HCT Glucose iCa) Creatinine Potassium
ions
Chloride
ions
carbon
dioxide
(TC02)
urea
nitrogen
(BUN)
sodium
ion
(Na)
anionic
gap
(AnGap)
Male Mean±SD 12.82±2.88 37.65±8.
57
100.44±25.82 1.11±0.29 1.19±0.42 3.87±1.38 103.94±
8.36
22.35±
7.3
15.35±1
3.26
134.65
±7.26
15.07±3.
1
Reference
Range
12-17 38-51 70-105 1.2-1.32 0.6-1.3 3.5-4.9 98-105 24-29 8-26 138-
146
24-29
Median 12.20 94.5 1.14 1.20 3.5 104 23.0 10 136 14.0
Female Mean±SD 11.02±3.68 32.73±10
.88
112.07±54.30 1.06±0.11 1.38±0.83 4.08±1.04 103.4±3.
48
21.5±3
.63
11.13±1
1.6
135.07
±
14.21±3.
26
Reference
Range
12-17 38-51 70-105 1.2-1.32 0.6-1.3 3.5-4.9 98-105 24-29 8-26 138-
146
24-29
Median 10.90 101.0 1.08 1.0 3.9 104 21.5 6 136 14.0
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6.5 CONCLUSION
Few studies have reported the prevalence of HIV in Sierra Leone. This study provides
additional evidence that the HIV epidemic is serious in the City of Bo Sierra Leone.  Since
only one catchment population was assessed for HIV, it is possible that this is just a hotspot,
and the result may not apply to the entire city of Bo or Sierra Leone. An independent country-
wide prevalence of HIV is recommended.
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CHAPTER SEVEN
COMMON FEBRILE ILLNESSES IN SIERRA LEONE: ETIOLOGY OF
UNDIFFERENTITAED FEBRILE ILLNESSES
7.1 ABSTRACT
Background
Undifferentiated febrile illnesses are common in resource-poor countries that are home to
multiple infectious diseases. Bacterial pathogens remain endemic together with presumptive
self-diagnosis and self-treatment practices, while patterns of resistance keeps changing with
several reports of multi-drug resistance.
Objectives
This study aims at investigating the etiology and prevalence of undifferentiated febrile
illnesses in Bo, Sierra Leone.fc
Methods
Blood, urine and stool samples were obtained from febrile patients recruited from the
catchment of Mercy Hospital in Bo. A tiered laboratory analyses was done involving LFIs,
PCR, Culture and RPM.
Results
Only 2 %( 29/1403) were positive for typhoid fever, but seroprevalence of positive widal
titres were 57.2% for Salmonella typhi ‘O’ and 62.3% for Salmonella typhi ‘H’ at ≥120 titres.
Neglected tropical diseases detected included: 19.3% Ascaris lumbricoides (95% CI: 14.2-
25.8); 10.8% hookworms (95% CI: 7.0-16.3); 6.3% Schistosoma mansoni (95% CI: 3.5-
10.8); 1.14% Schistosoma haematobium; 1.2% Strongyloides stercoralis (95% CI: 0.3-4.1);
and 2.8% Trichuris trichiura (95% CI: 1.2-6.5). Several bacterial pathogens and viruses
were also detected.
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Conclusion
Bacterial, viral, protozoan and helminthes are among frequent etiologic agents that cause
undifferentiated fever in Bo, Sierra Leone. Among the bacteria, Salmonella enterica serotype
Typhi is of importance as the population antibody levels has risen such that about three-fifth
of the study population had up to 1:120 titers of both Anti-O and Anti-H antibodies. A new
cut-off point for the Widal test at 1:180 or above is recommended to prevent over prescription
of antibiotics for cases not related to typhoid.
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7.2 INTRODUCTION
Fever typically originates from infection 1,2. It is a prominent clinical indicator of disease
processes in a mammalian host.3 Fever is also an ancient adaptive compensatory defense
mechanism that activates the immune system; resulting in a decrease in pathogen growth rate
and an increase in host survival, 4. It is a regulated increase in body temperature above normal
and mechanistically distinct from hyperthermia, 5.
Infections resulting to fever can either be acute or chronic. Both acute and chronic
undifferentiated febrile illnesses are common in resource-poor countries that are home to
multiple infectious diseases. When an acute undifferentiated fever becomes chronic, lasting
weeks, it becomes a fever of unknown origin, though the two terms are sometimes used
interchangeably.
Bacterial pathogens such as human Salmonella6,7,8 causing typhoid and paratyphoid fevers,
and non-typhoidal salmonellosis remain endemic in many poor countries of the world9,10 in
addition to other bacterial infections such as cholera11–13 and tuberculosis14. The gold
standard for  diagnosing  typhoid fever is by  culture15.  Culture has  a sensitivity of 40-60%16,
but low-cost tests for enteric fever, mainly the Widal Test, are more adaptable to resource
poverty and are commonly used in resource-poor settings17. Widal tests have been in use for
over 110 years, but the results are very controversial17–19 and the test suffer from low
specificity in endemic countries due to rise in population antibody levels18. Presumptive self-
diagnosis and  self-treatment, practices in these countries remain common,20 while patterns
of resistance in Salmonella keeps changing with many reports of multi-drug resistant
salmonellae21–23.
Understanding the undifferentiated febrile illnesses of a location requires multiple microbial
investigations such as bacteria in the urine, stool or blood samples; investigating other
etiologic agents such as helminths, viruses or protozoans. There is also a need for multiple
diagnostic approaches. These are difficult tasks in resource-poor settings, where diagnostic
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resources are limited, and people have been exposed to several infectious diseases to an
extent that they feel experienced in self-diagnosing.
Bacterial infections  may be frequent, but knowing the cause of a bacterial infection does not
suffice to provide adequate therapeutics; it is also important to understand if available
antibiotics are useful, because in resource-poor environments, antimicrobial resistance may
occur due to excessive use of over-the-counter drugs without prescription and little studies
have been done to account for the extent of such a pattern in Sierra Leone. Among the few
studies done include reports by Leski et al24,25 who reported  tet(X) gene24, that  encodes a
flavin-dependent monooxygenase that confers resistance to all clinically relevant tetracycline
antibiotics including tigecycline and multiple carbapenemase genes25 from clinical isolates
in Bo Sierra Leone.
This study aims at investigating the etiology and prevalence of undifferentiated febrile
illnesses in Bo, Sierra Leone.
7.2 METHODS
This laboratory-based study was preceded by a syndromic surveillance survey described
elsewhere20 where 60% of research participants indicated that they self-treat when febrile
and indicated several infectious diseases they suspect to have when febrile including typhoid
fever, malaria and a host of others.
A cohort of 1403 individuals was followed for a year and their febrile illnesses investigated
using a tiered laboratory analyses method comprising several diagnostic tests.
7.2.1 Rapid diagnostic tests
Blood samples  collected from febrile subjects  were used, with  500µl-1500 µl of blood used
for analyses. Up to 500µl -1000 µl  was used for storage and/ further
immunochromatographic test, (ICT) or lateral flow assay (LFA) analysis as required. ICT
tests used about 5 -100µl of blood. The following rapid tests were used: Chikungunya,
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malaria, typhoid fever, syphilis, HIV 1 and 2, dengue fever, leptospira, influenza A and B,
RSV and Strep A, HBsAg and Hepatitis Combo (HBsAg, HBeAg, HBsAb HBeAb, HBcAb),
Hepatitis C Virus, HCV and Hepatitis A Virus, HAV IgG/IgM (Standard Diagnostics, Seoul,
Korea). Images of ICT tests were uploaded via a portable, battery-operated LF assay
reader/imager (Deki reader, Fio Corporation, Toronto, Canada) to a cloud database at
www.fio.net.com for a quality assessment (Fig 4.1). The automated reader has been used
variously to confirm rapid lateral assays with congruent results26,27.
Widal tests were used for detection of antibody levels for Salmonella. Febrile antigens kits
(Biorex Diagnostics Ltd, Technology Park, Belfast Road, Antrim) were used to test for
Salmonella typhi using qualitative slide agglutination and semi-quantitative tube
agglutination tests. Screening for the presence of Salmonella typhi “O’ and Salmonella
surface “H” antibodies  was done with the slide test  using blood serum as sample. A drop of
each of the  “O” and “H” antigens in the Febrile Illness test kit,  on blood serum, rotated at
100RPM for a minute. Agglutination is indicative of a recent or current typhoid fever
infection. A tube agglutination test was  done on reactive slide agglutination samples.
Applications of serum samples and antigen drops in varying dilutions such as 1:20, 1:40,
1:80, 1:120, 1:160, 1:200, and 1:240 up to 1:640 constituted the test. An antibody titre of
1:160 done once or higher (without serial testing) was a positive result for Salmonella
antibodies in the patient.
7.2.2 Blood chemistry and urinalyses
Additionally, blood chemistry analyses were done using the iStat 300 platform. Moreover,
urinalyses were also done using the urine dipstick, Multistix® 10SG (Siemens Healthcare
Diagnostics Inc. Tarrytown, NY, USA). Centrifugation and microscopic smear were  done
with the Bayer Atlas of Urine Sediments (Siemens Healthcare Diagnostics Inc. Tarrytown,
NY, USA).
7.2.3 Tuberculosis tests
The SD Bioline TB antibody tests were done. The Rapid TB Test is an in vitro
immunochromatographic test for the detection of antibodies to Mycobacterium tuberculosis
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in human serum, plasma.   The TB point-of-care test is reported to have no cross-reactivity
with other species of Mycobacterium and does differential detection of tuberculosis IgG and
IgM with a sensitivity of 98.2%.
In addition, Ziehl–Neelsen staining was done to detect TB microscopically. TB samples were
obtained three times: spot, early morning and spot. Slides with smear were placed upwards,
on the staining rack over a sink, about 1 cm apart. New filter papers were put in a small funnel
over the slides and filled with carbol-fuchsin staining solution, so that the solution filters
through the paper, covering each slide completely. Slides were heated by a torch prepared
by burning cotton wool in ethanol and moved over them perpetually until steam rises;
repeating the process twice at intervals of 3-5 minutes. The solution was prevented from
drying, and fresh stain was added until staining contact time is at least 10 minutes. Slides
were tilted to drain off the stain solution and then rinsed with reverse osmosis (RO) water or
distilled water. Acid solution was then added over the smears, covering them completely for
3 minutes. They were drained of the acid and rinsed again. If macroscopically stains were
still present, the acid treatment was repeated, followed by methylene blue stain for 1 minute.
The slide was rinsed afterwards, dried and ready for use.
7.2.2 Culture and antimicrobial resistance testing
Urine and stool samples were cultured on agar media (Hardy Diagnostics, Santa Maria, CA)
or CHROMagar™ plates (CHROMagar, Paris, Fr.).Chromagar is powder based media with
agar, peptone and yeast extracts and chromogenic mix for differentiation or group
identification. Other types of media used were: Brain Heart Infusion (BHI) Agar, Tryptic Soy
Agar (TSA), MacConkey agar, Hektoen enteric (HE) agar, Salmonella Shigella Agar (SS)
(Hardy Diagnostics, Santa Maria, CA).
For  blood culture, blood samples were collected using aseptic techniques involving alcohol
wipes, BD Vacutainer®Safety-Lok™blood collection set with pre-attached holder (Becton
Dickinson and Company, Franklin Lakes, NJ, USA). Blood culture was done using the Oxoid
SIGNAL (Oxoid Ltd., Basingstoke, United Kingdom) blood culture system. The constitution
of the medium encourages the growth of aerobic, anaerobic and microaerophilic organisms.
Gas produced by bacterial metabolism, for a positive culture, makes the medium from the
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culture bottle to move to an upper reservoir via a hollow needle. Displacement of media may
provide a visual indication of the presence of both aerobic and anaerobic organisms in a
single medium28.
API20E for identification was used in concert with other methods of identification such as
by the CHROMagar plates, or by PCR. The API-20E test kit (bioMerieux, Inc., Hazelwood,
MO), is a standardized identification system for Enterobacteriaceae and other non-fastidious
gram-negative rods and it constitutes a plastic strip with twenty-one miniaturized
biochemical tests and a database with results. The mini-test tubes (20 in all) were inoculated
with a saline suspension of a pure culture thereby providing raw sample and also rehydrating
desiccated medium in each tube. The tube and cupules of mini tubes CIT, VP and GEL, were
filled completely with culture suspension. While filling only the tube and not the cupule of
mini tubes ADH, LDC, ODC, H2S, and URE and then overlaying with mineral oil to facilitate
anaerobic reactions. The strip is incubated in an oven at 37°C for 18-24 hours. During
incubation, bacterial metabolism produces color changes that are either spontaneous or
revealed by the addition of reagents.  After an incubation a TDA Test is done by adding one
drop of TDA reagent to the TDA mini-tube: a reddish brown color indicates a positive
reaction to being recorded on the provided result sheet.  The VP test is also done by adding
one drop each of VP1 and VP2 reagents to the VP mini-tube, and a positive outcome (pink
or red) obtained after 10 minutes, but slightly pink is negative. An IND test is also done by
adding one drop of JAMES reagent to the IND mini-tube; a pink colour is a positive IND
test. All positive colour readings add up to number codes, seven digits in all, called the
analytical profile index or API that pinpoints the genus and species of bacterium present in
the sample (Table 1). The reading was done from an API Reference Book or accessed from
the apiweb™ at https://apiweb.biomerieux.com.
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Fig. 7.1: API Identification
7.2.3 Sensitivity Tests
Pure isolates were subcultured with sensitivity disks. The single isolated colonies grown on
agar medium (Hardy Diagnostics, Santa Maria, CA) were transferred into tubes containing
0.9% sterile saline solution and were emulsiﬁed. The inoculum was then used to streak
Mueller–Hinton agar plates (Hardy Diagnostics, Santa Maria, CA), and antibiotic-containing
disks including azithromycin(15µg),  gentamicin(10 µg), kanamycin(30 µg),
ampicillin/sulbactam(20 µg),  sulﬁsoxazole (30 µg), ciproﬂoxacin(5 µg),
chloramphenicol(30 µg )and doxycycline(30 µg )((Hardy Diagnostics, Santa Maria, CA),
were dispensed onto the surface. Antibiograms were generated on each isolate using standard
disk diffusion methods specified by the Clinical and Laboratory Standards Institute (CLSI)
guidelines. All plates incubated for18-24 hours at 37˚C, and the diameters of inhibition zones
were then measured and interpreted.
7.2.4 Sequencing and multiplex reactions
Single colony isolates were obtained using flamed loops and transferred to 1.5ml Eppendorf
tubes for total genomic DNA extraction using a MasterPureTM Complete DNA and RNA
Puriﬁcation Kit (Epicentre Biotechnologies, Madison, WI). The isolates were identiﬁed
genetically after PCR ampliﬁcation and sequencing of a 16S rDNA amplicon that spanned
the V3 and V425 variable regions and the rpoB or gyrA gene previously described29,30,24.
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Blood culture results were obtained by using the FilmArray multiplex PCR platform (FA;
BioFire, Salt Lake City, UT)) using the Blood culture Identification (BCID) Pouch. The
methods of the test have been  previously described 31.
The Biothreat panel of the Filmarray system described previously32 was also used together
with the respiratory pouch. Pathogens that can be detected by the blood culture identification
panel (BCID) and the Biothreat Panel (BT Panel) are indicated in the following tables:
Table 7.1: Filmarray bcid panel
Gram Positive Bacteria
Enterococcus species
Listeria monocytogenes
Staphylococcus aureus
Streptococcus species
Streptococcus agalactiae
Streptococcus pneumoniae
Streptococcus pyogenes
Gram Negative Bacteria
Enterobacter cloacae
Escherichia coli
Klebsiella oxytoca
Klebsiella pneumonia
Serratia marcescens
Proteus Haemophilus
influenzae
Neisseria meningitidis
Pseudomonas aeruginosa
Fungi
Candida albicans
Candida glabrata
Candida krusei
Candida parapsilosis
Candida tropicalis
Antibiotic resistance genes
mecA gene
KPC gene
vanA gene
vanB gene
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Table 7.2: FilmArray Biothreat Panel
Bacillus anthracis
Brucella melitensis
Burkholderia mallei/pseudomallei
Clostridium botulinum
Coxiella burnetii
Francisella tularensis
Ricinus communis
Rickettsia prowazekii
Staphylococcal enterotoxin gene
Yersinia pestis
Ebola Zaire
Marburg virus
Orthopox genus virus
Variola virus
EEE virus
VEE virus
WEE virus
7.3 RESULTS
7.3.1 Enteric Fever
Of the 1403 febrile subjects enrolled in this study, 1095 were screened by the Widal test that
was used to screen for antibody levels to Salmonella typhi in the population.
57.2%(626/1095) were having ≥120 titres of Salmonella typhi “O” ,62.3% (682/1095) were
having ≥120 titres of Salmonella typhi “H” antibodies; this represents the reported rate of
typhoid fever locally based on titers of 1:120 which is used in many clinics in Sierra Leone
as a positive result. 109(10%) had 140 titres of Salmonella “O” and 101(9.2%) had 140 titers
of Salmonella “H” antibodies. The remaining, 360(32.9%) and 312(28.5%) were having
≥160 titers of Salmonella typhi “O” and “H’ antibodies respectively. Titre values of ≥160
done once were considered presumptively positive for typhoid fever infection.
However, further microbiological testing yielded only 2% (29/1403) positive cases of
typhoid fever (Table 7.3).
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7.3.2 Helminthiasis
Ova of several helminths were detected in stool samples of subjects and considered important
in the non-malarial febrile ecology in Bo, Sierra Leone.  Out of 176 stool samples examined
for worms (Table 7.3), 19.3% had Ascaris lumbricoides (95% CI: 14.2-25.8); 10.8% had
hookworms (95% CI: 7.0-16.3); 6.3% had Schistosoma mansoni (95% CI: 3.5-10.8); 1.14%
had Schistosoma haematobium; 1.2% Strongyloides stercoralis (95% CI: 0.3-4.1); and 2.8%
had Trichuris trichiura (95% CI: 1.2-6.5).
Schistosoma spp. Trichuris trichiura are neglected tropical diseases and also known as
diseases of poverty.
7.3.3 Non-typhoidal Bacterial infections
Several bacterial pathogens were detected in samples that were analyzed by culture from
stool, urine and blood and sputum smear. Frequent bacterial infections included:  16.9% of
Escherichia. coli (95%CI:11.6-23.9); 12.6% of Klebsiella pneumonia (95%CI: 8.2-19.2);
12% of Citrobacter freundii (95%CI:7.6-18.3); 8.5% of Enterobacter cloacae (95%CI: 4.9-
14.2), 7.5% Haemophilus influenzae (95%CI: 3.7-14.2), 5%Chlamydophila pneumonia
(95%CI: 2.9-11.6), 3.3% Moraxella catharrhalis (95%CI: 1.3-8.3), 2.8% Kluyvera spp. And
2.8% Serratia plymuthica /marcescens (95%CI: 1.1-7.0), 2.5% Mycoplasma pneumonia
(95%CI: 0.9-7.1), 1.6% Treponema pallidum (95%CI:  1.1-2.5) and 0.7% Enterobacter
intermedium, 0.7 Enterobacter aerogenes and 0.7% Escherichia hermannii (95%CI: 0.1-
3.9). (Table 7.3).
7.3.4 Viral Infections
Viral infections included 46% Chikungunya (95%CI 43.5-48.7), 24.2 Human Rhino
virus/enterovirus (95%CI: 17.4-32.6), 19.2% Corona virus (95%CI: 13.1-27.1), 9.7% HIV
(95%CI: 8.2-11.4), 8.5% Hepatitis B(HbSAg) (95%CI 7.1-10.1), 8.7%HAV(IgG)( 95%CI:
7.3-10.3), 8.3% Influenza B(95%CI: 4.6-14.7 ), 5% Adenovirus(95%CI: 2.1-11.0), 4.7%
Hepatitis C(95%CI: 3.7-5.9), 2.8% dengue fever (95%CI: 2.0-3.8), 1.7% parainfluenza virus
and 1.7% Influenza A(H1N1) (95%CI: 0.5-5.9), 0.8% cytomegalovirus(95%CI: 0.04-5.2) and
0.2 % Human Coxsackie virus A24 and A22(95%CI: 0.07-0.6) were detected (Table 7.3).
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Table 7.3: Fever Causing Pathogens Identified by a Tiered Laboratory Analyses (LFI’s, Microscopic
Smear, API20E & 32E, Multiplex PCR, Rpob Sequencing and 16s sequencing).
Etiologic Agent Infectious Agent Type No.
Positive
No.
Tested
%Positive
of Tested
95%CI
Citrobacter freundii Bacteria 17 142 12.0 7.6-18.3
Enterobacter cloacae Bacteria 12 142 8.5 4.9-14.2
Escherichia coli Bacteria 24 142 16.9 11.6-23.9
Escherichia hermannii Bacteria 1 142 0.7 0.1-3.9
Klebsiella pneumoniae Bacteria 19 158 12.0 7.8-18.0
Kluyvera Bacteria 4 142 2.8 1.1-7.0
Ent. aerogenes Bacteria 1 142 0.7 0.1-3.9
Ent. Intermedium Bacteria 1 142 0.7 0.1-3.9
Serratia plymuthica /marcescens Bacteria 4 142 2.8 1.1-7.0
Mycoplasma pneumonia Bacteria 3 120 2.5 0.9-7.1
Chlamydophila pneumonia Bacteria 7 120 5.8 2.9-11.6
Moraxella catharrhalis Bacteria 4 120 3.3 1.3-8.3
Streptococcus pneumonia Bacteria 12 120 10.0 5.8-16.7
Haemophilus influenzae Bacteria 9 120 7.5 3.7-14.2
Treponema palidum bacteria 23 1403 1.6 1.1-2.5
Salmonella typhi bacteria 29 1403 2.1 1.5-3.0
Ova of Ascaris lumbricoides helminth 34 176 19.3 14.2-25.8
Ova of Hookworm helminth 19 176 10.8 7.0-16.3
Schistosoma masonia helminth 11 176 6.3 3.5-10.8
Schistosoma haematobium helminth 2 176 1.1 0.3-4.2
Trichuris trichiura helminth 5 176 2.8 1.2-6.5
Strongyloides helminth 1 176 1.1 0.03-3.6
Mycobacterium tuberculosis bacterium 34 1403 2.4 1.7-3.4
Yersinia pestis bacterium 16 1403 1.1 0.7-1.8
Burkholderia pseudomallei bacterium 66 1403 4.7 3.7-5.9
Human coxackie virus A24 and A22. Viral 3 1403 0.2 0.07-0.6
Chikungunya viral 646 1403 46.0 43.5-48.7
HIV Viral 136 1403 9.7 8.2-11.4
HCV Viral 66 1403 4.7 3.7-5.9
HBsAg Viral 119 1403 8.5 7.1-10.1
HAV IgG Viral 122 1403 8.7 7.3-10.3
Dengue Viral 39 1403 2.8 2.0-3.8
Influenza A Viral 2 120 1.7 0.5-5.9
Influenza B Viral 10 120 8.3 4.6-14.7
Cytomegalovirus Viral 1 120 0.8 0.04-5.2
Corona Virus(0C43) Viral 23 120 19.2 13.1-27.1
Human Rhino virus/enterovirus Viral 29 120 24.2 17.4-32.6
Adenovirus Viral 6 120 5.0 2.1-11.0
Parainfluenza Viral 2 120 1.7 0.5-5.9
Malaria protozoan 331 1403 23.6 21.4-25.9
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7.3.5 Antimicrobial Resistance
Based on disk diffusion using the CLSI guidelines, the following pattern of resistance was
observed in 56 isolates: 85.71% Sulfisoxazole(G), 82.14% gentamycin(GM), 78.57%
Chloramphenicol(C), 58.9% aztreonam(ATM) 53.6% Ciprofloxacin(CIP), 51.8%
ceftazidime(CAZ), 42.86% doxycycline(D) and 32.1% azithromycin(AZM)(Table 7.4).
Tigecycliness (TGC) and impinem (IMP) were the most susceptible antibiotics.
Table 7.4: Antibiograms Generated from Clinical Isolates
Antimicrob
ial Agents
AZM AT
M
CAZ CIP IMP TGC C D G GM K SAM
Total 56 56 56 56 56 56 56 56 56 56 56 56
Mean disk
Diffusion
(mm)
16.5 17.9 18.2 14.2 24.0 19.8 10.0 11.4 6.3 10.6 16.1 11.8
±SD 6.1 6.1 4.9 7.2 3.3 2.2 7.32 3.72 2.41 5.99 4.0 3.58
Resistance
(%)
32.1 58.9 51.8 53.6 7.1 0.0 78.6 42.9 85.7 82.1 28.6 57.1
Intermediate
(%)
16.1 16.1 21.4 26.8 28.6 30.4 1.79 26.79 0.0 1.79 44.64 32.1
Susceptible
(%)
51.8 25.0 26.8 19.6 64.3 69.6 19.64 30.36 1.79 16.07 26.79 10.7
AZM:azithromycin, ATM:aztreonam, CAZ:ceftazidime, CIP: Ciprofloxacin, TGC:Tigecycline, IMP:impinem,
C:chloramphenicol, D:Doxycycline, G:Sulfisoxazole, GM:Gentamycin, K:Kanamycin, SAM:
ampicillin/Sulbactam.
Molecularly, the following resistant genes were detected: quinolone resistant gene (QNR),
C2, tet-X; blaOXA-51-like, blaOXA-58, blaDIM-1 and blaVIM carbapenemase genes.
7.4 DISCUSSION
The study population has high antibody levels for Salmonella enterica serotype Typhi with
almost 60% having ≥120 titers of anti-O and anti-H antibodies. High antibody levels are
associated with less reliability for the Widal test18 especially when the levels do not
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correspond to concomitant microbial detections by other assays such as culture. The high
antibody levels in this study do not correspond with the detections of Salmonella enterica
serotype Typhi pathogens and could be due to cross-reacting antigens. There exist up to 40
cross-reacting antigens between Salmonella enterica serotype Typhi and other
enterobacteriaceae33, in addition, cross-reacting antigens could also be from malaria,
brucellosis, dengue fever, chronic liver disease or endocarditis34.
The result also shows that multiple etiologic agents are responsible for undifferentiated fever
in Bo, Sierra Leone. The bacterial pathogens detected in this study probably constitute a
fraction of all bacteria that routinely infect people in Bo Sierra Leone. Since presumptive
treatment is common in this location20 both at the healthcare centers and at home to deal with
undifferentiated fevers, there is a possibility that even though pathogens are unknown they
could be treated  by the use of broad-spectrum antibiotics such as ciprofloxacin in the study
location. However, the existence of resistance to ciprofloxacin (53.6%) which is usually a
drug of choice is a grave concern. Also the observed resistance and resistant genes such as
QNR, C2, tet-X; blaOXA-51-like, blaOXA-58, blaDIM-1 and blaVIM carbapenemase genes,
mean that not all infections can be treated timely without combination therapy with multiple
antibiotics.
Further, the detections of pathogens Schistosoma spp. Trichuris trichiura and Wuchereria
bancrofti which cause neglected tropical diseases  is of importance, as over three rounds of
mass drug administration consisting a combination of Albendazole and Ivermectin have been
done in Sierra Leone to eliminate the transmission of helminths associated with NTDs35’36.
Thus, more MDAs could benefit the population to reduce transmission potential of NTDs
further.
And the detection of Yersinia pestis is an importrant public health finding, as it causes plague.
Plague, a murine zoonosis, is caused by Yersinia pestis, a gram-negative, non-motile, non-
sporulating, rod-shaped, bacterium of the Enterobacteriaceae family. The disease affects
humans, when they contact infected rodents, their respiratory secretions, or are bitten by
fleas. Humans can also get it through inhalation of aerosolized droplets from infected
persons, consumption of contaminated food or by laboratory exposure37–40.
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Clinically, plague occurs in three forms: bubonic plague, septicemic plague and pneumonic
plague41. Bubonic plague is characterized by fever, chills, weakness, headache and swellings
of lymph nodes or buboes commonly in the inguinal and groin femoral regions 39,41.
Septicemic plague   normally progresses from bubonic plague, but lacks buboes and
characterized by fever, gastrointestinal symptoms, such as nausea, vomiting, diarrhea and
abdominal pain; hypotension, disseminated intravascular coagulation, and multiorgan failure
develop in the later stages of the illness42. Pneumonic plague is characterized by sudden onset
of dyspnea, high fever, pleuritic chest pain, and cough that may be accompanied by
characteristic bloody sputum. Primary pneumonic plague is rapidly fatal unless an
appropriate antimicrobial agent is begun within the first day of illness42.
Similarly, Burkholderia pseudomallei, which was detected is believed to cause melioidosis
which kills between 20-50% of positive cases.43 Melioidosis is rare in Africa, but was
reported in a Sierra Leonean based in Gambia in 198544, the disease is common in Southeast
Asia and northern Australia45.
7.5 CONCLUSIONS
Bacterial, viral, protozoan and helminthes are among frequent etiologic agents that cause
undifferentiated fever in Bo, Sierra Leone. Among the bacteria, Salmonella enterica serotype
Typhi is of importance as the population antibody levels has risen such that about three-fifth
of the study population had up to 1:120 titers of both Anti-O and Anti-H antibodies. A new
cut-off point for the Widal Test above 1:120 is recommended to prevent over prescription of
antibiotics for cases not related to typhoid, however the new cut-off point should be
determined by additional studies to determine the sensitivity and specificity of widal at
different titre values.
Combination therapy with antibiotics should be emphasized, and the inclusion of tigecycline
and imipenem in the combination therapy should be encouraged since they have lower
resistance to them from bacterial pathogens in this study. However, the existence of QNR
genes and  carbapenemase resistance genes suggests that more resistance should be expected
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in the near future, something that can be averted by discouraging over-the-counter purchase
or prescription drugs without medical advice.
7.6 REFERENCES
1. Bartfai T, Conti B. Fever. ScientificWorldJournal 2010;10:490–503.
2. Mackowiak PA. Fever: blessing or curse? A unifying hypothesis. Ann Intern Med
1994;120:1037–40.
3. Ogoina D. Fever, fever patterns and diseases called “fever” - A review. J. Infect.
Public Health. 2011;4:108–24.
4. Mackowiak PA. What we do when we suppress fever. Curr. Infect. Dis. Rep.
2005;7:1–4.
5. Cannon JG. Perspective on fever: The basic science and conventional medicine.
Complement. Ther. Med. 2013;21.
6. Mamo Y, Belachew T, Abebe W, Gebre-Selassie S, Jira C. Pattern of widal
agglutination reaction in apparently healthy population of Jimma town, southwest Ethiopia.
Ethiop Med J 2007;45:69–77.
7. Feasey NA, Dougan G, Kingsley RA, Heyderman RS, Gordon MA. Invasive non-
typhoidal salmonella disease: An emerging and neglected tropical disease in Africa. Lancet.
2012;379:2489–99.
8. Leski TA, Ansumana R, Malanoski AP, et al. Leapfrog diagnostics: Demonstration
of a broad spectrum pathogen identification platform in a resource-limited setting. Heal. Res.
Policy Syst. 2012;10:22.
9. Parry CM, Wijedoru L, Arjyal A, Baker S. The utility of diagnostic tests for enteric
fever in endemic locations. Expert Rev Anti Infect Ther 2011;9:711–25.
138
10. Kingsley RA, Msefula CL, Thomson NR, et al. Epidemic multiple drug resistant
Salmonella Typhimurium causing invasive disease in sub-Saharan Africa have a distinct
genotype. Genome Res 2009;19:2279–87.
11. Von Nguyen D, Sreenivasan N, Lam E, et al. Cholera epidemic associated with
consumption of unsafe drinking water and street-vended water-Eastern Freetown, Sierra
Leone, 2012. Am J Trop Med Hyg 2014;90:518–23.
12. Dyer O. Cholera epidemic threatens Sierra Leone. BMJ. 1995;311:77.
13. WHO. Cholera in Sierra Leone - update [Internet]. Glob. Alert Response. 2012;
Available from: http://www.who.int/csr/don/2012_09_18b/en/index.html
14. Homolka S, Post E, Oberhauser B, et al. High genetic diversity among
Mycobacterium tuberculosis complex strains from Sierra Leone. BMC Microbiol
2008;8:103.
15. Prakash P, Mishra OP, Singh AK, Gulati AK, Nath G. Evaluation of nested PCR in
diagnosis of typhoid fever. J Clin Microbiol 2005;43(1):431–2.
16. WHO. Background document: the diagnosis, treatment and prevention of typhoid
fever.Vaccines and Biologicals. 2002.
17. Olopoenia LA, King AL. Widal agglutination test - 100 years later: still plagued by
controversy. Postgrad Med J 2000;76:80–4.
18. Clegg A, Passey M, Omena M, Karigifa K, Suve N. Re-evaluation of the Widal
agglutination test in response to the changing pattern of typhoid fever in the highlands of
Papua New Guinea. Acta Trop 1994;57:255–63.
19. Onuigbo MAC. Diagnosis of typhoid fever in Nigeria: Misuse of the Widal test. Trans
R Soc Trop Med Hyg 1990;84:129–31.
20. Ansumana R, Jacobsen KH, Gbakima AA, et al. Presumptive self-diagnosis of
malaria and other febrile illnesses in Sierra Leone. Pan Afr Med J [Internet] 2013;15:34.
139
Available from:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3758859&tool=pmcentrez&ren
dertype=abstract
21. Kariuki S, Revathi G, Kariuki N, et al. Increasing prevalence of multidrug-resistant
non-typhoidal salmonellae, Kenya, 1994-2003. Int J Antimicrob Agents 2005;25:38–43.
22. Parry CM, Threlfall EJ. Antimicrobial resistance in typhoidal and nontyphoidal
salmonellae. Curr Opin Infect Dis 2008;21:531–8.
23. Kaur J. Increasing antimicrobial resistance and narrowing therapeutics in typhoidal
Salmonellae. J. Clin. Diagnostic Res. 2013;7:576–9.
24. Leski TA, Bangura U, Jimmy DH, et al. Multidrug-resistant tet(X)-containing
hospital isolates in Sierra Leone. Int J Antimicrob Agents 2013;42:83–6.
25. Leski T a, Bangura U, Jimmy DH, et al. Identification of blaOXA-51-like, blaOXA-
58, blaDIM-1 and blaVIM Carbapenemase Genes in Hospital Enterobacteriaceae Isolates
from Sierra Leone. J Clin Microbiol [Internet] 2013;51:2435–8. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/23658259
26. Herrera S, Vallejo AF, Quintero JP, Arévalo-Herrera M, Cancino M, Ferro S. Field
evaluation of an automated RDT reader and data management device for Plasmodium
falciparum/Plasmodium vivax malaria in endemic areas of Colombia. Malar J [Internet] 2014
[cited 2014 Sep 25];13:87. Available from:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3995821&tool=pmcentrez&ren
dertype=abstract
27. Shekalaghe S, Cancino M, Mavere C, et al. Clinical performance of an automated
reader in interpreting malaria rapid diagnostic tests in Tanzania. Malar J [Internet]
2013;12:141. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/23617722\nhttp://www.biomedcentral.com/content/p
df/1475-2875-12-141.pdf
140
28. Trombley C, Anderson JD. SIGNAL blood culture system for detection of bacteremia
in neonates. J Clin Microbiol 1987;25:2098–101.
29. Tayeb LA, Lefevre M, Passet V, Diancourt L, Brisse S, Grimont PAD. Comparative
phylogenies of Burkholderia, Ralstonia, Comamonas, Brevundimonas and related organisms
derived from rpoB, gyrB and rrs gene sequences. Res Microbiol 2008;159:169–77.
30. Wang Q, Garrity GM, Tiedje JM, Cole JR. Naïve Bayesian classifier for rapid
assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol
2007;73:5261–7.
31. Altun O, Almuhayawi M, Ullberg M, Ozenci V. Clinical evaluation of the FilmArray
blood culture identification panel in identification of bacteria and yeasts from positive blood
culture bottles. J Clin Microbiol [Internet] 2013;51:4130–6. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/24088863
32. Seiner DR, Colburn HA, Baird C, et al. Evaluation of the FilmArray® system for
detection of Bacillus anthracis, Francisella tularensis and Yersinia pestis. J Appl Microbiol
[Internet] 2013 [cited 2014 Nov 24];114(4):992–1000. Available from:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3617465&tool=pmcentrez&ren
dertype=abstract
33. Parry CM, Hoa NT, Diep TS, Wain J, Chinh NT, Vinh H HT, White NJ FJ. Value of
a single-tube widal test in the diagnosis of typhoid fever in Vietnam. J Clin Microbiol
1999;37:2882–6.
34. Colle JG, Frason AG, Marmion BP SAM and MC. Practical Medical Microboiology.
New York: Churchill Livingston; 1996.
35. Hodges MH, Smith SJ, Fussum D, et al. High coverage of mass drug administration
for lymphatic filariasis in rural and non-rural settings in the Western Area, Sierra Leone.
Parasit Vectors [Internet] 2010 [cited 2014 Dec 3];3:120. Available from:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3018440&tool=pmcentrez&ren
dertype=abstract
141
36. Koroma JB, Sesay S, Sonnie M, et al. Impact of three rounds of mass drug
administration on lymphatic filariasis in areas previously treated for onchocerciasis in Sierra
Leone. PLoS Negl Trop Dis [Internet] 2013 [cited 2014 Dec 3];7(6):e2273. Available from:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3681681&tool=pmcentrez&ren
dertype=abstract
37. Prentice MB, Rahalison L. Plague. Lancet. 2007;369:1196–207.
38. Rollins SE, Rollins SM, Ryan ET. Yersinia pestis and the plague. Am. J. Clin.
Pathol. 2003;119 Suppl.
39. Butler T. Plague into the 21st century. Clin Infect Dis 2009;49:736–42.
40. Raoult D, Mouffok N, Bitam I, Piarroux R, Drancourt M. Plague: History and
contemporary analysis. J Infect 2013;66:18–26.
41. Rollins SE, Rollins SM, Ryan ET. Yersinia pestis and the plague. Am J Clin Pathol
2003;119 Suppl:S78–85.
42. USAMRIID. Medical Management of Biological Casualties Handbook. 7th ed. Fort
Detrick, Maryland: 2011.
43. Wuthiekanun V, Peacock SJ. Management of melioidosis. Expert Rev Anti Infect
Ther 2006;4(3):445–55.
44. Birnie E, Wiersinga WJ, Limmathurotsakul D, Grobusch MP. Melioidosis in Africa:
should we be looking more closely? Future Microbiol [Internet] 2015;10(2):273–81.
Available from: http://www.futuremedicine.com/doi/abs/10.2217/fmb.14.113
45. CDC. Melioidosis [Internet]. [cited 2015 May 31];Available from:
http://www.cdc.gov/melioidosis/
142
CHAPTER EIGHT
8.0 SUMMARY, CONCLUSIONS AND RECOMMENDATIONS
This section summarises and concludes the findings of the study. The study looked at a tiered
laboratory analyses of common infections to characterise febrile morbidity not related to
malaria in Sierra Leone. The results have been presented in six preceding chapters
encompassing different non-malarial febrile morbidity in Sierra Leone. An overall summary
and conclusion is outlined in the next section, followed by strengths and limitations of the
study and recommendations based on study results.
8.1 SUMMARY AND CONCLUSIONS
There was an average monthly, febrile illness of 160.25 SD±10.63 for the twelve months of
cohort study, with a significant difference in monthly febrile cases (P<0.001). The ages 5 to
14 years had an average of 25.83±7.85 cases per month. Those within 15 to 29 years had
average monthly cases of 48.83±6.7. Ages 30 to 44 had 41.66±4.2 while the age group ≥45
years had monthly cases of 43.91±6.7.
Results of this study showed that malaria accounts for less than 50% of febrile illnesses
investigated in the study location, but about 60% of participants in the study self-diagnosed
and self-treated malaria a month prior to the study. The high rate of self-diagnoses is of
concern, since treatment decisions that follow could be wrong, delaying recovery, increasing
disease burden with a possibility of nurturing antimicrobial resistance. Among the
medications used were herbs with unspecified dosages1. While herbs could treat certain
diseases, they also have the propensity to delay treatment outcomes or cause severe
complications from the toxicity of the herbs.
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Common non-malaria febrile illnesses in Bo, Sierra Leone include: Chikungunya which
accounts for over 40% of febrile disease morbidity in Bo but exists mainly in a transient form
with  symptoms such as arthralgia, chills, headaches and back pains, with the latter persisting
in affected patients2. Having an incidence or person-time rate of 573.7 per 1000 people per
year at a 95% confidence interval, the incidence of Chikungunya is higher than that of malaria
in this malaria endemic region. In a related study in Kenema which is 40km away from Bo
Town, Boissen et al3 reported 35%(27/77) prevalence of Chikungunya in suspected Lassa
Fever cases, indicating that ChikV is not only in Bo, but elsewhere in Sierra Leone.
Another common non-malaria febrile morbidity is viral hepatitis which was detected in this
study. Per month, an average of 10.4±1.9SD Hepatitis B and 5.5±2.5SD Hepatitis C were
recorded in Bo, Sierra Leone. With about 10% prevalence of hepatitis B and 5% prevalence
of hepatitis C. The viral hepatitis morbidity seems grim as treatment options are limited
within Sierra Leone. Available drugs are either expensive or hard to get. There is about 9%
IgG seroprevalence of viral hepatitis A, but this study did not detect any current infection of
HAV. It is possible that sampling at a different time could yield a high prevalence.
Furthermore, this study revealed a high seroprevalence of Salmonella typhi, about 60%
having ≥ 1:120 titres of typhi ‘O’ or ‘H’. However actual incidence of typhoid infection,
diagnosed by microbiological testing was lower at about 2% per year. The disparity between
the Widal test and the culture and API identification methods indicate that, the antibody
levels of Salmonella has increased in the Bo community. The increase may have resulted
from previous infections of Salmonella typhi. Not all widal positive cases are actually having
typhoid fever. This necessitates the revision of the widal titre levels accepted as positive
reading, since widal tests are predominantly used in Sierra Leone to test for typhoid fever.
To determine a new widal cut-off point, sensitivity and specificity of widal tests at different
titre levels should be determined.
HIV, which is still dreaded, is an important part of the non-malaria febrile morbidity in Bo,
Sierra Leone. The prevalence of HIV was about 9%; three-fifth of the cases were females
and overall about 11% were co-infected with Hepatitis B, while 3 % were having syphilis.
HIV patients assessed had a median Hb value of 10.90g/dl and 18.75% of  critically low
hematocrit values (≤27%PCV). The high prevalence of HIV in Bo is consistent with previous
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reports from the city. Kellie(2007)[unpublished dissertation]4 reported a prevalence of 8%
and other independent studies have been within the same range5,6.
Several other infections were also detected including Human Rhinoviruses(24%) corona
viruses(19%), E. coli 17%, Ascaris lumbricoides infections(19%), Citrobacter freundii
(12%), Klebsiella pneumonia (12%), 11%  hookworm infections, 10% Streptococcus
pneumonia, 9% Enterobacter cloacae, 8% Haemophilus influenza, 8% Influenza B, 6%
Schistosoma mansonia, 6% Chlamydophila  pneumonia and other infections. Worthy of
mention among the other infections are 16 cases of Yersinia pestis which causes bubonic
plague and 66 cases of Burkholderia pseudomallei which causes melioidosis. Melioidosis is
rare in Africa, but was reported in a Sierra Leonean based in Gambia in 19857. Thus Bo city
is home to diversity of infections.
Syndromic definitions of febrile illnesses in this location cannot be used as a proxy of actual
laboratory diagnosis because syndromes are not specific. Treatments based solely on
syndromes is therefore presumptive or assumptive. To avoid assumptive treatments, point of
care or point-of-need testing need to be adopted for malaria, where febrile subjects are first
tested in their remote locations by themselves or by community volunteers within their
communities.
Roukens and colleagues, demonstrated the possibility of malaria-self test and reported 3 %(
18/575) invalid results from self-test run by oil expatriates and compliance was higher with
instructions.
In Bo, Sierra Leone, Ranasinghe and colleagues1 reported preferences of malaria testing in
Bo with 69% rural residents, preferred a self/family- or CHV-conducted home-based malaria
test and 20% a laboratory-based test while urban residents preferred 38% and 44%,
respectively. If offered a home-based test, 28% of rural residents would prefer a self/family-
conducted test and 68% would prefer a CHV-assisted test1.
8.2 STRENGTHS AND LIMITATIONS OF THE STUDY
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This study has a key limitation of been too broad. Consequently, the scope of the
investigations of individual pathogens was limited. Some pathogens have unique methods
for investigating them, rather than the methods designed by this study, so it was impossible
to deeply carry out analyses of each pathogen investigated at an individual level.
Secondarily cost limitations prevented carrying out initial baseline screening of all subjects
thereby limiting the ability to determine incidence of diseases that exist as chronic infections
even though tests targeted febrile subjects within 72 hours of becoming febrile.
Furthermore, usage of subjects to self-diagnosis and presumptively treat themselves affected
effectiveness of the crowdsourcing system, such that subjects reported fever when the felt
they needed to rather than on onset.
Despite having good infrastructure for sample analyses, the lab was under biosafety level 3
and therefore unfit to probe further into certain cases such as Lassa, and Ebola and Yersinia
pestis. So the one Lassa case that was detected was sent to the Kenema Lassa Lab for testing.
Yersinia pestis which can best be confirmed by microbial culture and isolation of the
bacterium was only confirmed molecularly for fear of aerosolizing the pathogen from
cultures.
On the other hand, this study has many firsts in Sierra Leone. It is the first to report the re-
emergence of Chikungunya in Sierra Leone8. Chikungunya has certain symptoms that
persons with malaria could have. Symptoms such as fever, arthralgia and weakness are
presumptively associated with malaria within the study community. It was surprising to have
a disease with higher prevalence than malaria with the listed symptoms in the study
community.
This study also detected 16 Yersinia pestis Fraction-1(F1) antigens in febrile subjects in Bo,
Sierra Leone and 66 manno-heptose capsular polysaccharide (CPS) antigens for
Burkholderia pseudomallei which are the causative agents of bubonic plague and
melioidoses respectively. F1 is a capsule-like antigen encoded by the caf1 gene located on
the large 100-kb pFra plasmid, which is unique to Y. pestis9.   The positive samples were
clinically consistent with YP infection and a positive PCR confirmation was obtained by the
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multiplex PCR on BT Panel of the FilmArray Platform (Biofire Diagnostics, Salt Lakes City,
US).   Even though there was no outbreak of bubonic plague, such a finding is of importance
to the public health of Bo, Sierra Leone. Similarly, Burkholderia pseudomallei is believed to
cause melioidiosis which kills between 20-50% of positive cases10 but is common in
Southeast Asia and northern Australia11. Both infections are zoonotic infections, even though
Burkholderia could also be obtained from the environment, demonstrating clearly that the
closed proximity between animals and humans in Bo, Sierra Leone, coupled with poor
environmental sanitation, facilitates ease of transmission of infectious diseases.
Additionally, the resources used in this study became useful to protect healthcare workers
during the Ebola outbreak in Sierra Leone. In the study hospital, healthcare workers were
routinely screened for Ebola using the BT Panel of the FilmArray, whenever they became
febrile and one case who became positive treating a relative, was detected before he became
symptomatic, thereby saving lives including mine12. The scope of the study also made it
possible to contribute to science from a position of strength as demonstrated in the
correspondences on point of care tests in the Lancet Infectious Diseases13, Ebola in the
Lancet14 and New England Journal of Medicine15
8.3 RECOMMENDATIONS
It is recommended that point of care tests be made accessible in remote locations to facilitate
ease of testing and dissuade from presumptive diagnosis. Since clinicians could easily make
misdiagnosis because of overlapping symptoms of diseases in this location, it becomes much
more difficult for a non-clinician to make accurate presumptive diagnosis, but POCT can at
least exclude diseases such as malaria and also inspire laboratory testing.
Regulating purchase of drugs is highly recommended. Drugs should not be bought without a
prescription form. Pharmacies that sell drugs without prescription should be fined or closed.
Government should stock cost-recovery drugstores with more drugs to encourage more
people to buy there, since they sell based on prescription only.
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Widal test should be urgently revised based on evidence from sensitivity and specificity tests
done at different titre les Bureau. This is because the population antibody level has risen for
Salmonella typhi ‘O’ and ‘H’ making the widal test less specific and seemingly dangerous
as it facilitates prescription of antibiotics for typhoid fever, which, if done wrongfully, may
increase the tendency for antimicrobial resistance, which is a developing crisis in Sierra
Leone.
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Appendix 7: Informed Consent Forms
CENTRE FOR NEGLECTED TROPICAL DISEASES - Liverpool School of Tropical Medicine
STUDY: Tiered laboratory analysis for common infections to characterize febrile
morbidity not related to malaria in Sierra Leone.
Principal Investigator: Rashid Ansumana
This is a research study. Research studies include only individuals who choose to take part.
Please take your time to make your decision. Discuss it with your friends and family.
You and the members of your household are being asked to take part in this study because you
are in the neigbourhood of Mercy Hospital and also because you or members of your household
may be at risk for or may have non-malarial febrile illnesses.
WHY IS THIS STUDY BEING DONE?
The purpose of this study is to find out the incidence and distribution of non-malarial febrile
infections in Bo, Sierra Leone, using tiered laboratory analyses of blood samples from
outpatients that are having fever.
This research is being done to better understand how we can prevent infection and illness from
agents of nonmalarial febrile illnesses in Sierra Leone and other areas of the world where these
diseases are common.
HOW MANY PEOPLE WILL TAKE PART IN THE STUDY?
About 1180 persons over 4 years from the neighbourhood of Mercy Hospital will participate in
this study for blood sampling. All household heads, (about 1,027) within the neighbourhood of
Mercy Hospital shall be interviewed.
WHAT IS INVOLVED IN THE STUDY?
Initially, a community survey will be done in your town section in order to obtain baseline health
information about your community and to assess the occurrences of non-malarial febrile
infections in your community. We will ask your permission to collect information on your
property’s location, and other questions pertaining to health and well-being. You will also be
requested to send a text message about any febrile occurrence in your household to mobile
numbers: 033-410477/076-683832
When you visit the Mercy Hospital with a febrile illness during the sampling period, you will
be labeled and about 2-9mls of blood sample will be requested from you. Additionally, urine
sample, stool sample or nasal swabs may be requested from you. The draw of blood may involve
piercing your skin with a needle stick to obtain the blood and using pharyngeal swabs may be
slightly itchy.
After we obtain the information that will allow us to determine non-malarial febrile infection
and distribution, we will give this information to you and will provide treatment to those that
are having non-malarial febrile illnesses who demonstrate inability to afford treatment for
themselves.
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HOW LONG WILL I BE IN THE STUDY?
This study will take up to one year starting in July 2012 and will continue up to July 2013.
You or your family members can decide to stop participating at any time.  However, if you
decide to stop participating in the study, we encourage you to talk to the study PI first.
WHAT ARE THE RISKS OF THE STUDY?
The risk of this study is minimal. About 2-9mls of blood shall be obtained from your veins and
urine sample, stool sample or nasal swabs may be requested from you. The needle stick may
hurt. There is a small risk of bruising, and a rare risk of infection. Also using pharyngeal swabs
may be slightly itchy.
ARE THERE BENEFITS TO TAKING PART IN THE STUDY?
Your participation in this study will help to inform the appropriate persons about the incidence,
cause, different types and distribution of non-malarial febrile illnesses in your community.  This
may help prevent infections in other members of your community and family and will also
provide a guide for other communities in a similar setting.
WHAT ABOUT CONFIDENTIALITY?
Your participation in the study is confidential and your identification is anonymised. No
personal information will be released to any third party unless we are required to do so by law.
WHAT ARE THE COSTS?
Taking part in the household survey and hospital sampling are of no cost to any household
member. There shall be a compensation for text messages sent to inform about febrile conditions
in the form of talk-time credits.  In the case of injury or illness resulting from this study,
emergency medical treatment shall be available at the study Hospital.  320 mg ferrous sulfate
or equivalent for use, three times a day for one month will be available for subjects that are
anaemic.
WHAT ARE MY RIGHTS AS A PARTICIPANT?
Taking part in this study is voluntary. You may choose to remove your home from the study at
any time.  Leaving the study will not result in any penalty.  However, if you decide to stop
participating in the study, we encourage you to talk to the study PI first.
HOW WILL I KNOW THE RESULTS OF THE STUDY?
We will tell you/your household members about new information that may affect your health,
welfare, or willingness to stay in this study.
WHOM DO I CALL IF I HAVE QUESTIONS OR PROBLEMS?
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For questions about the study or a research-related injury, contact: Rashid Ansumana
(+23233-410477/+23276-683832) or Edries Tejan (+23233-313375) at Mercy Hospital and
Research Laboratory, Kulanda Town Bo; or  the Sierra Leone Ethics and Scientific Review
Committee (+23276463696) at the Directorate of Training, Non-Communicable Diseases and
Research, Connaught Hospital, Freetown.
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CONSENT OF HEAD OF HOUSEHOLD.
You must be an adult (age 18 or older) to answer the survey questions and head of
household to consent here for participation in the survey. Your wards must also be aged
5 or older to be a subject for sampling in the hospital when they have fever. You must
be a mother, father or guardian to grant assent for minors.  If you agree to participate or
your ward to participate in the entire study including responding to the questionnaire,
providing blood, urine, stool samples or pharyngeal swabs and sending text messages
about fever in your household please sign below:
Name (printed) Signature or thumbprint
Date
_____________________________________________
ASSENT OF HOUSEHOLD MEMBERS
Name (printed) Signature or thumbprint
Date
_____________________________________________
Name (printed) Signature or thumbprint
Date
_____________________________________________
Name (printed) Signature or thumbprint
Date
_____________________________________________
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ASSENT OF HOUSEHOLD MEMBERS (SUPPLEMENTARY)
Name of Minor (if applicable)                            Thumbprint                                         Date
Name of Minor (if applicable)                            Thumbprint Date
Name of Minor (if applicable)                            Thumbprint                                         Date
Name of Minor (if applicable)                            Thumbprint Date
Name of Minor (if applicable)                            Thumbprint                                         Date
Name of Minor (if applicable)                             Thumbprint                                         Date
_____________________________________________________________________
___
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KRIO VERSION OF INFORMED CONSENT
Stɔdi: Fɛnɔt wok bɔt dɛn kɔmɔn wam bɔdi sik we nɔ mix wit
maleria we kin kil pipul dɛm na salon
Di Men Pɔsin We De Du De Fɛnɔt: Rashid Ansumana
Dis na fɛnɔt wok. Fɛnot wok jis gɛt pipul dɛm we want fɔ do di wok. Duya tek yu tɛm fɔ disaid.
Tɔkam wit you padi dɛm ɛn yu fambul dɛm.
Yu ɛn dɛn wan dɛm we tap na yu os fɔ de pan dis wok bikɔs una de nia Maci Ɔspitul ɛn i
pɔsibul se una go kech dɛn wam bɔdi sik we nɔ mix wit maleria
Wetindu Dis Wok De Bi?
Dis wok na fɔ fɛnɔt aw dɛn sik  we de mek yu bɔdi wam we nɔ mix wit maleria de kech pipul
dɛn na Bo, insai salon, ɛn na blɔd sampul wi de yus from pipul dɛm we nɔ admit yet fɔ dɛn sik
dɛm. Dis fenɔt wok nafɔ mek wi no gud gud wan aw fɔ tap dɛn wam bɔdi sik dɛm  we nɔ mix
wit maleria from ɛni sai we wi kin get dɛm na salon ɛn ɔda sai dɛm nadiwɔl.
Ɔmɔs Pipul Dɛm Go De Pan Dis Wok?
Na bɔt wan tawzin, wan undrɛd ɛn eti(1180) pipul dɛm oba fo(4) yia we tap na di eria we Masi
Ɔspitul de, go de pan dis blɔd sampul wok. ɔl os edman dɛm (bot wan tawzin ɛn twɛnti sɛvin-
1027) pan dɛm pipul dɛm we tap na masi ɔspital eria go ansa quɛshɔn dɛm.
Wetin Dem De Pandis Wok?
Fɔs we go fɛnɔt na u eria fɔ no di wɛlbodi biznɛs bɔt aw dɛn wam bɔdi sik we nɔ mix wit
maleria de kech pipul dɛm de. We go beg padin fɔ no usai yu os de wit GPS ɛn sem we so, we
go ax bɔt welbodi biznes. Wi go ax yu iŊŋen fɔ sɛn tɛx bɔt ɛni wam bɔdi sik we no mix wit
maleria we de na yu eria, na dis number: 033-410477/076-683832.
Di tɛm we di blɔd sampul de keri on, if yu sik with wam bɔdi yu go Masi Ɔspitul, dɛn go ax fɔ
pul yu blɔd smɔl, lek nain mil(9mls). We go us nidul fɔ pul di blɔd. We wi dɔn fɛnɔt, wi go no
gud gud wan bɔt dɛn sik we nɔ mix wit maleria. We go tel yu ɛn wi go mɛn de wan dɛm we nɔ
ebul gɛt mɔni fɔ mɛn dɛnsɛf.
Aw Lɔnŋŋ Ago De Pan Dis Wok?
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Dis wok go de sote wan yia, bigin frɔm Januari, 2012 ɛn tap Disɛmba 2012. Yu ɔ yu fambul
dɛm kin disaid fɔ lɛf dis wok ɛni tɛm una want. But if yu want fɔ lɛf, duya mek lɛ di men pɔsin
we de du di fɛnɔt no se yu de lɛf.
Wetin Na Di Ɛngat Tin Dɛm Bɔt Dis Wok?
Di ɛngat tin dɛm nɔ bɔku. Na smɔl blɔd, bɔt nain mil(9mls)
nɔ mɔ wi de pul pan yu, na yu vɛn. Di nidul go at smɔl. Na smɔl pinch nɔmɔ dat go do pan yu
bɔdi ɛn yu no go ɛngat se yu go get ɛni sik.
Us Bɛtɛ Tin Dɛm De Pan Dis Wok?
Yu de wan pan dis wok go mek di big eleju dɛm no bɔt dɛn sik we de mek pɔsin ɛn bɔdi wam,
we nɔ to maleria na yu eria. Dis go ep tap dɛn kain sick dɛm na ɔda eria dɛm we fiba usai u de.
Aw Una De Kip Tin Dem Sikrit?
Wi go trai fɔ kip sikrit ɛnitin we na bɔt yu nɔmɔ, ɛn nobɔdi nɔ go no ɛnitin bɔt yu ɔ yu pipul
dɛm. ɛniwe, wi nɔ go tel yu se ɔltin go bi sikrit, bicɔs if di lɔ ax wi fɔ sho wetin we gɛt bɔt yu,
wi go duam.
Ɔmɔs Ibi Fɔ De Pan Dis Wok?
Nobɔdi no go pay wan sɛnt fɔ de pan dis wok. Smɔl kɔpɔ fɔ tɔp-ɔp go de fɔ dɛn tɛx mɛseg dɛm
we yu go sɛn bɔt dɛn wam bodi sik dɛm na yu ose. If yu wund ɔ sik fɔ seka dis wok, di ɔspitul
go mɛn yu kwik kwik wan. 320mg blɔd mɛrɛsin, tri tɛm fɔ de, fɔ wan mɔnt go de fɔ ɛnibɔdi we
in blɔd lo, wans yu de pan dis wok.
Wetin Na Mi Rait As Posin We De Pan Dis Wok?
Fɔ de pan dis wok nɔto baifɔs, na we yu lek. If yu want, yu kin pul yu fambul dɛm pan dis wok
ɛni tɛm ɛn yu nɔgo gɛt ɛni problɛm. Bɔt ɛni we, if yu disaid fɔ lɛf, du ya na fɔ tɛl di men pɔsin
fɔ dis fɛnɔt .
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Aw Ago No Wetin Kɔmɔt Pan Dis Fɛnɔt?
We go tɛl yu ɔ yu pipuldɛm bɔt niu tin dɛm we go gɛt fo du sɔmtin wit yu welbɔdi wan o yu
gri wan fo de pan dis wok.
Udat A Go Cɔl If A Wan Ax Sɔmtin Ɔ A Get Prɔblem?
Fɔ ax ɛni tin bɔt dis wok we dis fɛnɔt wok de bɔt, na fo si: Rashid Ansumana, Masi Ɔspitul,
fɛnɔt wok sai, Kulanda tɔn na Bo, yu kin kɔlam na +23233-410477/+23276-683832
Fɔ Mɛk Yu No.
Yu fɔ bi big pɔsin we ole tin(18) yia ɔ oba fɔ ansa de fɛnɔt kuɛshon dɛm ɛn yu fɔ ol faiv yia o
oba fɔ gi blɔd, ɛn  mama, papa ɔ yu we de mɛn pikin fɔ gri fɔ dɛn smɔl pikin dɛm fɔs. If yu gri
fɔ de pan dis wok o yu pikin duya sain bɔttɔm
Nem                                                          sain/tɔmbprint  Det
Nem fɔ smɔl piki                                        tɔmbprint  Det
(if dat de wok)
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Appendix 8: Clinical Addendum
CENTRE FOR NEGLECTED TROPICAL DISEASES - Liverpool School of Tropical
Medicine
STUDY: Tiered laboratory analysis for common infections to characterize febrile
morbidity not related to malaria in Sierra Leone.
Principal Investigator: Rashid Ansumana
A. HOW TO DETERMINE SUBJECTS THAT CANNOT AFFORD TO PAY
The method used at Mercy Hospital to determine those that cannot afford to pay include:
1. Subjects that are aged, impoverished; who present unwell, and cannot pay for their treatments
2. Subjects that have in previous months before the onset of the research, being unable to pay for
their treatments
3. Those subjects that lack all the money needed to purchase prescribed drugs at the pharmacy
4. Inpatients, that are subjects, without family to assist them during their admission and/ without
employment and without money to pay for their treatment costs.
B. MONETARY CEILING FOR TREATMENT OF DESTITUTE SUBJECTS
For outpatients at Mercy Hospital, about 13 destitute persons were treated in January 2012 and
none in February 2012. The average cost of treatment provided to destitute outpatients in January
was Le 29,000 (about 7 USD). For inpatients in January, 7 were present, the average cost was Le
96, 428 (22 USD). In February, there was no destitute outpatient or inpatient. Based on the
January data, the following monetary ceiling has been considered for destitute subjects in the
form of drugs that are prescribed and are available at the hospital.
1. A ceiling of 7 USD for outpatients that satisfy A. 1, 2 and 3 above
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2. A ceiling of 22 USD for inpatients that satisfy A. 1-4.
3. Monthly ceiling of 200 USD for both outpatients and inpatients.
Please note below that:
1.  While treatment is been provided for destitute subjects, only treatment that are stipulated above
will be provided.
2. The cost stipulated above is the ceiling. Outpatients and inpatients that cannot afford to pay
will be treated for less if that is what their condition demands.
C. SIGNATURE
The patient/authorized individual has read this form or had it read to him or her.
The patient/authorized individual states that he or she understands this information.
The patient/Authorized individual has no further questions.
Date_________________ Time_________________ Signature___________________
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Appendix 9: SYNDROMIC STUDY QUESTIONAIRE
Household Address:
_____________________________________________________________________________
Household ID:  ___________________
SOCIO-DEMOGRAPHIC INFORMATION
How many households (families) currently live in this house?  ____________
How many people currently live in this household (family)?  ______________
Only count people who spend at least half of the year at this residence.  Exclude students at
boarding school and adults who spend most of their time working in another town.
Personal
ID#
Relationship to Head
of Household
Sex
(M/F)
Age
(years)
Under-5
(U5) or
Mother
(M)?
01 Head of Household
02
03
04
05
06
07
08
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09
10
11
12
13
14
15
16
 Put a star (*) next to the person answering this survey. Use a continuation page if needed.
How many people (adult or child) who were living in this household one year ago (or born in the
past year) died in the past one year?  _________
Age
Sex
(M /
F)
Cause of Death
1
2
3
Use a continuation page if needed.
HOUSING AND UTILITIES
1.  What is the primary material used for the construction of the house?
□ Concrete block □ Mud and sticks □ Mud block □ other: ______________
2.  What is the primary material used for the roof of the house?
□ Zinc □ Thatch □ Tarpaulin □ other: ____________
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3.  What is the main floor material used in the house?
□ covered with floor tile□ Concrete floor □ Muddy floor □ Other: ______
4.  Does the house have electricity? □ Yes □ No
5. Do the beds in the household have mosquito nets? □ Yes □ No
6.  What is your primary source of water for drinking?
□ Well □ Stream / River □ Spring □ Standpipe / Piped water
□ Enclosed pump □ Bottled water / Pure water
7.  Does your household use the same source for drinking water and cooking water?
□ Yes □ No □ Not sure
8.  How close to your home is your source of drinking water?
□ <50 meters □ 50-150 meters □ 151-500 meters □ >500 meters
9. Do you have any trashcan in your household □ Yes □ No
10.  If yes, is it covered? □ Yes □ No
11.  What type of toilet facility is used by your household?
□ Bucket toilet □ Flush latrine □ Pit latrine
□ Uncovered pit□ other:
12.  If applicable, about how frequently do you empty your toilet? □ Not applicable
□ 1 time per day □ 1 time each month □ 1 time per year
□ 1 time every few years □ other:
__________________________________________
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13.  If applicable, who does the emptying of the toilet?
□ Household member □ Hired worker □ Other: _________________________
14. How many rooms in your house are used for sleeping?  _______
15.  How many people usually sleep in this house each night? _______
16.  In the past month, did you see any cockroach in your house? □ Yes □ No
17.  In the past month, did you see any rat in your house? □ Yes □ No
18. Do you have a pet in your house? □ Yes □ No
19 What type of animal(s) do you have as a
pet?__________________________________________
HOUSEHOLD FEBRILE INFORMATION
20. Has anyone currently living in this household had malaria in the past one month?
□ No □ Yes □ Not sure
21. If yes, was the person(s) diagnosed in a hospital? □ No □ Yes
22. If more than one person in this household had malaria, state:
Number tested in a lab___________________ Number not
tested____________________________
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23. Has anyone currently living in this household ever had fever in this year?
□ Yes □ No
24. If yes, how many times did the household member have fever in the past months of this year?
Member ID_________________ No of Fever in this year_______________ Approx. time of fever:
□ 1 Month or Less □ 2 months or Less □ 3 months or Less □ Over 4 months
Member ID_________________ No of Fever in this year_______________ Approx. times of fever:
□ 1 Month or Less □ 2 months or Less □ 3 months or Less □ Over 4 months
Member ID_________________ No of Fever in this year_______________ Approx. times of fever:
□ 1 Month or Less □ 2 months or Less □ 3 months or Less □ Over 4 months
Member ID_________________ No of Fever in this year_______________ Approx. times of fever:
□ 1 Month or Less □ 2 months or Less □ 3 months or Less □ Over 4 months
Member ID_________________ No of Fever in this year_______________ Approx. times of fever:
□ 1 Month or Less □ 2 months or Less □ 3 months or Less □ Over 4 months
Member ID_________________ No of Fever in this year_______________ Approx. times of fever:
□ 1 Month or Less □ 2 months or Less □ 3 months or Less □ Over 4 months
Member ID_________________ No of Fever in this year_______________ Approx. times of fever:
□ 1 Month or Less □ 2 months or Less □ 3 months or Less □ Over 4 months
Member ID_________________ No of Fever in this year_______________ Approx. times of fever:
□ 1 Month or Less □ 2 months or Less □ 3 months or Less □ Over 4 months
Member ID_________________ No of Fever in this year_______________ Approx. times of fever:
□ 1 Month or Less □ 2 months or Less □ 3 months or Less □ Over 4 months
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Member ID_________________ No of Fever in this year_______________ Approx. times of fever:
□ 1 Month or Less □ 2 months or Less □ 3 months or Less □ Over 4 months
Member ID_________________ No of Fever in this year_______________ Approx. times of fever:
□ 1 Month or Less □ 2 months or Less □ 3 months or Less □ Over 4 months
Member ID_________________ No of Fever in this year_______________ Approx. times of fever:
□ 1 Month or Less □ 2 months or Less □ 3 months or Less □ Over 4 months
Member ID_________________ No of Fever in this year_______________ Approx. times of fever:
□ 1 Month or Less □ 2 months or Less □ 3 months or Less □ Over 4 months
Member ID_________________ No of Fever in this year_______________ Approx. times of fever:
□ 1 Month or Less □ 2 months or Less □ 3 months or Less □ Over 4 months
Member ID_________________ No of Fever in this year_______________ Approx. times of fever:
□ 1 Month or Less □ 2 months or Less □ 3 months or Less □ Over 4 months
Member ID_________________ No of Fever in this year_______________ Approx. times of fever:
□ 1 Month or Less □ 2 months or Less □ 3 months or Less □ Over 4 months
26. Was the fever without any localized source of infection? □ No □ Yes
27. Was the fever of 14 days or less in duration? □ No □ Yes
28. Was the fever, with a symptom or sign? □ No □ Yes
29.  Was it (a fever–arthralgia?), a fever and tenderness over three or more joint areas? □ No
□ Yes
30. Was it a fever (fever–myalgia syndrome?): fever with body ache or headache?
□ No □ Yes
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31. Was it a fever with altered behaviour? □ No □ Yes
32. Was it a fever with jaundice? □ No □ Yes
33. Was any test done to find out the cause of the fever? □ No □ Yes
34. If yes, what was the cause of the fever?____________________________________________
35. If no, was clinical examination done? □ No □ Yes
36. Did the household member regain his/her health? □ No □ Yes
37. Has anyone currently living in this household ever had any of the following conditions?
Hepatitis B □ No □ Yes □ Not sure
Hepatitis C □ No □ Yes □ Not sure
Typhoid Fever □ No □ Yes □ Not sure
Lassa Fever □ No □ Yes □ Not sure
Yellow Fever □ No □ Yes □ Not sure
Pneumonia □ No □ Yes □ Not sure
Influenza □ No □ Yes □ Not sure
Common Cold □ No □ Yes □ Not sure
Asthma □ No □ Yes □ Not sure
TB □ No □ Yes □ Not sure
Rift valley fever □ No □ Yes □ Not sure
Crimean-Congo hemorrhagic fever □ No □ Yes □ Not sure
Dengue fever □ No □ Yes □ Not sure
Bacterial meningitis □ No □ Yes □ Not sure
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Others
Specify_________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
___________
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Abstract
Introduction: The objective of this study was to evaluate the prevalence of self-diagnosis of malaria and other febrile illnesses in Bo, Sierra
Leone. Methods: All households in two neighboring sections of Bo were invited to participate in a cross-sectional survey. Results: A total of 882
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the household considered to be malaria in the past month, only 41% were diagnosed by a healthcare professional or a laboratory test. Of the
1402 individuals reported to have had any type of febrile illness within the past six months, only 34% had sought a clinical or laboratory diagnosis. Self-
diagnosis of influenza, yellow fever, typhoid, and pneumonia was also common. Conclusion: Self-diagnosis and presumptive treatment with antimalarial
drugs and other antibiotic medications that are readily available without a prescription may compromise health outcomes for febrile adults and children.
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Introduction
The overuse or inappropriate use of antimalarial medications and
antibiotics is a growing concern in many parts of the  world,
including Sierra Leone, a post-conflict country in West Africa. In Sierra
Leone, these drugs are dispensed by government-run clinics and
hospitals, private healthcare facilities, licensed pharmacies, and through
the informal sector [1]. Because medications are readily available
without   a prescription,   people   with self-diagnosed infections can
access treatments without first  seeking a formal clinical consultation
and/or laboratory-confirmed diagnosis. A survey conducted in April
2009 in several parts of Sierra Leone — including the city of Bo, the
focus of this paper — found that 50.8% of anti- malarial drugs were
dispensed without a prescription [1].
Easy access to antimalarial drugs and other antibiotic agents may
compromise patient health outcomes. If the medications purchased for
an infection are inappropriate — such as antibiotics taken for a viral
infection or chloroquine taken for a chloroquine-resistant case of
malaria — or if medications are not taken in the appropriate dosage and
for an appropriate length of time, self-diagnosis and treatment may
contribute to prolonged illness, more  severe morbidity, and an
increased risk of mortality. A study in Bo district in
2008 found that only 48.3% of malaria-positive  patients at  a
hospital that offered free care completed the full course of
prescribed antimalarial treatment [2]. Given that low rate of
adherence to prescribed treatment regimens, it is likely that few
patients who access over-the-counter antibiotics complete a full course
of an appropriate, government-recommended formulation. The
antimalarial medications available over-the-counter are rarely the
formulations recommended by the national government and the World
Health Organization (perhaps a good sign that national health system
drugs are not leaking into the private market), and the 2009 study
found a very low level of knowledge  about national  and
international antimalarial policies and regulations among private- sector
sellers of medication, compared to a high level of knowledge among
public-sector providers [1].
Furthermore, misuse of antimicrobial agents can contribute to the
emergence of drug resistance, which is a growing concern in Sierra
Leone. A 2002-2003 study found treatment failure among more
than half of pediatric malaria patients treated with chloroquine, and
treatment failure was also frequently observed for sulphadoxine-
pyrimethamine (SP) [3]. These results suggest that drug-resistant
malaria is already common in the study area. Evidence of drug- resistant
bacterial infections has also been reported, including outbreaks of
multidrug-resistant Shigella dysenteriae in 1999-2000 [4] and drug
resistant Staphylococcus aureus among children during a 2008-2009
study in Freetown [5]. Sierra Leone has one of the highest rates of
multidrug-resistant tuberculosis (MDR-TB) in sub- Saharan Africa [6].
Over-diagnosis of malaria, in particular, may  be  common. Even
clinicians can find it difficult to diagnose malaria accurately solely based
on symptoms. A study in the Bo district in 2005 found that
82% of children suspected by clinical officers to have malaria based on
physical symptoms such as fever, splenomegaly, and vomiting
tested positive for parasitemia by a Paracheck-pf® rapid diagnostic
test (RDT) and 18% did not [7]. Between 2004 and 2006 in the
same region of Sierra Leone, only 65% of the Paracheck® RDTs
performed on pediatric patients with clinically — suspected malaria were
positive, suggesting that antimalarial medication may have been
significantly over-prescribed without the use of confirmatory laboratory
tests [8]. It is important to note that some children in highly-endemic
areas test negative for malaria at the beginning of a febrile illness,
such as a case of pneumonia,  but then  become
malaria-positive later in their course of illness due to their weakened
state. (Additionally, many children test positive for malaria even
when they  are  asymptomatic.) Parents without  clinical training
might be more likely than healthcare professionals to diagnose any
febrile illness as malaria and to seek presumptive antimalarial
treatment. While presumptive treatment may  be helpful — and
perhaps even lifesaving — when the  child actually  does have
malaria, a misdiagnosis may result in delayed treatment for the
actual cause of the fever, and the delay in seeking professional medical
care may increase morbidity and mortality [9]. The goal of this paper
was to evaluate the prevalence of  self-diagnosis of malaria and
other febrile illnesses in Bo, Sierra Leone's second largest city.
Methods
Sampling Strategy. All households within the Kulanda Town and
Njai Town sections (neighborhoods) of the city of Bo were eligible
for participation. The research laboratory has previously mapped all of
the buildings within these sections and conducted a household census,
in 2010, to identify which structures were residential ones [10]. The
resulting geographic information system (GIS) was used to create a
map of all of the homes within the study community. In June 2012,
members of the research team visited each household on the map,
as well as 11 new households (which were added to an updated map),
to ask for their participation. Of the 1038 households in these sections,
882 (85.0%) agreed to participate. For each of these households, one
adult, usually the head of the household, was interviewed to gather
information about the whole household.
Data Collection. Each interview began with questions about the
household's environmental   characteristics,   such   as   building
materials and access to utilities, and about household
demographics, such as the age and sex of each current resident.
Students at boarding school, adults working in another town and
not sleeping at the residence in Bo, and others who spent at least 6
months of the past year living elsewhere were not considered to be
current household members.
Then a series of questions were asked about febrile illnesses
experienced   by household members.   These   questions were
developed in consultation with residents of the Kulanda Town / Njai
Town sections to ensure clarity, and asked about all household
members of all ages. First, the household representative was asked
whether anyone currently living in the household had been ill with what
the household considered to be malaria in the past one month. If
malaria was reported to have occurred, follow-up questions asked
where those with malaria were diagnosed (such as at a hospital or
clinic, at home by a nurse, or at home by an untrained person —
that is, self-diagnosis) and whether they were tested for malaria by
a laboratory.  A  second set of questions asked whether  anyone
currently living in the household had a febrile illness earlier in 2012
(that is, in the 6 months prior to the interview). Follow-up questions
asked about the frequency  and duration of febrile illnesses;
symptoms associated with these fevers (such as joint tenderness,
headaches, altered behavior, and jaundice); and whether the febrile
person was examined by a clinician and/or had a laboratory test to
determine the cause of the fever. A final set of yes/no questions asked
whether the household considered anyone currently living in the
household to have ever had any of more than a dozen listed
communicable  and non-communicable  conditions,  and whether
those diagnoses were made by a doctor or were self-diagnosed.
Data Management and Analysis. Responses were entered by
the interviewers directly into a Filemaker Pro 12 relational database
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on   a   password-protected tablet   computer. Households were
identified by a number linked to a map stored at the research laboratory;
these codes were random and not related to the geographic coordinates
of the map. Data were analyzed using the statistical software program
SPSS (version 20). Proportions, means, and standard deviations were
used to describe the variables. Chi- squared tests were used to compare
rates in independent populations, such as different age groups.
Ethical Considerations. Adults ages 18 and older   were
interviewed   after providing informed   consent,   which   was
documented with a signature or a thumbprint. The consent form
and study materials were available in both English and Krio, the
local language in Sierra Leone. No compensation or other incentive was
offered. To protect the confidentiality of information shared with the
research team, no names or addresses were entered into the database.
The data entered into each tablet computer were deleted daily after the
data files on the tablets were downloaded to a password-protected
desktop computer in a locked and guarded research facility. The
research protocol was approved by the Sierra Leone Ethics and
Scientific Review Committee and  by Njala University (Sierra Leone),
the Liverpool School of Tropical Medicine (UK), the U.S. Naval Research
Laboratory (USA), and George Mason University (USA).
Results
The 882 participating households contained 5410 individuals, with a
mean household size of 6.1 persons. The households reported a
somewhat diverse set of socio-environmental characteristics. While
1186 (66.7%) of the 1778 beds reported to be located in the
participating homes were said to have bednets, 328 (37.2%) of
households reported having no bednets. In total, 877 (99.4%) of
households reported seeing a rat in the house in the past month,
860 (97.5%) reported seeing cockroaches in the house in the past
month, 677 (76.8%) had a tile or concrete rather than dirt floor,
546 (61.9%) had a trash bin in the home (of which 153 covered the
bin), 353 (40.0%) had electricity, and 155 (17.6%) had a drinking
water source within 50 meters of the home.
In total, 675 (76.5%) of the 882 households reported at least one case
of malaria (as defined by the household) in the month prior to the
survey, with a total of 910 (16.8%) of the 5410 individuals reported to
have had malaria during that time period. However, 540 (59.3%) of
these 910 individuals were presumptively diagnosed by the ill person or
a household member, and only 370 (40.7%) were diagnosed following
laboratory testing.
A total of 1402 (25.9%) of the individuals within participating
households were reported to have had any type of febrile illness
(whether caused by malaria or another condition) within the past six
months. The rate of fever reported differed by age group and by
sex, with young children (those 0 to 4 years old) having the highest rate
(p<0.001) and females reporting more fevers than males (p<0.001)
(Table 1). Only 33.9% of  people  with fever were reported to have
had laboratory tests to determine the cause of the fever. There were
significant differences in the likelihood of testing by age (p=0.011).
Households with indicators of higher socioeconomic status (SES), such
as those with electricity in the home or a drinking water source very
near to the home, generally reported slightly lower rates of febrile illness
within the household (Table 2). Markers of household SES were not
significantly associated with reported testing rates.
Self-diagnosis of several other conditions was common (Table 3).
All of the 234 individuals reported to have ever had influenza, as
defined by the household, indicated a self-diagnosis. More than
96% of the 160 persons reported to have had what the household
considered to be yellow fever (which had been the focus of a recent
vaccination campaign [11]) reported self-diagnosis,  as did more
than 60% of the 445 persons reported to have had typhoid (which
is a relatively common laboratory diagnosis in Bo, as per Widal
tests). More than half of the 317 people reported to have had what
the household designated as pneumonia were self-diagnosed.
However, diagnosis of less common and more specific conditions, such
as  bacterial meningitis, hepatitis B, and hepatitis C, were nearly
always reported to have been diagnosed by a doctor and not self-
diagnosed by the household.
Discussion
We found that the majority of febrile illnesses in Bo, Southern
Province, Sierra Leone, are self-diagnosed without clinical examination
or laboratory testing, including the more than half of suspected
malaria cases that are treated presumptively without any clinical
diagnostics. The fact that households with greater numbers of
individuals were more likely to report that at least one household
member had been tested for a febrile illness supports the validity of
reports about diagnosis and testing rates, since a greater number of
persons in the household increases the probability of a severe illness
occurring for at least one resident. The validity of the survey
instrument is also supported by the low numbers of households
reporting uncommon diseases such as bacterial meningitis unless
these conditions were diagnosed by a doctor.
These results are similar to those from studies in other parts of
West Africa which have found that more than half of adults self-
diagnose fevers and self-medicate for what they consider to be
malaria [12,13]. Of those who self-treat, only a small proportion
know the correct dosage for common antimalarial medications [12].
This high rate of self-treatment is concerning, since it is likely that a
significant proportion of these presumptive cases are treated
inappropriately (as per the introduction to this paper). Some people
who would benefit from antibiotic and supportive therapy may not
be receiving adequate care, and many people who purchase
medication for their self-diagnosed malaria or other conditions may be
taking drugs that are ineffective for their condition. Febrile individuals
who self-treat may experience disease complications and increased
treatment costs resulting from delayed access to appropriate
medications and other therapy [14]. Taking the wrong medication,
such as taking antimalarials for a fever caused by a different infectious
agent, generally means that the actual infection remains untreated for
at least several days.
When tests are available at  a reasonable cost, testing before
treating may significantly reduce the inappropriate use of antimicrobial
medications. For example, a cohort study of children ages 1 to 10
years in Uganda found that only 32% of fevers were caused by
malaria,  and the researchers concluded that  a test- before-treating
approach in that study population would reduce the use of
antiparasitic drugs by two-thirds [15]. The reduction of unnecessary
treatment achieved by a test-then-treat approach will, by definition,
be lower in higher-endemicity areas, including parts of Sierra Leone,
where a recent community-based study in the Bo area found that 83%
of febrile women and young children who were tested had malaria
[16]. Even so, testing may significantly reduce the number of people
taking unnecessary medications. The 17% of the 17,130 tested
individuals who were malaria-negative in the Bo
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area study represented nearly 3000 people who avoided the
unnecessary use of antimalarial drugs [16].
Testing does not have to occur in a clinical setting. In rural Sierra Leone,
free malaria testing by community health workers (CHWs) has
increased access to diagnosis for thousands of households [16]. Those
who test positive for malaria are treated by the CHWs, and those with
negative malaria tests or complicated malaria cases are referred to a
nearby hospital for advanced care (although the follow-up rate for
referrals from this program has been shown to be very low). In some
places, testing and treatment by CHWs has been found to be preferred
over home treatment [17]. However, one potential  challenge to testing
programs is convincing healthcare providers and patients not to
prescribe or take antimicrobials after a negative test result. A study
from Ghana found that more than half of patients who tested negative
for malaria were prescribed antimalarials anyway [18], and some
studies from other parts of Africa have found similar   results [19].
Taking antimalarial medication "just in case" may be seen as the best
option when households do not have the resources to travel to and
pay for further clinical examination and testing.
Besides the direct benefits to patients, expanded use of testing
before treatment may slow the further development of drug resistance
by reducing the proportion of the population accessing pharmaceutical
agents without prescriptions tailored to their actual diagnoses. Patients
who have seen a clinician and have a confirmed diagnosis may be more
likely than others to complete a full course of an appropriate antibiotic
or antimalarial, especially if their treating clinicians counsel them about
the importance of compliance with prescribed treatments (an
occurrence dependent on those practitioners having the time and
resources to provide health education). Community-based behavior
change communication processes may also help to promote healthy use
of pharmaceuticals by households and communities, but when these
public health structures are not in place the burden of health education
typically falls on clinicians.
Limitations. This study had several limitations that require a
conservative interpretation of the findings. No laboratory tests were
conducted to confirm the reported causative agents for participants'
febrile illnesses, so we do not know how often their self-diagnoses were
accurate. Additionally, participants were not asked about their use of
antibiotic and antiparasitic drugs, such as what medications they
preferred to take when febrile or where they procured these
medications. Because these questions were not part of the survey, we
have limited information about whether the self-treatment used by
febrile participants was appropriate for their illnesses.
Conclusion
This study provides evidence that self-diagnosis and self-medication for
malaria  and other febrile illnesses is common in Bo, Sierra Leone.
In order to better understand the implications of self- diagnosis and
presumptive treatment on patient health outcomes, we recommend
that further studies evaluate the types of infections common in this
population to see how well clinical laboratory results match self-
diagnoses. Future research should also examine the pharmaceutical
access and use habits of local residents to  see whether appropriate
courses of medication are being taken by those with and without
prescriptions from a clinician. Understanding the knowledge, attitudes
and beliefs, and health practices and behaviors of residents regarding
diagnosis and treatment of fevers may contribute to improved health
services, policies, and practices.
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Table 1: Prevalence of reported febrile illnesses and testing in the past 6 months, by age and sex
Age
Group Total Females Males
p-value for Chi-
squared test of
difference by sex
(2-tailed)
n
n (%)
reported
to have
had fever
Of those
reported to
have had a
fever, n (%)
who had tests
to determine
the cause of
the fever
n
n (%)
reported
to have
had fever
Of those
reported
to have
had fever,
n (%)
tested
n
n (%)
reported
to have
had fever
Of those
reported
to have
had fever,
n (%)
tested
reported
fever
cases
testing for
cause among
those
reported to
have had
fever
0-4 705 368(52.2%) 136 (37.0%) 348
193
(55.5%)
72
(37.3%) 357
175
(49.0%)
64
(36.6%) 0.088 0.885
5-14 1527 423(27.7%) 128 (30.3%) 835
233
(27.9%)
77
(33.0%) 692
190
(27.5%)
51
(26.8%) 0.847 0.169
15-29 1739 293(16.8%) 99 (33.8%) 973
181
(18.6%)
53
(29.3%) 766
112
(14.6%)
46
(41.1%) 0.027 0.040
30-44 803 136
(16.9%)
58 (42.6%) 423 86
(20.3%)
30
(34.9%)
380 50
(13.2%)
28
(56.0%)
0.003 0.018
45-59 381 95(24.9%) 36 (37.9%) 180
56
(31.1%)
19
(33.9%) 201
39
(19.4%)
17
(43.6%) 0.009 0.351
≥60 255 87(34.1%) 19 (21.8%) 134
52
(38.8%)
12
(23.1%) 121
35
(28.9%) 7 (20.0%) 0.090 0.749
Total 5410 1402(25.9%) 476 (34.0%) 2893
801
(27.7%)
263
(32.8%) 2517
601
(23.9%)
213
(35.4%) 0.001 0.309
1402 (25.9%) of household members reported fever, of whom 476 (34.0%) were tested to determine the cause of the fever. In total, 801 (27.7%)
females and 601 (23.9%) males reported fever, and 263 (32.8%) of females and 213 (35.4%) of males with fever were tested. The rate of fevers
reported was different by sex and by age group, but there were not significant age and sex differences in testing.
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Table 2: Household environmental characteristics and reported febrile illnesses in the household (HH)
Household
(HH) feature
(among 882
households)
1+ HH member reported to have
had malaria in the past month
Of those HHs with malaria,
1+ person with malaria reported
to have had malaria testing
1+ HH member reported to have
had any febrile illness in the past
6 months
Of those HHs reporting fever,
1+ person with fever reported
to have had a formal diagnosis
among
HHs
with this
feature
among
HHs
without
this
feature
p-
value
among
HHs
with this
feature
among
HHs
without
this
feature
p-
value
among
HHs
with this
feature
among
HHs
without
this
feature
p-
value
among
HHs
with this
feature
among
HHs
without
this
feature
p-
value
Fewer than
six
individuals
in the
household
(n=552,
62.8% of
HHs)
417
(75.3%)
258
(78.7%) 0.252
125
(30.0%)
102
(39.5%) 0.011
453
(81.8%)
269
(82.0%) 0.932
129
(28.5%)
172
(63.9%) <0.001
Households
with at least
one bednet
(n=691,
78.3%)
517
(74.8%)
158
(82.7%) 0.020
176
(34.0%)
51
(32.3%) 0.686
584
(84.5%)
138
(72.3%) <0.001
248
(42.5%)
53
(38.4%) 0.387
Having a tile
or concrete
floor rather
than a dirt
floor
(n=677,
76.8%)
508
(75.0%)
167
(81.5%) 0.055
177
(34.8%)
46
(27.5%) 0.081
539
(79.6%)
183
(89.3%) 0.001
217
(40.3%)
84
(45.9%) 0.183
Having a trash
bin in the
home (n=546,
61.9%)
388
(71.1%)
287
(85.4%)
<0.001 138
(35.6%)
85
(29.6%)
0.105 428
(78.4%)
294
(87.5%)
0.001 163
(38.1%)
138
(46.9%)
0.018
Having
electricity
(n=353,
40.0%)
264
(74.8%)
411
(77.7%) 0.320
90
(34.1%)
133
(32.4%) 0.641
271
(76.8%)
451
(85.3%) 0.002
112
(41.3%)
189
(41.9%) 0.880
Using a
drinking water
source
within 50
meters of
the home
(n=155,
17.6%)
106
(68.4%)
569
(78.3%)
0.010 27
(25.5%)
196
(34.4%)
0.070 124
(80.0%)
598
(82.3%)
0.505 52
(41.9%)
249
(41.6%)
0.949
Malaria and febrile illnesses were significantly more likely to be reported by households without at least one bednet, those with a dirt floor, those without
a trash bin in the home, those without electricity, and those without a drinking water source near the home. Testing of at least one household
member was less likely to be reported by smaller households and those without a trash bin in the home.
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Table 3: Reports of family medical history, by source of diagnosis
Condition
n (%) of households reporting
that someone currently living in
the household has
ever had this condition
Of households reporting this
condition, n (%) reporting that
the condition was
diagnosed by a doctor
Of households reporting this
condition, n (%) reporting that
the condition was
self-diagnosed
Influenza 234 (26.5%) 0 (0%) 234 (100%)
Lassa fever 5 (0.6%) 0 (0.0%) 5 (100%)
Yellow fever 160 (18.1%) 6 (3.8%) 154 (96.3%)
Common cold 774 (87.8%) 180 (23.3%) 594 (76.7%)
Asthma 79 (9.0%) 21 (26.6%) 58 (73.4%)
Typhoid fever 445 (50.5%) 177 (39.8%) 268 (60.2%)
Pneumonia 317 (35.9%) 151 (47.6%) 166 (52.4%)
Bacterial meningitis 10 (1.1%) 8 (80.0%) 2 (20.0%)
Hepatitis B 5 (0.6%) 5 (100%) 0 (0.0%)
Hepatitis C 1 (0.1%) 1 (100%) 0 (0.0%)
Tuberculosis 0 (0.0%) 0 (0.0%) 0 (0.0%)
Rift Valley fever 0 (0.0%) 0 (0.0%) 0 (0.0%)
Dengue fever 0 (0.0%) 0 (0.0%) 0 (0.0%)
Households reported a high rate of self-diagnosis for conditions such as influenza (100% of reported cases self-diagnosed), yellow fever (96.3%
self-diagnosed), colds (76.7% self-diagnosed), typhoid fever (60.2% self-diagnosed), and pneumonia (52.4% self-diagnosed).
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Reemergence of
Chikungunya Virus
in Bo, Sierra Leone
Rashid Ansumana, Kathryn H. Jacobsen,
Tomasz A. Leski, Andrea L. Covington,
Umaru Bangura, Mary H. Hodges, Baochuan Lin,
Alfred S. Bockarie, Joseph M. Lamin,
Moses J. Bockarie, and David A. Stenger
We diagnosed 400 possible IgM-positive cases of
chikungunya virus in Bo, Sierra Leone, during July 2012–
January 2013 by using lateral flow immunoassays. Cases
detected likely represent only a small fraction of total cases.
Further laboratory testing is required to confirm this out-
break and characterize the virus.
utbreaks of infection with chikungunya virus
(CHIKV), an alphavirus that is transmitted by bites
of infected Aedes spp. mosquitoes, were frequent in sub-
Saharan Africa and southern and Southeast Asia during the
1950s–1970s, but the infection largely disappeared in the
1980s; only sporadic cases were observed (1). The virus re-
emerged in the early 2000s; major outbreaks were reported
in Kenya, some island nations in the Indian Ocean, and sev-
eral countries in Asia (2,3).
The primary symptoms of CHIKV infection are high
fever (>38.5°C [102°F]) and severe pain in the distal joints
of the extremities or the lumbar spine. A maculopapular
rash, sensorineural impairment, severe headache, and other
nonspecific symptoms may also occur. Symptoms usually
resolve within 1–2 weeks after onset of fever, but for a
sizeable proportion of patients, arthralgia and arthritis be-
come chronic and pain persists for years (2,3).
A nationwide serosurvey in Sierra Leone in 1972 de-
tected cases of CHIKV infection throughout the country
(4), but we are not aware of any cases reported since the
mid-1970s. Two recent developments made reemergence
appear imminent. First, outbreaks of reemerging CHIKV
have been reported in neighboring Guinea (5) and in Sen-
egal (6). Second, recent yellow fever cases in Sierra Leone
have shown that Aedes spp. mosquito–borne infections are
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common (7). Thus, it was not surprising when we initiated
an infectious disease surveillance study in July 2012 in the
city of Bo, in Southern Province, Sierra Leone, that we
detected possible chikungunya virus infections. We report
initial results of our investigation.
The Study
On July 7, 2012, the Mercy Hospital Research Labo-
ratory (MHRL) in Bo, Sierra Leone, initiated a 1-year
infectious disease surveillance program to identify the
diversity of pathogens causing febrile illness in the city.
A tiered analysis approach was used. First, all specimens
from febrile study participants were tested for 12 infec-
tions with various pathogens, including CHIKV, by com-
mercially available test kits. Specimens that showed nega-
tive results in this first round of testing were further tested
by using cultures, multiplex PCR, and resequencing patho-
gen microarrays. The research protocol was approved by
Njala University, George Mason University, the Liverpool
School of Tropical Medicine, the US Naval Research Lab-
oratory, and the Sierra Leone Ethics and Scientific Review
Committee.
During July 7, 2012–January 10, 2013, MHRL con-
ducted first-tier lateral flow immunoassay (LFI) tests of
blood samples from all 932 outpatients >5 years of age who
had been clinically examined at the hospital, were found to
have febrile illness, and consented to having blood drawn
for laboratory testing. LFI test kits (SD Bioline; Standard
Diagnostics, Inc., Seoul, South Korea) were used for diag-
nosis of IgM against CHIKV; IgG and IgM against den-
gue virus and hepatitis A virus; hepatitis B virus surface
antigen, hepatitis C virus, HIV-1/2, and antibodies against
these viruses; and IgG and IgM against Leptospira spp.,
Salmonella enterica Serovar typhi, and syphilis.
Most patients reported that they had sought medical
care within several days after the onset of their febrile ill-
nesses. Levels of IgM against CHIKV are usually detect-
able by immunochromatographic methods within a few
days after infection and persist for 3–4 months (1,2). The
LFI test kits for CHIKV were reported by the manufac-
turer to have a sensitivity of 97.1% and a specificity of
91.1% compared with those of ELISA (8). An independent
evaluation found a sensitivity of 50.8% and a specificity of
89.2% for the kits; sensitivity ranged from 40.9% 1–5 days
after onset of illness to 65.4% 16–20 days after onset (9).
Specificity decreases after the first week (10).
More than half of the cases tested during the first
week of the surveillance program were positive by LFI
for CHIKV. Thus, we notified the Sierra Leone Ministry
of Health and Sanitation of a possible CHIKV outbreak.
By January 10, 2013, 400 (42.9%) of 932 febrile patients
were positive by LFI for CHIKV (Figure 1). Ages of the
400 CHIKV IgM-positive patients ranged from 6 years to
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85 years; 172 (43.0%) were male patients. Of these 400
patients, 220 (55.0%) reported arthralgia, 189 (47.3%)
chills, and 156 (39.0%) headaches. Co-infections were
common; 92 (23.0%.) were co-infected with malaria, 37
(9.3%) with HIV, 33 (8.3%) with hepatitis B virus, and
smaller numbers with hepatitis A, hepatitis C, tuberculosis,
typhoid, and syphilis. Four CHIKV-positive samples were
also positive for dengue.
On July 28, MHRL launched an Ushahidi-based web-
site (www.ushahidi.com) to compile case reports. Details
about the patients who were positive for CHIKV were up-
loaded to the MHRL website (www.mhrlsl.com/GIA/usha-
hidi) and, if possible, were geolocated on an open street
map (www.openstreetmap.org) that linked to a map of
Bo created by MHRL for health research purposes (11).
The map showed that the cases were located throughout
Bo (Figure 2). Of the 400 LFI-positive case-patients, 319
Chikungunya Virus in Sierra Leone
Figure 1. Weekly number of
IgM-positive chikungunya virus
test results at Mercy Hospital
Research Laboratory, Bo,
Sierra Leone, July 7, 2012–
January 4, 2013.
(79.8%) could be mapped; the remainder did not provide a
home street address on the laboratory patient information
form. However, the sample was not population-based be-
cause Mercy Hospital is 1 of several hospitals serving Bo,
so a city-wide attack rate could not be determined.
Results of attempts by the US Naval Research Lab-
oratory to confirm the LFI results by using semi-nested
reverse transcription PCR on fast technique for analysis of
nucleic acid–preserved samples were inconclusive, pos-
sibly because of genetic sequence variation from well-
characterized strains or because of the timing of specimen
collections. Viral loads for humans with CHIKV infection
decrease after the second day of symptoms, and viral titers
may be low after the fifth day (12,13). Because CHIKV
nucleic acids are only detectable in serum for a few days,
reverse transcription PCR results are often discordant with
those of serologic (IgM and IgG) assays. Confirmation that
Figure 2. Residence
locationsforIgM-positive
cases of infection with
chikungunya virus, Bo,
Sierra Leone, July 7,
2012–January 4, 2013.
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an outbreak occurred is dependent on isolation of the vi-
rus, followed by molecular characterization, full-genome
sequencing, and phylogenetic mapping.
Conclusions
Our results suggest that an outbreak of chikungunya vi-
rus occurred in Sierra Leone. The exact time of the reemer-
gence of this virus cannot be pinpointed, but retrospective
analyses of outpatient charts suggested that, on the basis of
syndromic criteria, the first cases occurred in January 2012
and the outbreak peaked during the rainy season in 2012.
Other outbreaks reported in central and west Africa have
also occurred during the rainy season, which is typical for
Aedes spp. mosquito–borne infections (6,14,15). Because
Mercy Hospital serves only a relatively small proportion of
the residents of Bo, the cases detected likely represent only
a small fraction of the total cases that have occurred. Fur-
ther study will be required to confirm the laboratory results
and, if further investigation is warranted, to document the
extent of the outbreak.
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We present a case of congenital lymphedema in a 7-year-old boy in Sierra Leone with active ﬁlarial
infection and penile edema. The genital edema with onset at 6 months of age may have been due to
a congenital abnormality in lymphatic drainage. Other possible causes of childhood lymphedema,
including Milroy’s disease, are discussed.
© 2014 The Authors. Published by Elsevier B.V. This is an open accessarticle under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-
sa/3.0/).
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1. Introduction endemic areas up to 10% of childrenunder the age of 15 years are
infected (Bockarie et al., 2002). In 2000, the WorldHealth Organiza-
tion launched the Global Program to Eliminate LF (GPELF) using the
pro-poor strategy of preventive chemotherapy and transmission
control (PCT) together with vector control,morbidity management,
and disability prevention (WHO, 2013). The mass drugadministra-
tion (MDA) strategy used for PCT combines albendazole with either
ivermectin or diethylcarbamazine citrate (DEC). However, not all
at-risk children in high-risk areas are able to access MDA.
Lymphatic ﬁlariasis caused by Wuchereria bancrofti is highly
endemic in Sierra Leone,where more than 90% of the 6.6 million
people are at risk of acquiring the infection. (Hodgeset al., 2012;
Koromaet al., 2012) Filarial disease is common in all the endemic
districts in the country, but there is no record previously of
lymphedema in a child less than 10 years old. Here we present a
case of lymphedema in a 7-year-old boy with patent LF.
Lymphatic ﬁlariasis (LF) is a major cause of acute and chronic
morbidity manifested as lymphedema and hydrocele. The clinical
signs and symptoms of LF affectmore than 40 million people glob-
ally, making the disease the second-largest cause of permanent
and long-term disability worldwide (Shenoy and Bockarie, 2011;
Chu et al., 2010). LF is a major obstacle to socioeconomic
development in the 73 countries across Africa, Southeast Asia, the
Americas, and the Paciﬁc region that are known to be endemic for
themosquito-borne disease (WHO, 2013; Addiss,2010).
LF infection is often acquired in childhood in areas of high trans-
mission intensity, but infected individuals usually do not develop
clinicaldisease until years later when they are adults. More than
250 million children are exposed to LF worldwide, and in high 2. Case report
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cess o f four rounds of MDA on reducing LF transmission in north
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Fig. 1. Lymphedema of Right LowerExtremity. Fig. 2. Deformed Prepuce.
Both Bombali and Kono Districtswere endemic for LFprior to the
MDA and the birth of the boy (Koromaet al., 2013).
As part of the investigation of the child’s disease, family mem-
bers were examined for LF. The mother tested LF positive based
on both ICTand night bloodsmear examination,and reported tak-
ing only one round of MDA during her lifetime. The boy’s father
and the boy’s only sibling both tested negative. Noneof the imme-
diate familymembers had anatomical abnormalities related to LF.
However, a familyhistory suggested that the boy’s deceasedmater-
nal grandmother likely also had an advanced ﬁlarial infection, as
she hadprogressivelymphedema of the lowerrightextremitythat
developedover the last ﬁve years of her life.
Two months after the boy’s initial diagnosis, following pre-
scribed treatment with ivermectin and albendazole, a night
blood smear test showed no evidence of circulating microﬁlaria.
A com- plete blood count, comprehensive metabolic panel, and
urinalysis were all found to be within normal limits. A physical
examination revealed no evidence of another inciting condition.
Both the child and his father were also tested at this time for
several other infec- tious  diseases, including human
immunodeﬁciency virus (HIV), dengue, leptospirosis,
chikungunya, malaria, syphilis, onchocerci- asis, and hepatitis A, B,
and C. Both tested positive for malaria, with all other tests
negative.
The patient was prescribed a daily dose of  200 mg of doxy-
cycline, which has been shown to cause signiﬁcant reductions
in lymphedema in patients with Grade II–III LF following 12–24
months of treatment, regardlessof circulatingﬁlarialstatus (Mand
et al., 2012). Although some risk of adverse  effects has been
reported in administration of doxycycline to children under 10
years old, the treating physicianconcludedthat with appropriate
safetymonitoring the beneﬁts of doxycycline for this patient out-
weighed the potential risks. Additionally, the ballooning foreskin
of the boy was removed through circumcision. The biopsiedtissue
was unremarkable.
central Pujehun District, Sierra Leone, a 7-year-old boy from a
rural village presented with chronic progressive lymphedema of
the right lowerextremity. The overlying tissue of the distalextrem-
ity was indurated, possibly due to secondary infection and tissue
trauma, and there were dermatologic changes of the right foot
con- sistent with elephantiasis (Fig. 1). The temperature of the
swollen areas was normal, with no signs of nodular or warty
excrescences. The boy’s father reported that asymmetrical non-
pitting edemahad been present since birth, and had increased in
severity over time. Keratosis spots were present over the entire
body, and the pre- puce of the penis showed a signiﬁcant
deformity that the father said had been present since the child
was six months of age (Fig. 2). The father gave permission for
photographs of the child and case information to be published.
The boy tested positive for circulating ﬁlarial antigenemia using
a BinaxNOW ﬁlariasis Immuno Chromatographic Test (ICT) (Inver-
ness Medical Professional Diagnostics, Preehold, NJ, USA), and a
night blood smear examination with Giemsastain conﬁrmed Ban-
croftian ﬁlariasis with 313 W. bancrofti mf/ml of blood prior to
treatment. The parasite was sheathed with nuclei in the tail end
and was morphologically distinguishable from the Mansonella
species which can also be found in human blood in Africa. These
observa- tions and the species-speciﬁc ICTpositiveresult conﬁrmed
that the microﬁlaria observed in the blood were W. bancrofti.
Initial treat- ment prescribed for the active ﬁlarial infectionwas a
6 mg dose of ivermectin and a 400 mg dose of albendazole every
three months with follow-up. The father reported that the boy
hadnot beenpre- viously treated for LF infection.
The boy had livedwith his parents in rural Pujehun District for
the past four years, and they previously resided in Kono District
(Fig. 3). Beforeher pregnancy with the boy and during the end of
her ﬁrst trimester, his mother hadresided in Kono Districtwithher
grandmother,a residentof BombaliDistrict,whohadelephantiasis.
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Fig. 3. Map of Sierra Leone Showing Location of CasePatient and Familial Relations.
3. Discussion lymphedema,but up to 10%of personswithMilroy’s disease may be
asymptomatic (Brice et al., 2005). Advanced molecular diagnostics
would be required to conﬁrmthat the lymphedemain the 7-year
old observed in Sierra Leonewas due to Milroy’s disease.
This study suggests that lymphedemadue to LF in childrenmay
be difﬁcult to diagnose because of the rarity of symptomatic LF
in the pediatric population. In LF-endemic areas, the possibility of
other causes of lymphedema in infected children should be care-
fully considered and Milroy’sdisease should not be prematurely
excluded as a possible diagnosis.
Lymphatic ﬁlariasis is rarely symptomatic in children, espe-
cially those who are less than 10 years old, and when children do
have symptoms LF rarely presents as lymphedema (Bockarieet al.,
2009). A comprehensive meta-analysis of LF in children by Witt and
Ottesen (2001) identiﬁed only 5 cases of lymphedema or elephan-
tiasis of a limb in children less than 10 years old in the published
literature, most of which occurred in the mid-20th century. A study
from the mid-1990s of 441 Indian children (ages 1–14 years) with LF
found only 12 cases of lymphedema (Harinath et al., 2000). Thus, the
casepatient appears to have an unusual presentation of lower limb
enlargement in a 7-year old boy infectedwith W. bancrofti.
One possible cause of this congenital deformity is Milroy’s dis-
ease, an autosomal dominant genetic disorder characterized by
lymphedema, especially lymphedema of the legs, that is present
at birth or develops in infancy (Makhoul et al., 2002). A 2011 case
report from an LF non-endemic area described a healthy full-term
newborn with no complications during pregnancy or delivery who
developed swelling of his right leg soon after birth (Perez-Crespo et
al., 2011). As observed in our case, the lower limb swelling was
more pronounced in the distal part of the leg and foot. The skin
showed non-pitting edema and no swelling signs in the area. The
family history was also similar to ours. The grandmother and some
maternal relatives were also found to be affected with lym-
phedema, including the child’s grandmother. Based on the family
history and clinical examination alone, the patient was diagnosed
with Milroy’s disease. Similar cases described elsewhere were also
clinically diagnosed as Milroy’sdisease (Connell et al., 2008; Kitsiou-
Tzeli et al., 2010). Milroy’s disease had also been associ- ated with
swellingof the genitals, as per a case report fromGueglio et al. (2003)
of giant scrotal lymphedema due to Milroy’s disease. No relative of
the 7-yearold boy wasknownto havebeenbornwith
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Sequence Variability and
Geographic Distribution of
Lassa Virus, Sierra Leone
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Stenger, Rashid Ansumana, Daniel G. Bausch, Baochuan Lin
to various estimates, 300,000–500,000 cases of LF result
in 5,000–10,000 deaths annually in West Africa (6,7). An
analysis based on seroepidemiologic data suggested that
the number of cases might be much higher, reaching 3 mil-
lion cases and 67,000 fatalities per year (8). Overall, the
population at risk might include as many as 200 million
persons living in a large swath ofWestAfrica from Senegal to
Nigeria and beyond (4).
LASV can cause infection in the multimammate rat
(Mastomys natalensis), a natural host and reservoir of this
pathogen (9,10). The multimammate rat is a commensal
rodent ubiquitous in Africa (11,12). Although the routes of
LASV infection are poorly characterized, humans probably
get infected by eating contaminated food (13), by inhal-
ing virus-contaminated aerosols (14), or while butchering
infected rat meat (15). Person-to-person transmission of
LASV is well documented, mostly in the form of nosoco- mial
outbreaks (13).
Like other arenaviruses, LASV is an enveloped virus with
a bisegmented single-stranded RNA genome encod- ing 4
proteins using an ambisense coding strategy (16). The
small segment contains genes for the glycoprotein precursor
(GPC) and nucleoprotein (NP), which serves as the main viral
capsid protein. The large segment encodes the small zinc-
binding protein (Z), which contains a RING motif, and
another gene (L) containing the RNA-dependent RNA
polymerase domain.
Complete genome sequences are available for sev-
eral LASV strains, as are a considerable number of par-
tial sequences from isolates originating from humans and
rodents (17–20). Their analysis revealed the existence of
high sequence diversity (up to 27% nt) and 4 major lineag-
es of LASV, which correlate with geographic location (17).
Lineages I, II, and III, and the greatest diversity of LASV
strains, were found among isolates from Nigeria, whereas
strains from Guinea, Sierra Leone, and Liberia seemed to be
more closely related and belong exclusively to lineage IV.
Sequence of the AV strain (21) and recently published
sequences from rodent LASV isolates from Mali (18)
Lassa virus (LASV) is endemic to parts of West Africa and
causes highly fatal hemorrhagic fever. The multimammate
rat (Mastomys natalensis) is the only known reservoir of
LASV. Most human infections result from zoonotic transmis-
sion. The very diverse LASV genome has 4 major lineages
associated with different geographic locations. We used re-
verse transcription PCR and resequencing microarrays to
detect LASV in 41 of 214 samples from rodents captured
at 8 locations in Sierra Leone. Phylogenetic analysis of
partial sequences of nucleoprotein (NP), glycoprotein pre-
cursor (GPC), and polymerase (L) genes showed 5 sepa-
rate clades within lineage IV of LASV in this country. The
sequence diversity was higher than previously observed;
mean diversity was 7.01% for nucleoprotein gene at the
nucleotide level. These results may have major implications
for designing diagnostic tests and therapeutic agents for
LASV infections in Sierra Leone.
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case-fatality rates (1). LF differs from most viral
hemor-rhagic fevers in that it is endemic to a large
geographic area of sub-Saharan Africa. Human cases of
LF have been reported in (or imported from) Guinea,
Sierra Leone, Liberia, Mali, Burkina Faso, and Nigeria;
however, LF outbreaks seem to be restricted to Guinea,
Sierra Leone, Liberia (the Mano River Union region), and
Nigeria (2–4). In some ar- eas of Sierra Leone and
Guinea, more than half of the pop- ulation has
antibodies against Lassa virus (LASV; familyArenaviridae), the etiologic agent of LF (5,6). According
Lassa fever (LF) belongs to a group of viral
heh morrhagic
hemorrhagic fevers characterized by a febrile
syndrome and high
RESEARCH
suggest the existence of an additional clade (proposed as
lineage V) (22). LASV sequences of isolates from humans
and rodents are found interspersed throughout the
phyloge- netic tree, which is consistent with the notion
that human cases typically result from transmission from
rodents (17).
The high degree of sequence divergence of LASV
genomes is a major problem affecting the development
of molecular and immune-based diagnostic technologies,
vaccines, and possibly antiviral drugs (13,16,17,23–25).
Forty-seven  unique  partial  LASV  sequences  from  Si- erra
Leone were available in GenBank at the time of this
analysis, which included fragments of NP (27 sequences),
GPC (9 sequences), L (9 sequences), and Z (2 sequences)
genes plus full sequences of small and large segments of 2
strains—Josiah and NL. Most of these sequences are from
isolates collected >30 years ago; only 2 more recent se-
quences (GPC and L gene fragments) from strain SL06-
2057 were isolated in 2006 (17,19).
To fill this gap, we investigated the sequence diversity
of strains circulating among small rodents captured in peri-
domestic settings in Sierra Leone. In 2014, we screened
214 samples collected during 2009 from several species of
rodents trapped in villages where LF was reported in hu-
mans. We used diagnostic reverse transcription PCR (RT-
PCR) and high-density resequencing microarrays to detect
LASV and amplify fragments of NP, GPC, and L genes. The
obtained amplicons were sequenced and compared with
previously published sequences from Sierra Leone to
obtain a more complete and updated picture of the
strains circulating in this country.
the villages according to approved guidelines (26). The animals
were anesthetized with isoflurane, and their morpho- metrics
recorded. Animals were euthanized by exsangui- nation using
cardiac puncture or cervical dislocation, and necropsies were
performed. Spleen sections were stored in RNALater or TRIzol
for RNA extraction (Life Technolo- gies, Grand Island, NY, USA).
Rodents were identified to the genus level in the field. Animals
identified as Mastomys sp. were further identified down to
species level by using molecular methods as described
previously (27).
Nucleic Acid Extraction
RNA from 10 mg of spleen of each rodent was extracted
with TRIzol following the manufacturer’s recommenda-
tions. The samples were stored at –80°C.
RT-PCR and Sequencing
RNA were reverse-transcribed by using the SuperScript III
Reverse Transcriptase kit (Life Technologies) according to the
manufacturer’s instructions, and RT products were stored at –
20°C. Specific oligonucleotide primer pairs were used for the
PCR targets of interest (Table 1) at final con- centrations of
0.25 μM each. For PCR, 2 μL of RT reaction was used as
template in 25 μL reactions containing 1.25 mM dNTPs, 1× Taq
buffer, 0.2 μM each of primers, and
1.25 U FastStart Taq enzyme (Roche Diagnostics, India- napolis,
IN, USA). NP targets were amplified by using an initial 2-min
denaturation at 95°C, followed by 40 cycles of 95°C for 30 sec,
55°C for 30 sec, and 72°C for 1 min. Some specimens produced
poor PCR products, with low yields or multiple bands when we
used published primer pair 1010C/ OW1696R (17); 1 μL of PCR
product from those speci- mens was amplified in nested PCR
by using the primer pair LAS_NP_F_1/LAS_NP_R_1 and the
same thermal cycling program to generate DNA fragments
suitable for sequencing (Table 1). GPC targets were amplified
by us- ing 36E2 and LVS339-rev primers (24) and a PCR profile
consisting of 2-min denaturation at 95°C, followed by 45 cycles
of 95°C for 30 sec, 58°C for 30 sec, and 72°C for 1 min. L gene
targets were amplified by using modified prim- ers, LVL3359-F
and LVL3754-R, based on published se- quences (28) and a PCR
program consisting of 2-min dena- turation at 95°C followed by
45 cycles of 95°C for 30 sec,
Methods
Rodent Sample Collection
The rodent samples collected were part of a separate
project (L.M. Moses, unpub. data). Thirteen locations were
select- ed for study in the LF-endemic region of eastern
Sierra Le- one. The geographic coordinates of the sampling
locations and details of rodent trapping methods are
available in the online Technical Appendix (Technical
Appendix Table 1, Rodent Trapping Procedures,
http://wwwnc.cdc.gov/EID/ article/21/4/14-1469-
Techapp1.pdf). Traps with captured small animals were
processed in remote areas outside of
Table 1. PCR and sequencing primers used in study of Lassa virus, Sierra Leone*
Primer name Sequence, 5′ 3′ Target gene Amplicon size Reference
1010C
OW1696R
LAS_NP_F_1
TCIGGIGAIGGITGGCC
AIATGAIGCAGTCCAIIAGTGCACAGTG
GGGTGGCCATAYATTGCATC
NP 670 (17)
(17)
This study
650
LAS_NP_R_1 GTCCAGGAGTGCACAGTGAG This study
36E2 ACCGGGGATCCTAGGCATTT GPC 317 (24)
(24)
LVS339-rev GTTCTTTGTGCAGGAMAGGGGCATKGTCAT
LVL3359-F AGAATYAGTGAAAGGGARAGCAATTC L 394 (28)
(28)
LVL3754-R CACATCATTGGTCCCCATTTACTRTGATC
*GPC, glycoprotein precursor; L, polymerase; NP, nucleoprotein.
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Lassa Virus, Sierra Leone53°C for 30 sec, and 72°C for 1 min. PCR amplicons were
size-confirmed by electrophoresis by using 1.2% FlashGel
DNA cassettes (Lonza, Walkersville, MD, USA) and puri-
fied on Zymo DNA Clean & Concentrator columns (Zymo
Research, Irvine, CA, USA). All DNA sequencing was per-
formed by Eurofins MWG Operon (Huntsville, AL, USA).
The sequences were deposited into GenBank under the
following accession numbers: NP sequences, KM406518–
KM406556; GPC sequences, KM406590–KM406623; and L
sequences, KM406557–KM406589.
Appendix Table 2). These samples were obtained from
rodents captured at 13 locations in 3 districts within the
southern and eastern provinces of Sierra Leone (Figure 1;
online Technical Appendix Table 1). The rodents belonged
to 6 genera; 199 were identified as M. natalensis, which
is consistent with published data on the ubiquitous pres-
ence of this species in domestic environments in West Af-
rica (11,12). The other rodents (identified to genus level
only) were Rattus sp. (9 [4.2%] rodents); Cricetomys sp. (3
[1.4%] rodents); and Mus sp., Praomys sp., and Hylomys-
cus sp. (1 [0.5%] rodent each).
We screened all samples for LASV by RT-PCR using
pan–Old World arenavirus (OWA) primers (17), which am-
plify a 670-nt section of NP gene. Because of poor results
of NP amplification using OWA primers (inefficient ampli-
fication,multiple bands), we modified the screening proto-
col to include a second nested PCR using primers internal
to the OWA amplification product, designed to amplify
650-nt segment of NP sequence and be more specific for
lineage IV NP gene sequences. We obtained sequencing-
quality NP amplicons from 39 samples using this protocol.
For all of these NP-positive samples, we attempted to ob-
tain RT-PCR amplicons for fragments of GPC and L genes
using previously published or modified primers (17,24,28).
The GPC and L amplifications were successful for most NP-
positive samples and failed only in 5 and 6 samples,
respectively (Table 2).
In addition, we screened a randomly selected subset of 51
samples (representing 8 collection sites and 4 rodent gen-
era; online Technical Appendix Table 2) for nucleic acids of
84 different pathogens using RPM-TEI v. 1.0. Of the 51
samples tested using RPM-TEI, 9 were positive for LASV,
and no other pathogens were detected in the analyzed
samples. Although the percentage of positive samples was
similar to that from RT-PCR results, the RPM-TEI failed to
detect LASV in 3 samples that were positive for the NP
gene by 2-step RT-PCR (LM34, LM58, and LM68). All these
samples originated from the same village (Bumpeh), and
no sample from this site was RPM-TEI positive, which
suggests that detection failures might have been caused by
inefficient amplification of the sequence variant of LASV
circulating in the Bumpeh area with the RPM-TEI primers.
On the other hand, RPM-TEI detected viral RNA in 2 RT-
PCR–negative samples (LM591 and LM649), bringing to41
the number of samples positive for LASV nucleic
acids(Table 2).
In summary, 41 LASV-positive samples were obtained from
animals captured in 8 locations: Barlie (13 samples), Largo
(8 samples), Bumpeh (7 samples), Ngiehun (4 sam- ples),
Koi and Yawei (3 samples each), Taiama (2 sam- ples), and
Saama (1 sample) (Figure 1). No LASV RNA was detected in
samples collected from Gouma, Joru, Ken- ema, Panguma,
or Segbwema. Lack of LASV detection in
RPM-TEI Microarray Analysis
The  resequencing  pathogen  microarray  (RPM) analysis
was conducted by using Tropical and Emerging Infections
microarrays (RPM-TEI v. 1.0; TessArae, Potomac Falls, VA,
USA). The RPM-TEI microarray enables detection of84
biothreat agents, including all lineages of LASV (29). Sample
preparation was conducted as previously described (29).
Pathogen identification was performed using the
“C3Score” identification algorithm (30).
Phylogenetic Analysis
We conducted the sequence alignment using the MUSCLE
algorithm implemented in the MEGA 6.0 software pack-
age (31). In addition to partial NP, GPC, and L sequences
obtained in this study, we included in the alignments all ho-
mologous sequences from these genes in samples
collected in Sierra Leone (or clustering with Sierra Leone
sequences) available in GenBank. Twenty-seven NP, 10
GPC, and 8 L sequences were available that meet these
criteria. To root the trees, sequences from more distantly
related, lineage IV isolate Z-158, which originated from
Macenta district in Guinea, were used as an outgroup on
the basis of the previ- ous phylogenetic analyses (17). We
also used MEGA 6.0 to perform statistical selection of the
nucleotide substitution model for each sequence
collection. We selected the Tamu- ra 3-parameter model
with discrete γ-distributed rate varia- tion as the best-
fitting model for NP and L sequence sets and the Kimura
2-parameter model with a fraction of evo- lutionary
invariant sites for GPC sequences. The phylog- enies were
inferred by using the Bayesian, Markov Chain Monte Carlo
method, as implemented in MrBayes v3.2.2 (32). The
analysis was run without an assumption of a mo- lecular
clock. The resulting phylogenies were presented as 50%
majority rule consensus trees in which the branches with
posterior probability <0.5 were collapsed into polyto-mies.
We manually adjusted the trees using FigTree v1.4.2
(http://tree.bio.ed.ac.uk/software/figtree).
Results and Discussion
We collected 681 small mammals during the field survey.
Of these, we analyzed 214 for this study on the basis of RNA
availability at the time of the study (online Technical
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Table 2. Results of Lassa virus detection among rodent samples with >1 positive test result, Sierra Leone*
Collection site PCR†
Sample Date collected Village/town District NP GPC L RPM‡
LM0034
LM0036
LM0047
LM0054
LM0058
LM0064
LM0068
LM0087
LM0091
LM0092
LM0093
LM0111
LM0122
LM0123
LM0124
LM0224
LM0250
LM0273
LM0395
LM0396
LM0434
LM0473
LM0513
LM0582
LM0591
LM0610
LM0619
LM0645
LM0649
LM0657
LM0660
LM0661
LM0676
LM0677
LM0678
LM0680
LM0714
LM0716
2009 Jan 27
2009 Jan 27
2009 Jan 28
2009 Jan 28
2009 Jan 29
2009 Jan 30
2009 Jan 30
2009 Feb 3
2009 Feb 3
2009 Feb 3
2009 Feb 3
2009 Feb 4
2009 Feb 5
2009 Feb 5
2009 Feb 5
2009 Feb 18
2009 Feb 19
2009 Feb 20
2009 Jul 22
2009 Jul 22
2009 Jul 23
2009 Jul 24
2009 Aug 1
2009 Aug 8
2009 Aug 8
2009 Aug 8
2009 Aug 8
2009 Aug 8
2009 Aug 8
2009 Aug 8
2009 Aug 8
2009 Aug 8
2009 Aug 8
2009 Aug 8
2009 Aug 8
2009 Aug 8
2009 Aug 14
2009 Aug 14
Bumpeh
Bumpeh
Bumpeh
Bumpeh
Bumpeh
Bumpeh
Bumpeh
Largo
Largo
Largo
Largo
Largo
Largo
Largo
Largo
Koi
Koi Koi
Ngiehun
Ngiehun
Ngiehun
Ngiehun
Saama
Barlie
Barlie
Barlie
Barlie
Barlie
Barlie
Barlie
Barlie
Barlie
Barlie
Barlie
Barlie
Barlie
Yawei
Yawei
Yawei
Taiama
Kenema
Kenema
Kenema
Kenema
Kenema
Kenema
Kenema
Kenema
Kenema
Kenema
Kenema
Kenema
Kenema
Kenema
Kenema
Kenema
Kenema
Kenema
Kenema
Kenema
Kenema
Kenema
Kenema
Bo
Bo
Bo
Bo
Bo
Bo
Bo
Bo
Bo
Bo
Bo
Bo
Bo
Kenema
Kenema
Kenema
Kenema
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
Neg
+
+
+
Neg
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
Neg
+
+
+
+
+
+
+
+
+
+
+
Neg
+
+
Neg
+
Neg
+
Neg
+
Neg
+
+
+
+
+
+
+
+
+
Neg
+
+
+
Neg
+
+
+
Neg
Neg
+
+
+
+
+
+
+
+
+
+
+
+
+
+
Neg
+
Neg
+
+
+
Neg
+
+
+
+
+
+
+
Neg
+
Neg
+
Neg
NT
NT
NT
Neg
NT
Neg
NT
+
NT
NT
NT
NT
NT
NT
NT
NT
NT
+
+
+
NT
NT
NT
+
+
NT
NT
+
NT
NT
NT
NT
NT
NT
NT
NT
+
+
NT
Z0007 2009 Dec 17 Taiama Kenema + + + NT
*GPC, glycoprotein precursor; L, polymerase; Neg, negative; NP, nucleoprotein; NT, sample not tested; RPM, resequencing pathogen microarray; +,
positive.
†Results of PCR detection using appropriate diagnostic primers.
‡Results of RPM-TEI detection of LASV.
Kenema, Panguma, and Segbwema, areas well known to
have regular LASV transmission, might be due to the small
number of traps used. The town of Joru was extensively
trapped, and no LASV was found. This finding is not sur-
prising because Joru is so th of the area where LASV is
usually found.
All positive samples came from multimammate rats,
which is considered the sole vector species for LASV (13).
The results of LASV detection using several different RT-
PCR strategies and a broad-range resequencing microarray
(RPM-TEI v. 1.0) showed that none of the techniques ap-
plied alone detected viral RNA in all positive samples. This
result underscores the difficulty of developing a truly uni-
versal diagnostic assay for this highly variable virus, even in
the case of closely related strains belonging to lineage IV.
The analysis of the new sequences of LASV strains
circulating in rodents in Sierra Leone indicated that the
viral genome diversity is higher than previously estimated
(17). For all available Sierra Leone sequences (including this
study) the mean difference calculated for partial P, GPC,
and L sequences was 7.01% nt, 8.92% nt, and 9.83% nt,
respectively, and 2.82% aa, 4.06% aa, and 0.71% aa, re-
spectively (Table 3). These differences are higher than the
reported 4.6% nt and 1.7% aa differences based on partial
NP sequences in a study with fewer isolates (17). The L
gene fragment seemed to vary the most at the nucleotide
level, followed by GPC and NP, which is consistent with
previous observations (33). However, at the amino acid
level, the GPC gene varied most, followed by the NP and L
genes. The high conservation of the protein sequence of L
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Table 3. Estimates of average evolutionary divergence of NP,
GPC, and L gene fragments for Lassa virus strains,
Sierra Leone* Difference†
Gene, grouping Nucleotide Amino acid
NP Overall
Clade A
Clade B
7.01
5.03
0.62
2.82
2.06
0.77
Clade C 6.44 2.42
GPC
Overall
Clade A
Clade B
8.92
6.26
0.68
4.06
2.60
0.49
Clade D 7.49 3.29
L
Overall
Clade A
Clade B
9.83
6.59
0.89
0.71
0.58
0.00
Clade D 0.88 0.00
*GPC, glycoprotein precursor; L, polymerase; NP, nucleoprotein.
†The numbers of nucleotide and amino acid differences per site from
averaging over all sequence pairs or all sequence pairs within a clade
multiplied by 100 are shown. All positions containing gaps and missing
data were eliminated. Values for clade E defined for GPC and L
sequences were not calculated because clade E contained only 1
sequence.least 3 distinct major clades (posterior probability 1.00 in
all cases): the first clade (A), including a large cluster of
strains originating from a group of villages to the north and
east of Kenema in the Eastern Province (Bumpeh, Gon-
dama, Koi, Konia, Largo, Ngiehun, Panguma, Segbwema,
Taiama, Tongo, and Yawei; Figure 1); the second clade (B),
including several strains isolated from rodents cap- tured
in Barlie (located a few kilometers southeast of Bo) and 1
isolate from Saama (located northeast of Kenema); and the
third clade (C) represented by just 2 older human isolates
from Mano and Mobai.
Phylogenetic trees based on GPC and L sequences
(Figures 3, 4) had similar topology and supported existence
of clades A (with posterior probabilities 0.74 and 1.00, re-
spectively) and B (with posterior probabilities 1.00 for both
trees). However, the clade C was not present because the
sequences for GPC and L gene fragments were not avail-
able for the strains forming this cluster in theNP-based tree.
In addition to clades A and B, GPC- and L-based trees sug-
gested existence of 2 additional and distinct clades. Clade
D was represented by 2 sequences from human isolates
SL25 and SL26, which formed a separate cluster (posterior
probability 1.00 for both trees), and clade E represented by
sequences obtained from a single strain isolated in 2006
(SL06–2057). These clades are defined by a very small
number of sequences, and the GPC- and L-based trees dis-
agree on the order of their separation from other clades.
In addition, no data have been published on geographic
origin of clade D and E samples. More data are needed
(including corresponding NP sequences) to establish the
existence and position of clades D and E with more
certainty.
Figure 1. A) Locations of origin for Lassa virus (LASV) nucleic
acid sequences, Sierra Leone. B) Enlarged view of region from
which rodent specimens were collected. Major roads (red) and
waterways (blue) are indicated. Symbols indicate major cities and
towns (stars); sites in this study with rodent samples that were
PCR positive for LASV (circles); sites in this study from which all
samples from mulitmammate rats were PCR negative for LASV
(squares); and sites from which published LASV sequences
originated (diamonds). The color of the symbols in panel B
indicates the clade for nucleoprotein sequence: black, clade A;
green, clade B; blue, clade C. Fractions indicate, for each site
included in this study, number of PCR-positive samples and total
number of samples. Other designations for published sequence
sites indicate type of isolate (H, human; R, rodent) and year(s)
of isolation. No published information about geographic origin
was available for the following strains: 807875, 331, 523, IJ531,
Josiah, NL, SL06–2057, SL15, SL20, SL21, SL25, SL26, SL620.
gene fragment analyzed in this study (0.71% mean differ-
ence) seemed have resulted from selection of a highly con-
served part of L gene (located in RNA polymerase domain)
when the diagnostic assay was designed (28).
The analysis of phylogenetic trees constructed by us-
ing all available partial sequences of NP, GPC, and L genes
from Sierra Leone confirmed previous findings that the
strains circulating in this country belong to lineage IV and
are closely related to each other (17,19). The topology of
the largest NP-based tree (Figure 2) strongly supports the
hypothesis that the isolates from Sierra Leone belong to at
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Figure 2. Phylogenetic analysis of Lassa virus isolates from Sierra Leone based on partial nucleoprotein (NP) gene sequences.
The homologous NP fragments of 621 nt were aligned. The isolate Z-158, which originated from Macenta district in Guinea, was
used as outgroup based on the previous phylogenetic analyses to root the tree. The 50% majority rule consensus tree was estimated by
using Bayesian Inference method implemented in MrBayes software (32) using the Tamura 3-parameter substitution model with discrete
γ-distributed rate variation. The strain labels contain information on the country of origin (SL, Sierra Leone; GUI, Guinea), strain
designation, village or town of origin, type of isolate (H, human; R, rodent), and year of isolation. The numbers next to the branches
indicate the posterior probability of particular clades. The clades as defined in this study (clades A, B, and C) are also indicated next to
the appropriate branches. Scale bar indicates substitutions per site.
All of the trees indicate a high degree of geographic
clustering of the strains. This kind of clustering has been
reported previously over large geographic distances and is
believed to have resulted from limited dispersal and migra-
tion of the host species (17,19). Results of this study show
that this phenomenon also can be observed over relatively
short distances. Isolates originating frommultimammate rat
specimens obtained in a particular location tended to clus-
ter, and conversely sequences present in specific branches
of the trees in many cases originated from a single location
or few locations not far from each other. This kind of clus-
tering could be observed especially well in samples from
Barlie, Largo, Bumpeh, Konia, and Yawei (Figures 2–4).
In addition to the general pattern of geographic cluster-
ing, in several cases single isolates clustered with strains
from different locations. For example, the sequence from
a single sample from Saama (LM513) was closely related to
that of strains from Barlie (based on NP sequence analy-
sis). In another example, 1 GPC sequence originating from
Liberia (523) clustered with Sierra Lone clade A sequences.
In some cases (e.g., Saama sample LM513), such unusual
clustering patterns may be explained by cross contamina-
tion or mislabeling of the samples. They also might result
from relative proximity of all sampling sites and inadver-
tent anthropogenic transfer of rodents. Massive popula-
tion movements that occurred in Sierra Leone during the
1991–2002 civil war could contribute to the process of
mixing multimammate rat subpopulations carrying differ-
ent LASV strains (34).
The geographic location of human cases at such a fine
spatial scale can be problematic because humans canmove
large distances after exposure before disease is detected.
For the human isolates, the clustering inconsistent with
geographic location might have resulted from recording of
the hospital location or patient’s current location as strain’s
origin instead of the actual location of rodent–human
trans- mission. For example, the NP-based phylogenetic
tree in- dicates that human isolates from Segbwema and
Gondama
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Figure 3. Phylogenetic analysis of Lassa virus (LASV) isolates from Sierra Leone based on partial glycoprotein precursor (GPC) gene
sequences. The homologous GPC fragments of 284 nt were aligned. The isolate Z-158, which originated from Macenta district in
Guinea were used as outgroup based on the previous phylogenetic analyses to root the tree. The 50% majority rule consensus tree
was estimated by using Bayesian Inference method implemented in MrBayes software (32) using the Kimura 2-parameter substitution
model with a fraction of evolutionary invariant sites. The strain labels contain information on the country of origin (SL, Sierra Leone;
GUI, Guinea; LIB, Liberia), strain designation, village or town of origin, type of isolate (H, human; R, rodent), and year of isolation. The
numbers next to the branches indicate the posterior probability of particular clades. The clades as defined in this study (clades A, B, D,
and E) are also indicated next to the appropriate branches. Scale bar indicates substitutions per site.
(obtained in 1996 and 1977, respectively) most likely
originated from the Yawei village area because they clus-
ter closely. A few other human isolates (SL15, SL20, and
SL21) for which no location information is available also
clustered with Yawei isolates on the basis of GPC and L
sequences, suggesting their origin in the same area. These
sequences were obtained in 2002 from United Nations
peacekeepers stationed in this part of Sierra Leone (28,35).
Recent epidemiologic data show that LF was detected
in 10 of 13 districts in Sierra Leone, which suggests that
the infection is much more common that previously rec-
ognized (36). Phylogenetic analysis of the sequences re-
vealed that strains circulating in districts to thewest of the
traditional hyperendemic area fromwhichmost sequence
information is available differ significantly (clade B),
which suggests that these could be distinct LASV strains
that circulated in local multimammate rat populations for
a long time since diverging from a common ancestor and
are unlikely to have resulted from recent expansion of this
rodent to new areas, as was recently suggested to explain
emergence of cases from districts in which LF was not
previously reported (36). Furthermore, the presence of
LASV in Barlie with such high prevalence was surpris- ing
because this area historically has had few reports of LASV
until 2 human LF cases reported in 2009 (L.M. Moses,
unpub. data). The lack of reported LF cases from this area
leads to speculation that clade B may be a less pathogenic
form of LASV, and transmission to humans might have
occurred previously but went unrecognized because of
milder, nonhemorrhagic symptoms. In fact, the
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Figure 4. Phylogenetic analysis of Lassa virus (LASV) isolates from Sierra Leone based on partial polymerase (L) gene sequences.
The homologous L fragments of 373 nt were aligned. The isolate Z-158, which originated from Macenta district in Guinea, was used as
outgroup based on the previous phylogenetic analyses to root the tree. The 50% majority rule consensus tree was estimated by using
Bayesian Inference method implemented in MrBayes software (32) using the Tamura 3-parameter substitution model with and a fraction
of evolutionary invariant sites. The strain labels contain information on the country of origin (SL, Sierra Leone; GUI, Guinea), strain
designation, village or town of origin, type of isolate (H, human; R, rodent), and year of isolation. The numbers next to the branches
indicate the posterior probability of particular clades. The clades as defined in this study (clades A, B, D, and E) are also indicated next
to the appropriate branches. Scale bar indicates substitutions per site.
idea of broader area of LASV endemicity in Sierra Leone
is consistent with results of serosurveys conducted dur-
ing the 1980s by McCormick, who found seroprevalence
levels ranging from 8% in southern coastal areas to 15% in
villages in Northern Province (6).
Molecular characterization of isolates from a wider
geographic area of the country is needed to fully under-
stand the diversity of the LASV strains in Sierra Leone and
its impact on disease distribution and risk. Such informa-
tion would be useful for developing efficient viral detection
technologies, for example, enabling design of PCR
primers and antibodies specific for a broad range of
LASV types.
These diagnostic tests are extremely relevant to disease
surveillance and monitoring and evaluation of interven-
tions to prevent primary LASV infection in humans. More
extensive information about sequence diversity affecting
the antigenicity of the virus or the function of its RNA-
dependent RNA polymerase may help in the development
of vaccines and antiviral drugs. It will also lead to deeper
understanding of the biology and pathogenesis of
LASV.
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Abstract
Background: Resource-limited tropical countries are home to numerous infectious pathogens of both human and
zoonotic origin. A capability for early detection to allow rapid outbreak containment and prevent spread to non-
endemic regions is severely impaired by inadequate diagnostic laboratory capacity, the absence of a “cold chain” and
the lack of highly trained personnel. Building up detection capacity in these countries by direct replication of the
systems existing in developed countries is not a feasible approach and instead requires “leapfrogging” to the
deployment of the newest diagnostic systems that do not have the infrastructure requirements of systems used in
developed countries.
Methods: A laboratory for molecular diagnostics of infectious agents was established in Bo, Sierra Leone with a hybrid
solar/diesel/battery system to ensure stable power supply and a satellite modem to enable efficient communication.
An array of room temperature stabilization and refrigeration technologies for reliable transport and storage of reagents
and biological samples were also tested to ensure sustainable laboratory supplies for diagnostic assays.
Results: The laboratory demonstrated its operational proficiency by conducting an investigation of a suspected avian
influenza outbreak at a commercial poultry farm at Bo using broad range resequencing microarrays and real time RT-
PCR. The results of the investigation excluded influenza viruses as a possible cause of the outbreak and indicated a
link between the outbreak and the presence of Klebsiella pneumoniae.
Conclusions: This study demonstrated that by application of a carefully selected set of technologies and sufficient
personnel training, it is feasible to deploy and effectively use a broad-range infectious pathogen detection technology
in a severely resource-limited setting.
Background
Developing countries in tropical regions of the world are
the  home for numerous important infectious pathogens [1-
3]. Many of these infectious agents may have their reservoirs
in domesticated or wild animals [4-8]. Since inhabitants
of these countries live in relatively closer contact with
animals, than populations of highly
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†Equal contributors
1Center for Bio/Molecular Science and Engineering, Naval Research
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developed countries, the  chance of transmission of zoo-
notic  infections to humans is much greater [9]. Some of
these pathogens not only have severe  impact on public
health in countries where they are endemic,   but may
also be rapidly disseminated to non-endemic regions
through global transportation networks  (air, freight con-
tainers), migratory birds, and expanding   wildlife trade
[10-15]. While outbreaks caused by highly lethal patho-
gens such as Ebola, Nipah or H5N1 influenza viruses are
usually followed by high profile epidemiologic investiga-
tions, the everyday infectious disease diagnostics and
epidemiological surveillance systems in many of these
© 2012 Leski et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
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regions are  only rudimentary, sub-Saharan Africa being
one of the prime examples [16,17]. This situation is
compounded by serious shortages of resources and
trained personnel capable  of performing diagnostic pro-
cedures. As a consequence, infectious disease outbreaks in
these   settings are detected relatively late in their course.
A typical example  of the problem was the recent yellow
fever outbreak that began in October 2010 in Uganda.
The outbreak, initially suspected to be caused by Ebola
virus, started in early October and  was subse- quently
misdiagnosed as amoebic dysentery, alcohol poi- soning, and
plague before being  correctly identified as yellow fever at
the end of December. By the time of con- firmation, there
were approximately 200 confirmed cases and nearly 50
deaths were recorded [18,19].
Rapid and  efficient infectious disease surveillance sys- tems
are necessary to improve   outbreak management and
mitigate the consequences of  outbreaks. However, direct
replication the   infectious outbreak surveillance systems
in their current form that exist in developed countries is not
practical due to many reasons including absence of detailed
maps and lack of basic laboratory in- frastructure needed  to
support traditional diagnostic sys- tems. Our previous work
on participatory mapping and surveying methods has
indicated promising solutions to the first problem [20]. The
issues related to inefficiency of current infectious  disease
diagnostics based on culture and  simple molecular assays
remain a serious challenge. Microbial  culture, while still a
“gold standard” technique for identification of bacteria,
cannot be applied  for de- tection of viral pathogens. In
addition, microbial culture is labor intensive, time consuming
and requires qualified and experienced technicians which
are   frequently in short supply in these locations.
Molecular assays are rapid and sensitive but due to  their
low level of multi- plexing usually a number   of different
molecular assays needs  to be performed sequentially to
achieve definitive diagnosis. This is especially relevant in
cases of infec- tious syndromes of diverse  etiologies but
manifested by similar symptoms [21]. Reliance on these
technologies results in  significant delays between specimen
isolation and pathogen identification. An additional difficulty
experienced by many regions of the  developing world  is
the lack of a reliable  cold chain capability necessary for
transport and preservation of biological samples and
diagnostic reagents in hot climate due   to unreliable
power and a lack of basic refrigeration equipment.
One of the  ways to significantly improve the microbial
diagnostic capacity in developing  countries may be ‘leap-
frogging’ or skipping  some stages of technological devel-
opment that other countries have passed or  are passing
through [22,23]. A good example of the “leapfrog”
phenomenon is the   use of mobile phone technology,
which has   enabled the communication in villages in
developing countries   that have never had land phones
with their associated expensive infrastructure [24]. In case
of microbial diagnostics, developing countries may need
to jump  directly to broad-range microbial diagnostic sys-
tems, which are capable of one-step detection and identifi-
cation of large number of diverse  pathogens in a single,
highly automated, assay. Advanced broad-range diagnostic
technologies have  the potential of making the pathogen
identification process simpler and faster leading  to more
efficient  detection and management of infectious disease
outbreaks both in humans and animals.
The purpose of this study  was to test the feasibility of
application of a broad-spectrum diagnostics/surveillance
platform for microbial detection in a resource-limited
setting. This  feasibility study was the result of a collab-
orative effort between  the US Naval Research Laboratory
and Njala University, which led to the establishment of a
molecular diagnostic laboratory at  Mercy Hospital Re-
search Laboratory, Bo, Sierra Leone.
Setting up this type of facility required solving a num- ber
of issues typical for developing countries with a trop- ical
climate including securing a reliable  power supply,
implementing cold chain and complementary methods
of preserving biological samples  and reagents, and enab-
ling efficient communication by setting up an internet
linked computer network. This paper describes how a
broad spectrum diagnostics system was successfully
deployed using a set of “leapfrog” technologies that were
found to be critical in  establishing an efficient labora-
tory. The resequencing-microarray-based diagnostic sys-
tem was subsequently applied for investigation of a
suspected   avian influenza outbreak at the commercial
poultry farm.
Methods
Laboratory setup
The molecular diagnostic laboratory was   set up in
Mercy Hospital Research Laboratory (MHRL) located in
the city of Bo, Sierra Leone. Bo is the second largest city
in Sierra Leone and the capital of the Southern Prov-
ince. The 1,200 square foot laboratory   was located on
the Mercy Hospital campus in Kulanda Town section of
Bo. All equipment, which required temperature within
certain  limits for proper operation (including PCR
instruments, Affymetrix fluidics stations, hybridization
ovens and microarray scanner) was located in  two air-
conditioned rooms. An additional air-conditioned
laboratory    area detached from the main laboratory
building was equipped   with a PCR  laminar flow hood
and used for sample preparation for PCR, RT-PCR and
sample   processing for resequencing pathogen micro-
array (RPM) assays.
For cold storage,  the laboratory was equipped with two
57 liter AcuTemp AX56L/HemaCool mobile refrigerator/
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freezers (AcuTemp,    Dayton, OH), four Fridge-Freeze
60 liter portable vaccine refrigeration units (two freezers
and two refrigerators) with ability to be powered with 12/
24-volt DC or 110/240-volt AC  (Fridge-Freeze Inc. San
Diego, CA) and one upright Kenmore  freezer model 2804
(Sears, Roebuck and Co., Hoffman Estates, IL). HemaCool
freezers can  be adjusted for freezing (−20°C) or refriger-
ation (+4°C) and can be run for 16 hrs continuously in the
absence of external power on internal batteries.
The power for the laboratory operation was supplied by
two hybrid power subsystems, one operating at
230 V, 50 Hz (used for powering European and African
made equipment) and another one operating at 120 V,
60 Hz (for powering US made scientific instruments).
Both systems relied on combination of solar power with
battery storage and  diesel generator backup. The 230 V
subsystem was additionally connected to municipal
power grid and used municipal   power when available.
The detailed description of the power system and its
performance was published previously [25,26].
Communication
A stand-alone solar powered C-band satellite communi-
cation system   was configured by Satcom Resources
(Avon, CO) and deployed at MHRL. Bandwidth (512/
128 (kb/s) up/down) was provided by Constellation Net-
works Corp. (Traverse City,  MI) and served up to 20
users simultaneously via intranet across  the Mercy Hos-
pital campus. The  diagram of the network configuration is
included in supplementary data   (Additional file 1: Figure
S4). Teleconferencing for training   purposes and data
exchange was conducted using Skype platform (Skype
Technologies S.A., Rives de Clausen, Luxembourg).
Ambient temperature stable reagents
Ambient temperature stabilized  reagents for PCR, real-
time PCR or resequencing microarray protocols were ei- ther
obtained commercially or developed in-house using
lyophilization techniques (see Additional   file 2: Tables S3
and S4 for listing of  stabilized reagents tested and used
for all molecular diagnostics protocols).
FTA paper - sample stabilization and recovery
Flinders  Technology Associates filter paper (FTA paper,
Whatman/GE Healthcare, Florham Park, NJ) [27] was
used in this work to explore its suitability for dry storage of
RNA preparations and for stabilization of field sam- ples
collected from poultry. Either  Indicating FTA Mini Cards
(WB120356, Whatman) or Indicating FTA Classic Cards
(WB120206, Whatman) were  used depending on the
application. An aliquot of RNA samples was spotted on the
card or swabs containing field samples were pressed
against an FTA card in order to transfer the maximum
amount of fluid from swab to the FTA paper.
Subsequently the FTA cards were air dried at ambient
temperatures for 40 minutes. Dry FTA cards were stored
at ambient temperatures unless otherwise indicated.
To recover the nucleic  acids for use in diagnostic pro-
cedures, the FTA paper embedded   samples were pro-
cessed using the following procedure modified from a
protocol developed by Rogers and Burgoyne [28]. Circu-
lar punches (1 mm or 3 mm in  diameter) of the FTA
paper from the areas of sample deposition   were taken
using  Harris Uni-Core punch (Ted Pella Inc., Redding,
CA). The punches were placed into 0.5 mL microcentri-
fuge tubes and incubated for 5 min. with gentle shaking
in 200 μl of solution A (4 M LiCl solution in 50% etha-
nol). The incubation was repeated once with fresh solu-
tion A.  After incubation, the disks were washed with
gentle shaking for 5 min. in 200 μl of solution B (50 mM
Tris–HCl solution   in isopropanol), then washed twice
for 5 min. with 200 μl of 70% ethanol. After the final
wash, the samples were air dried at 42°C for at least
30 minutes to remove the traces of ethanol completely.
RNA purification
The RNA was purified from influenza  B/Lee/40 prepara-
tions (Advanced Biotechnologies, Inc.,  Columbia, MD)
using MasterPure DNA and RNA purification kit (Epi-
centre Biotechnologies, Madison,   WI) using manufac-
turer recommended protocol.
Testing viral RNA stabilization efficiency on FTA paper
Influenza B RNA samples (5 μl each of 106, 104 or 102
genome copies/μl dilutions) were spotted on Indicating
FTA Mini Cards (Whatman). The cards were incubated
under one of three conditions: at room temperature 20-
25°C (on a laboratory bench), 30°C (incubator) and 30-
45°C (outdoors, protected from  light) for up to 10 days.
Three 1 mm punches were removed from the FTA cards
at 24 hours, 3 days, and 10 days). The punches were
processed as described above (see “FTA paper - sample
stabilization and recovery” section).
Collection of poultry pharyngeal samples
Pharyngeal swabs  were collected on March 30th, 2009,
using sterile techniques from 136 chickens housed in 9
different poultry farms. The farms were located in  Bo
and in the vicinity of Freetown (Figure 1),  their geo-
graphic coordinates were determined using handheld
Garmin GPSMAP 60CSx GPS unit (Garmin Inter-
national Inc.,  Olathe, KS). Basic farm information, the
numbers of samples   taken at each farm and general
health characteristics of  the poultry on farms sampled
are included in Table 1. The collected   swab samples
were stabilized and stored on FTA  cards. After trans-
porting to the laboratory in ambient temperatures, the
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FTA embedded s p e c i m e n s w e re placed in −20°C freezer
for long term storage.
Resequencing microarrays
The resequencing microarray analysis was conducted
using RPM-Flu v. 3.1  (RPM-Flu) and RPM-TEI v. 1.0
microarrays (RPM-TEI)  in March 2010. Poultry samples for
analysis were selected using a two-stage process. First the
samples for which  the  amount of deposited samples was
small (judged by  the size of spot with change of color
on indicating FTA card) were rejected. The remaining
FTA samples  were blindly drawn to select 15 samples from
Bo farm and 3 samples each from 5 other farms. RPM-Flu
v. 3.1 was designed  to detect all known subtypes of influenza
A viruses  and 84 other viral and bacterial respiratory
pathogens [29], while the RPM-TEI microarray was
designed for detection of a broad range of biothreat agents
[30] some of  them (such as Lassa virus) endemic to West
Africa. Sample processing was conducted as previously
described [30-32] with the
following modifications related to the  use of FTA paper
embedded samples. Briefly, reverse transcription using
random primers was used to  obtain cDNA from RNA
templates potentially  present in a processed FTA paper disk
for each analyzed sample. The resulting mixture was
separated from the FTA paper disk and split into four
aliquots of equal volume for  multiplex PCR reac- tions
using either RPM-Flu or RPM-TEI microarray spe- cific
primer cocktails. Modified version of this protocol for
testing   the lyophilized/ambient temperature stabi- lized
reagents is included as Supplementary Data.
Pathogen identification was performed using previously
developed Computer-Implemented Biological Sequence
Identifier (CIBSI) 2.0 software [33]. Although the microar-
rays are designed with  tiles for specific pathogen targets
[29,30,32], they  are capable of detection and correct se-
quence determination of targets differing by up to  15%
from the sequence present on the microarray. This allows
for detection of target variants and near-neighbor
discrimination.
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Table 1 Farm and chicken sample information
No.
Town
Farm location
Coordinates
No. of
sheds
No. of
samples
collected
Sample
designations
Condition of chickens
1 Bo 7°57.911'N 11°44.767'W 1 40 B1-B40 Outbreak affecting 15% of chickens
2 Hamilton 8°23.275'N 13°15.453'W 4 20 H1-H20 All healthy
3 Oogu 8°24.256'N 13°15.612'W 1 16 O1-O16 All healthy
4 Wellington 8°27.222'N 13°10.242'W 3 12 W1-12 Some chickens sick
5 Allen Town 8°24.266'N 13°8.742'W 11 16 A1-16 All healthy
6 Hastings 8°22.776'N 13°8.094'W 1 8 HA1-HA8 All healthy
7 Hastings 8°22.622'N 13°7.997'W 1 4 HB1-HB4 All healthy
8 Hastings 8°22.403'N 13°7.925'W 2 8 HC1-HC8 All healthy
9 Joe Town 8°19.549'N 13°2.535'W 3 12 J1-12 Some chickens sick
Reverse transcription and real time PCR (RT-PCR)
In order to detect influenza B RNA in testing RNA
stabilization on FTA 1 mm processed disks were placed in a
0.5 mL PCR tube, and subjected to one step reverse
transcription and PCR (RT-PCR)  using Qiagen OneStep RT-
PCR Kit (Qiagen, Valencia, CA) according  to the man-
ufacturer’s instructions. Positive controls were prepared using
liquid preparations of influenza B RNA stored at
−20°C. The RT-PCR reaction was run in 25 μl total vol- ume
using previously published BMA-F1 and BMA-R1 primers for
detection of influenza B [31] and the following thermal
cycling protocol: 50°C for 30 min; 95°C for
15 min.; 40 cycles of 94°C for 30 sec., 54°C 30 sec., 72°C
30 sec.; 72°C 10 min. The expected amplicon was a 162 bp
segment of the influenza B matrix gene. The amplification
results were analyzed using 2% TAE agarose gels contain- ing
ethidium bromide. The  bands were visualized in UV light
and images captured using UVP BioDoc-It System, model
M-20 (UVP, Upland, CA).
Real-time RT-PCR for universal detection of influenza A
(based on  detection of fragment of the Matrix gene) was
performed using previously published PCR primers: MatrixF1
and  MatrixR1 [34]. A preparation of influenza A H3N2
control strain was used as a positive control, water and
blank processed FTA paper  discs were used as negative
controls. Reverse transcription (RT) was per- formed using
AccuPower Cyclescript RT  premix (Bio- neer, Alameda,
CA).   The total volume of the RT reaction was 20 μl
containing 500 nM each of forward and reverse primers.
The reaction mixture was subjected to 12 cycles of
incubation at 25°C for 1 min. and 50°C
thermal  cycling and fluorescent signal detection was per-
formed   in a CFX96 real-time PCR detection system
(Bio-Rad Laboratories) with the following thermal cyc-
ling conditions: initial incubation at 98°C for 2 min. fol-
lowed by 40 cycles of 98°C for 2 sec. and 60°C for 5 sec.
The amplification cycle was followed  by melting curve
analysis. The results were analyzed with CFX Manager
software ver. 1.5.534.0511 (Bio-Rad Laboratories).
The protocols for RT-PCR and real-time RT-PCR for
detection of influenza  A using ambient temperature sta-
bilized reagents are described in Supplementary Data
(Additional file 2), and the reagents  used with these pro-
tocols are listed in (Additional file 2): Tables S3 and S4.
Results and discussion
Laboratory operation
This study was intended to identify the suite of technolo-
gies necessary to deploy and successfully apply an
advanced, “leapfrogging”, technology for broad range
pathogen identification in a severely resource-limited
Table 2 Technologies applied to deploy broad-range
infectious pathogen diagnostics
Problem Solution/s applied Unreliable
power Efficient hybrid solar/diesel power system Lack of
“cold chain” On-site refrigeration
FTA paper for sample collection, transport and storage
Ambient temperature stabilized reagent sets
Delivery of regular reagents on dry-ice
for 4 min. and single final incubation at 95°C for 5 min.
The real-time PCR amplification reactions   were con-
ducted using SsoFast EvaGreen reaction mix (Bio-Rad
Laboratories, Hercules, CA) according to  the manufac-
turer’s instructions. The reaction was carried out in
20 μl total volume containing 500 nM of each primer
with 2 μl of the RT reaction mixture as a template. The
Lack of efficient
communication
Inadequate personnel
expertise
Wired/wireless, hi-speed campus
network connected
with Internet via satellite
Hands-on training in reference laboratory (NRL)
and on-site.
Remote technical support by email
and Skype videoconferencing.
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setting. The typical major challenges in  setting up a la-
boratory in a  developing country are listed in Table 2.
They needed  to be addressed in order to make the labora-
tory operational and capable of reliably running high qual- ity
molecular diagnostic protocols. While the general class of
solutions was easy to recognize, the actual solution
implemented depended intimately on the local conditions.
Stable power
One   of the most significant difficulties in establishing
stable operation of the molecular diagnostics  laboratory in
Bo was inadequate power necessary to run laboratory
equipment. Due to the reliance on hydroelectric power
generation in  Sierra Leone, the availability of municipal
electricity (supplied by Bo/Kenema Power Service –
BKPS) varies throughout the year and power is mostly un-
available during the dry season spanning from November to
April. Even  when available, the electricity is of poor quality
due to inadequate design  of electrical grid and is not suitable
for  powering sensitive scientific equipment [26]. To
overcome this problem an innovative hybrid power system
composed two self-contained local grids with two hybrid
power subsystems (230 V, 50 Hz and
120 V, 60 Hz) was designed and deployed [25,26]. The sys-
tem combined solar power generation with battery storage
and diesel generator backup  to provide reliable power for
both basic laboratory infrastructure (e.g. lights, air condi-
tioners)   as well as sensitive scientific instruments (e.g.
PCR cyclers, GenChip scanner).
Personnel training
Training is another key component of a  successful la-
boratory set up. The laboratory personnel   have under-
gone 10-week training    in basic molecular biology
diagnostic techniques including various PCR, and rese-
quencing microarray technologies at Naval Research La-
boratory (NRL) located  in Washington, DC. A follow up
training was conducted in Bo by NRL personnel.
Personnel from MHRL also  obtained scanner mainten-
ance  and calibration training from Affymetrix to ensure
proper functioning of the scanner since this was the
most delicate instrument of the system and needed  to be
periodically recalibrated. The proficiency of trained personnel
was successfully demonstrated by conducting the
investigation of an outbreak at the poultry farm that is
described   below. In addition to initial training, the NRL
personnel were remotely supporting MHRL scien- tists
taking advantage of  the Internet connected com- puter
network and Skype based videoconferencing.
Stabilization of field samples and molecular biology
reagents
While the stable power and use of freezers and refrigera-
tors with battery backup solved the problem of storing
perishable reagents and  samples in the laboratory, it did
not address the issues related to preservation samples
collected  in the field. Transport of temperature sensitive
reagents needed for diagnostic procedures was also a
significant problem due to  unavailability of commercial
“dry-ice” refrigerated transport service  in  Sierra Leone.
To overcome these difficulties we explored applicability
of two technologies: FTA paper for field sample collec-
tion and transport as well as stabilization of molecular
biology reagents by freeze drying or related techniques.
FTA paper
FTA paper  is a well-established technology for ambient
temperature preservation of   nucleic acids and was
designed to protect   nucleic acids of the stored sample
from degradation caused   by nucleases, oxidation, UV
light and other processes [35,36]. FTA paper  also rapidly
inactivates pathogens    making the infectious samples
safer to handle by untrained personnel [35-37]. While it
was shown that FTA cards are  able to  adequately store
DNA samples  at room temperature for at least 17 years
without significant degradation [38,39], only limited data
is available on the stability of RNA on FTA paper, espe-
cially when stored  at elevated temperatures [28,35,40]. A
series of experiments was conducted to find out  if FTA
technology might be suitable for short-term preservation
of samples containing RNA viruses at high ambient tem-
peratures characteristic for a tropical  country such as Si-
erra Leone. Influenza B was used as a model organism
for testing. Three different concentrations of influenza B
RNA were spotted on FTA Minicards and stored  at vari-
ous temperature conditions for 1–10 days. The higher
concentration of RNA (106 and 104 copies/μl) was con-
sistently detectable after 10 days even when incubated at
the  highest tested temperatures (Table  3 and Additional
file 1: Figures S1-S3). Although the lower concentration
of RNA (102 copies/μl) was not detectable in more than
half  of the analyzed samples, the lack  of detection did
not seem to correlate with storage   conditions. These
results indicated that in addition to the  established cap-
ability to maintain stable DNA, the FTA cards could also
be used to collect and store RNA samples for a time
frame sufficient to transport and test samples. Inconsist-
ent results of recovery of low concentrations of influenza
B from FTA paper most likely reflected the phenomenon
of dilution of samples deposited   on FTA or inefficient
recovery rather than degradation of the RNA.
Reagent stabilization
In an effort to overcome the  problems with the delivery
of temperature sensitive reagents   to Sierra Leone, we
made an attempt to  design molecular diagnostic proto-
cols taking  advantage of ambient temperature stabilized
reagents. Commercially available stabilized reagents were
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concentration
(copies/ 1
24
2 3 1
72
2 3 1
240
2 3
(°C)
microliter)
106 + + + + + + + + + 20-25 (RT)
+ + + + + + + + + 30
+ + + + + + + + + 30-45 (outdoors)
104 + + + + + + + + + 20-25 (RT)
+ + + F + + + + + 30
+ + + + + + + + + 30-45 (outdoors)
102 − − − + + F − F F 20-25 (RT)
− − − F F − − − − 30
F F F − F F − − − 30-45 (outdoors)
106 (control RNA) + + + −20 (freezer)
102 (control RNA) + + + −20 (freezer)
Table 3 Efficiency of detection of Influenza B RNA stored on FTA paper incubated at elevated temperatures1
Influenza B
RNA
Duration of incubation (hours) Incubation
temperatures
1Each experiment for particular combination of sample concentration and temperature was run in triplicate. Plus sign indicates that RT-PCR detection produced strong
band of expected size that was observed on a gel; F indicates a faint band  and a minus sign indicates absence of an amplification product detectable by visual
inspection on a gel.
used for reverse transcription, PCR, and  real-time PCR
together with modified  protocols optimized for use with
these regents. However in case of RPM platform,  the sta-
bilized reagents were developed   in-house since there
were no commercially stabilized    reagents available.
These reagents were  developed by adaptation of previ-
ously  published methods [41-43]. Details of the proto-
cols, commercial reagents tested and custom reagent
composition and stabilization procedures are described in
supplementary data (Additional file 2).
While these ambient-temperature-stabilized   reagent sets
were very stable  in high ambient temperatures, the testing
results showed  that diagnostic assays using these reagents
were significantly less sensitive than traditional reagents (data
not shown). Due to financial and time constraints,
optimization of the stabilized reagents was not pursued.
While the stabilized reagents were not used for the
subsequent epidemiological  investigation, the re- agent
stabilization technology   has a great potential to make the
molecular diagnostics more accessible in developing countries
by eliminating the cold chain, greatly lowering power
requirements that are dominated by refrigeration equipment
and making the diagnostic protocols significantly less
complex  and error prone [41-
43] and should be further explored in future.
As an  alternative, reagents were transported as carry- on
“dry ice” package in accordance with all airline regu- lations.
The packages were prepared    with sufficient amount of
dry ice for 48 hours  and passed through x-ray examination.
Testing conducted with these reagents showed no
noticeable difference in performance. Since US based
personnel overseeing   Mercy Hospital travel
regularly (every 1–2 months) to the site, it was possible
to ship reagents to maintain operation of the molecular
diagnostics laboratory for sustained periods of time.
Poultry outbreak investigation
To  test the operational capabilities of MHRL molecular
diagnostics laboratory broad-range microbial detection
assays were used to investigate   an outbreak that oc-
curred at one   of the few commercial poultry farms
located in Bo. The  concern was that the outbreak might
have been  caused by a highly pathogenic influenza virus
which might be potentially transmitted to farm workers
or poultry  kept by individual owners. This is a significant
risk especially in developing countries where it is a com-
mon  practice to keep chickens in close proximity to the
household and potentially expose the whole  families to
the poultry pathogens.
Two different assays, RPM-Flu and RPM-TEI, were
used to analyze the outbreak samples. The analysis strat-
egy relied on using microarray based broad-range detec-
tion assay to analyze just a small percentage of collected
samples and follow up using single specific PCR based
assays for larger numbers of samples based on the
results of  microarray analysis. Therefore only 15 ran-
domly selected samples (see methods    for selection
process details) out of a total of 40 pharyngeal swab
samples collected in the farm located in Bo  and pre-
served on FTA paper were tested   using resequencing
assays. For comparison, 15   additional samples were
selected from 5 other farms located  in the Freetown area
which housed mostly healthy chickens were also ana-
lyzed  using the same microarrays. The results of RPM
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Table 4 Results of pathogen detection using RPM-Flu 3.1
microarray
Farm Sample Most likely ID*
1 B1 K. pneumoniae, P. stutzeri
B2 K. pneumoniae, P. stutzeri B3 K.
pneumoniae
B4 no detection B5 no
detection B11 no detection
B12 K. pneumoniae, P. aeruginosa, Staph. (mecA gene) B13
K. pneumoniae, Pseudomonas
B14 K. pneumoniae, P. aeruginosa, Staph. (mecA gene) B15
K. pneumoniae, P. putida, Staph. (mecA gene)
B25 K. pneumoniae, Pseudomonas
B26 K. pneumoniae
B27 K. pneumoniae, P. putida
B28 K. pneumoniae, P. aeruginosa, Staph. (mecA gene) B35
no detection
2 H2 no detection
H3 no detection
H4 (P. aeruginosa or M. catarrhalis)
6 HA5 (P. aeruginosa or M. catarrhalis)
HA6 no detection
HA7 Pseudomonas
5 A1 no detection
A2 P. putida
A16 no detection
9 J2 P. aeruginosa, E. sakazakii
J7 no detection
J10 no detection
4 W3 K. pneumoniae
W4 P. aeruginosa
W6 (Pseudomonas or Moraxella or Methylobacillus)
*Most likely ID was determined using CIBSI algorithm and based on similarity
analysis of the sequences obtained from the microarray with sequences
deposited GenBank at the time of conducting the analysis (April 2010).
Abbreviations used: K. pneumoniae = Klebsiella pneumoniae, P.
stutzeri = Pseudomonas stutzeri, Staph. = Staphylococcus spp., P.
aeruginosa = Pseudomonas aeruginosa, P. putida = Pseudomonas putida, M.
catarrhalis = Moraxella catarhalis, E. sakazakii = Enterobacter sakazakii. Organism
names enclosed in parentheses denote result of hybridization of a single
microarray tile, which cannot be unambiguously identified based on the
obtained sequence.
microarray analysis of selected samples are summarized
in Table 4 and described below.
Bacterial pathogens
While no viral pathogens were detected using RPM assays, a
number of bacterial pathogens including Klebsiella
pneumoniae and several Pseudomonas species were found
in analyzed samples.
An assortment of closely related Pseudomonas species (P.
stutzeri, P. aeruginosa, P. putida) or undefined
Pseudomonas was detected in 16 of  the 30 analyzed
samples. The ubiquitous presence of Pseudomonas spp.,
a known opportunist organisms colonizing the avian re-
spiratory tract  [44], indicated that it played no significant
role  in the outbreak. K. pneumoniae on  the other hand
was found mostly in the samples from farm in Bo (73%,
12 out of the 15 analyzed samples), while only one sam-
ple from farms outside of Bo was positive for this organ-
ism (7%, Table 4). This result suggested a link between
the outbreak and the presence   of K. pneumoniae. Al-
though K. pneumoniae is usually considered an environ-
mental contaminant, it  may sporadically cause embryo
mortality, yolk sac infections and mortality in young
chickens, turkeys and ostriches. In addition, the concur-
rent infection of young turkeys with  K. pneumoniae is
known   to increase the severity of respiratory disease
caused by other pathogens [44]. The presence of K.
pneumoniae in the majority of  outbreak samples sug-
gested that it is an opportunist pathogen colonizing/
coinfecting sick chickens and increasing the severity  of
infection caused by another    (unidentified) pathogen.
This  notion was also supported by the fact that higher
percentages of outbreak samples were testing positive
for more than one pathogen simultaneously (60% vs. 6%
of healthy samples).
In   addition to previously mentioned bacteria, the
RPM-Flu microarray also detected mecA (methicillin re-
sistance) gene in four samples collected from the farm in
Bo. The  mecA gene is responsible for staphylococcal re-
sistance to a broad range of β-lactam   antibiotics [45].
While  mecA carrying bacteria in chickens were reported
before [46], it is unknown if the staphylococci carrying
this gene were acquired by poultry from  humans or the
spread   of this resistance mechanism was purely zoo-
notic. Nonetheless, the prevalence of mecA gene (at least
10% of analyzed samples collected in Bo) in the
staphylococci colonizing/infecting the analyzed popula-
tion  of chickens is a cause of concern due to a potential
of spread to humans and warrants further study.
Influenza virus
Lack of  positive detection of influenza in all samples
tested with RPM-Flu assay indicated that it is unlikely
that the outbreak was caused by any known  strain of in-
fluenza virus as it was initially suspected. To independ-
ently confirm the RPM-Flu assay and expand the results
of influenza A detection, all 136 collected samples were
analyzed using a published  real-time RT-PCR assay [34].
This assay, amplifying a conserved  segment of influenza
matrix gene to detect influenza A regardless of serotype,
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also did not detect the presence of this virus in any of
the analyzed samples (data not shown).
Based on the obtained   results, it was impossible to
exclude the   possibility that the outbreak was caused
by one of the major poultry respiratory pathogens
(such as avian paramyxovirus type 2 [47] or avian
metapneumovirus [48]) that are   not represented on the
RPM-Flu microarray, since this assay  was targeted for
detection of human pathogens.
Although, the conclusive determination of the  cause of the
outbreak and the  roles of particular identified patho- gens
was not possible based on the available data, the out- break
investigation demonstrated potential usefulness of the broad-
range microbial detection technology in future investigations.
The recent emergence and spread of highly pathogenic avian
influenza strains has raised concern about outbreaks in
poultry farms. As a result, the local health authorities usually
treat poultry farm outbreaks as a potential deadly threat to
humans, and order all the birds in  the affected farms to be
culled as a precaution. This practice results in a very
significant  economic burden to farm owners in developing
countries  and it may be avoid- able. In this study, the delay of
completion of the molecu- lar analysis (approx. 11 months)
caused by problems associated  with logistics of reagent
delivery did not enable us to prevent the slaughtering of the
flock, however, the study indicated that application of
broad–spectrum mi- crobial diagnostics might make it
possible in future out- breaks. While cost of conducting a
single RPM assay (approx. $100-200) is too  high for routine
diagnostics in resource-limited settings, the technology may
be a cost ef- fective way for national surveillance of avian
influenza and other important human pathogens. The power
of a single set of RPM assays allows detection of a panel of
pathogens that would  otherwise require a full national
reference la- boratory infrastructure, which would costs
millions of USD. In the case of this project the total cost of
setting up the laboratory   to run RPM based assays was
approxi- mately $250 thousand, including the building for
labora- tory set up, power equipment, scientific instruments,
telecommunication infrastructure and training.
Conclusions
The project has  shown that successful deployment and
application of an advanced  diagnostic technology in the
conditions of low-resource tropical country is  feasible.
One of the most important outcomes of this effort was
identification of a set of technologies that  are needed to
achieve this goal  in an extremely challenging environ-
ment. Laying this groundwork will help us and others to
build infectious  pathogen diagnostic capacity in develop- ing
world in an efficient way by taking advantage of technological
“leapfrogging”.
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Abstract
Background: Spatial epidemiology is useful but difficult to apply in developing countries due to the low
availability of digitized maps and address systems, accurate population distributions, and computational tools. A
community-based mapping approach was used to demonstrate that participatory geographic information system
(PGIS) techniques can provide information helpful for health and community development.
Results: The PGIS process allowed for the rapid determination of sectional (neighborhood) boundaries within the
city of Bo, Sierra Leone. When combined with data about hospital laboratory visits, a catchment area for one
hospital in Bo could be established. A survey of households from within the catchment area determined that the
average population per household (about 6 individuals) was similar to that found in the 2004 census. However, we
also found that the average house was inhabited by more than one household, for an average of 17.5 inhabitants
per residential building, which is critical information to know when estimating population size using remote
imagery that can detect and enumerate buildings.
Conclusions: The methods developed in this paper serve as a model for the involvement of communities in the
generation of municipal maps and their application to community and health concerns.
Background
Low-income countries would benefit significantly from
the expanded use of Geographic Information Systems
(GIS) in the analysis of disease distribution, since GIS
could provide more accurate information about disease
incidence and prevalence rates and would allow for bet-
ter allocation of the limited resources available for pub-
lic health [1-5]. However, these areas face significant
barriers to the implementation of GIS for spatial epide-
miology, due both to a lack of disease data (because of
limitations in disease detection and reporting systems)
and to the non-existence of detailed maps, especially in
areas affected by conflict, population displacement, and
rapid urbanization. Without accurate population, dis-
ease, and spatial data, it will not be possible to imple-
ment effective surveillance systems in these countries.
Increasing the accuracy of these measures will require
* Correspondence: anthony.malanoski@nrl.navy.mil
† Contributed equally2Center for Bio/Molecular Science and Engineering, Naval Research
Laboratory, Washington, DC 20375 USA
Full list of author information is available at the end of the article
an improvement in data collection and management sys-
tems as well as a significant increase in the ability of
scientists in low-income countries to apply epidemiolo-
gical, laboratory, and GIS techniques to local health
concerns [6-8].
Freely-available mapping and analysis tools and free or
low-cost data and image sources (such as Google Earth)
can be a greatly beneficial starting point for generating
basic map features in areas where this information is
not already available. However, effective disease surveil-
lance requires that physical geographic information be
supplemented by data about social and population fac-
tors that can be mapped at a fine scale. Combining
information about distances from water, waste disposal
areas, swampy areas, and other physical characteristics
as well as information on population density, economic
factors, and the location of health resources provides a
more complete picture of health and disease by provid-
ing information about potential mitigating and debilitat-
ing factors. Even simple information about the location
of patients’ homes and the characteristics of those dwell-
ings can provide helpful information about both physical
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and socioeconomic parameters that can be incorporated
into a health GIS, information that is rarely available in
low-income countries with limited access to technology.
As the amount of remote imagery available for use in
lower-income areas is expanding, so is the need for
ground-truth validation of these high-resolution maps,
which must be completed before advanced GIS analysis
can be conducted [9-14].
Methods that engage and empower communities and
allow local residents to incorporate their knowledge into
the production of a GIS are a promising emerging
approach for assembling ground truth data. Public Parti-
cipation Geographic Information Systems (PPGIS)
emerged in the 1980s as a formal method to involve the
“public” in the creation and use of geographic informa-
tion [15-17]. PPGIS and related approaches, such as par-
ticipatory GIS (PGIS), community integrated GIS, and
GIS for participation, have been adapted for use in a
variety of settings with various levels of local participa-
tion, different types of communities, and a range of
intended applications [17-20]. In each of these models,
the goal is to integrate local knowledge with “expert”
data and techniques.
In this study, we developed and used participatory
methods to provide a low-cost solution to address map-
ping issues in Bo, Sierra Leone, and to begin populating
a GIS with population statistics that can be used to
address many community issues. Our specific aims were
as follows: (1) to create a map of the sections (neighbor-
hoods) of Bo by employing a participatory mapping
method, which included interviews of knowledgeable
long-term local residents and consultation with munici-
pal authorities in the Bo City Council and local officials
and (2) to estimate total population in a few sections by
combining data from the map, the 2004 census, and
population data obtained from household surveys. As
part of the first aim and an example of how maps can
be applied to health-related research, an analysis of visits
to the Mercy Hospital Laboratory was performed using
hospital records. Future studies will use the information
from the map and surveys of households sampled from
residential buildings identified on the map to assist with
the initiation of an active infectious disease surveillance
system and the analysis of the social and environmental
factors contributing to the incidence and prevalence of
diseases.
Results
Sectional mapping
Our first goal was to use a participatory process to cre-
ate a map of the boundaries for each section within the
city of Bo, which is the second largest city in Sierra
Leone and the urban center of Bo District (the equiva-
lent of a state or province). Although sections are
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formally-recognized and distinct areas of the city, no
official map of the sections in Bo has been made since
1964, when the Directorate of Overseas Surveys (D.O.S.)
produced a map of Bo with sectional information and
street addresses for Sierra Leone’s Ministry of Lands,
Housing, Country Planning, Forestry and the Environ-
ment (MLCPE). This map is now obsolete due to the
significant growth of the city over the past forty years
and to a civil war from 1991 to 2002 that destroyed
much of the country’s infrastructure and capacities.
Now that peace has been re-established, new maps are
required to provide accurate current information. The
Development Assistance Coordination Office (DACO)
and the Sierra Leone Information System (SLIS) have
developed a map of main roads and landmark buildings
from 2002 Ikonos imagery, but this map does not show
the location of the sections of Bo city.
The participatory process employed in this study
resulted in the mapping of 68 sections within the 30.1
km2 area encompassed by the city of Bo. Each section
has a unique shape (Figure 1) and size (Table 1), with
sectional areas ranging from 0.02 km2 (Toubu) to 2.33
km2 (Bo Government Reservation). The section map
provides organizational information about the city of
Bo, and additional information, such as the locations of
hospitals and large clinics (Figure 1), can be displayed at
the sectional level.
Catchment area study
The sectional map will be useful for a variety of applica-
tions, including public planning and social and health
research. A brief illustration of this applicability involves
the use of the map to define a catchment area for one
of the hospitals in Bo, Mercy Hospital, which is on the
north side of the city (Figure 1). A summary of the resi-
dents of Bo who visited Mercy Hospital Laboratory for
clinical testing and provided the name of their home
section is shown in Table 1. (Patient information was
extracted from the hospital’s computerized database.)
Figure 1 shows the home sections for those 797 patients
(which represent only 52% of the 1810 total laboratory
patients) using a darker grey to represent sections that
are home to more Mercy Hospital patients. As might be
expected, the majority of laboratory patients (n = 274)
live in the section in which Mercy Hospital is located,
Kulanda Town. The number of patients is smaller in
other sections (n = 0 to 55), and the number decreases
as the distance from the hospital becomes greater. The
section map will make it easier for future patients to
identify their home neighborhoods, which will increase
the proportion of patients who can be included in the
GIS.
Figure 1 also shows that 13 sections have half or more
of their area located within 1 km of Mercy Hospital.
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Figure 1 Sectional map of Bo. Bo, Sierra Leone, with sections and major roads indicated. The locatio of all hospitals and large clinics are
marked with point. Concentric circles in the northern part of the city with 0.5 km, 1.0 km, and 1.5 km radii are marked to indicate distance from
Mercy Hosptial (marked as small square) to various sections of the city. Fill color is indicative of the number of patients who had lab tests from
each section.
From Table 1, it can be determined then that 509 (64%)
of hospital patients with a known residential section live
in one of these nearby sections, which represent only
12.5% (3.76 km2) of the total area of Bo. This demon-
strates that the pool of people who normally visit Mercy
hospital was strongly associated with distance from the
hospital.
Population estimation
Many public policy decisions and community health
assessments are based on rates and other characteristics
rather than just counts. The calculation of a rate
requires an accurate numerator - a subset of the popula-
tion that meets certain criteria - as well as an accurate
denominator, such as the total population in a section
of a city or the age- and/or sex-specific count of resi-
dents. The total number of residents can be projected
from the number of houses in each section and the
average household density of a section. The sectional
map for Bo can serve as a baseline for estimating the
current population of Bo, which is an essential step
toward having an accurate “denominator” for the
estimation of rates of disease and other characteristics
of residents of Bo.
A preliminary examination of population size was
conducted in the two sections of Bo located nearest to
Mercy Hospital, Kulanda Town and Njai Town. First,
remote sensing was used to identify structures. Then,
census data from 2004 was used to estimate the popula-
tion size. Finally, a household survey was conducted to
determine the total number of inhabited buildings and
the total number of residents in each of the residential
structures. These participatory methods could later be
implemented in the other sections of Bo identified on
the section map. Figure 2 shows the household map for
Kulanda Town and Njai Town. There were 316 poten-
tial residential structures in Kulanda Town and 260 in
Njai Town.
An estimate of population density per household was
possible based on the estimated number of buildings
shown in remote imagery and data from the 2004
national census data. In 2004, Bo District had a popula-
tion of approximately 450,000, of which about 150,000
resided in the urban center of Bo [21,22]. The average
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Table 1 Sections (neighborhoods) of Bo, sectional areas, and number of Mercy Hospital Laboratory patients
Location Area (km2) Visits Location Area (km2) Visits
All 30.10 797 New Site North 0.32 4
Kulanda Town * 0.30 274 Fargoya 0.54 3
Samami† 0.59 55 CKC area† 0.46 3
Bo No. 2† 0.48 55 Hangha 0.09 3
Bo No. 2 Extension 1.08 Yemoh Town 0.40 3
Njai Town† 0.21 47 Kebbie Town 0.28 3
Kissi Town† 0.20 36 Salina 0.47 2
Sewa Raod area 0.64 33 Fulawahun 0.08 2
Njaboima 1.75 31 Kindia Town 0.15 2
New London 0.60 28 Clerks’ Quarter† 0.08 2
Manjama 0.74 23 Komende 0.20 1
Manjama Extension 0.70 Dodo 0.05 1
Kennedy 0.64 19 Goma 0.27 1
New York 1.51 17 Bo Commercial† 0.18 1
Simbo Town† 0.14 16 Bo Airfield 0.43 1
Nduvuibu† 0.49 15 Tengbewabu 0.68 1
Messima 0.49 15 Old Police Barracks 0.23 1
Bo Central 0.07 13 Toubu 0.02 1
Korwama 0.30 11 New Site South 0.69 1
Kandeh Town 0.54 9 Bunumbu 0.18 1
Kandeh Town Extension 1.32 Brima Town 0.19 0
Kortubguma 0.52 9 VO Vaama 0.15 0
Dorba Ground 0.63 9 Kortumahun 0.35 0
Lewabu 0.48 8 Eastern Police Barracks 0.23 0
Moriba Town 0.25 6 Kpetewoma 0.20 0
Torkpoi Town 0.55 6 Nikibu 0.10 0
Bumpewulo 0.15 6 Kpandobu 0.03 0
Gbondo Town 1 0.72 5 Mulema Town 0.43 0
Gbondo Town 2 0.31 Roma 0.04 0
Reservation 2.33 5 Borbor Kombor 1.22 0
Goba Town† 0.21 5 Moibawo Farm 0.50 0
Gbanja Town 0.64 Chinese Farm 0.10 0
Gbonda Town† 0.12 4 Clock tower area 0.11 0
Joe Town 1 0.12 Mendewa 0.47 0
Joe Town 2† 0.42
Note: The second column shows the areas of each section of Bo; the third column shows the number of people from each section who were tested at the Mercy
Hospital Laboratory. (* denotes the section in which Mercy Hospital is located and † denotes sections with at least half their area within 1 km of Mercy Hospital.
Some adjacent sections are grouped together for visit analysis.)
number of residents per household ranged from 6.0 to
7.0 within the various census tracts within Bo [22]. If
each building is home to one household and each has
an intermediate household density of about 6.5 resi-
dents, then about 3700 individuals (2000 in Kulanda
Town and 1700 in Njai Town) were estimated to reside
in the two sections. However, this estimate was sus-
pected to be inaccurate both because it is difficult to
distinguish rooftops of residences from rooftops
buildings used for other purposes and because of
expected population growth between 2004 and 2010.
To obtain a better estimate of the current population
density within houses in Bo, we conducted a census of
Kulanda Town and Njai Town. As an initial step, the
number of actual residential structures was determined
to be 197 in Kulanda Town and 130 in Njai Town,
which was less than the number of building rooftops
identified from the remote imaging. The average
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Figure 2 Building structures in Kulanda Town and Njai Town. Results of the Kulanda Town and Njai Town rooftop extraction (dark blue)
with roads (red lines), section boundaries (black lines), and farmland (green areas). The dark grey boxes are the results of digitization of building
rooftops from images.
household population size was 6.1 people. This was
within the range of estimates from the 2004 national
census. However, we found that many houses that
would typically be classified as modest single-family resi-
dences were home to multiple semi-independent house-
holds (often composed of relatives who maintain
separate sleeping and cooking areas). The 327 houses
were home to 1027 households (637 in Kulanda Town
and 390 in Njai Town) with a total of 6245 residents,
for an average of 19.0 people per building (19.7 for
Kulanda Town and 17.9 for Njai Town). The total num-
ber of residents in Kulanda Town is then not the 2000
estimated from the map and 2004 census data, but
3894, a striking difference.
Based on the new population estimate for the section,
we estimate that 7.0% of Kulanda Town residents were
tested at the Mercy Hospital Laboratory during the
study period. Having a more accurate denominator for
the rate significantly reduces the estimate of the propor-
tion of residents of Kulanda Town who visited the
laboratory for testing during the study period from
13.7% to 7.0%. For Njai Town, the total resident popula-
tion was 2351, and only 2.4% of Njai Town residents
were tested at Mercy Hospital Laboratory during the
study period. This more accurate number is essential for
health services planning. In this example, the lower pro-
portion of the population being served by Mercy Hospi-
tal may provide evidence that the local population is
underserved by health service providers. Additional sur-
vey work in other sections of Bo with varying numbers
of residential structures and expected population densi-
ties will be required to better understand how to infer
population size and density from remote sensing, and
how to better define hospital catchment areas and utili-
zation of health care resources.
Conclusions
Participatory methods made possible the creation of
detailed, accurate maps for Bo, Sierra Leone, and deter-
mined the population of two sections despite a very lim-
ited budget for the project. The importance of maps for
public policy and other applications was highlighted by
two simple demonstrations, the identification of a catch-
ment area for one hospital and the use of the new sec-
tional map to identify houses eligible to participate in a
community census. This analysis showed that the major-
ity of the hospital’s patients reside within the area adja-
cent to the hospital and that the number of patients
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from a section decreases as the distance from the hospi-
tal increases. Some sections outside this area had
non-negligible numbers of visits but determining the
significance of this is not possible at this time since this
study showed that population counts from the 2004
census were not accurate estimates of the current popu-
lation. Those sections might have a high population
density, which would mean that the rate of attendance
at Mercy Hospital was not elevated compared to other
sections equally distant from the hospital.
It is interesting to note that although we determined
that the average population per household was similar
to that found in the 2004 census, the average house was
home to 3.1 households. Multiple households within
one house could be caused by several factors alone or in
combination: unavailability of housing in a rapidly urba-
nizing area, lack of affordability of housing due to
demand that raises prices, or cultural factors that value
living in close proximity to relatives and extending hos-
pitality to family members in need. Further interaction
with community informants could provide insight into
the mechanisms at work in Bo.
The methods developed in this paper build on pre-
vious PGIS and PPGIS papers [15-20] and serve as a
model for the involvement of communities in the gen-
eration of municipal maps and their application to social
and health concerns. One of the key observations during
field work is that community involvement is often the
only way to acquire accurate information about bound-
aries in areas where residential areas often begin as
informal settlements. This study demonstrated effective
participatory methods to determine the population of a
section and to identify geographic information about the
section. Together these will improve the application of
spatial epidemiology in low- and middle-income coun-
tries by allowing for the calculation of more accurate
rates. This paper demonstrates that a participatory map-
ping approach can mitigate some of the challenges
inherent to mapping in low-resource areas and can be a
first step toward implementing GIS for public applica-
tions, such as disease surveillance, the determination of
the preferred location of public services, and the man-
agement of future outbreaks.
Methods
Sectional mapping
As a first step toward generating a sectional map, we
interviewed knowledgeable long-term local residents
and, in consultation with municipal authorities in the
Bo City Council and local officials of the MLCPE,
sketched out the boundaries of each section. We then
georeferenced these boundaries using GPSMAP 60Cx
Hiking GPS receivers (Garmin International, Inc.,
Olathe, KS), to the extent that it was possible to do so
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given that some of the terrain involved physical obsta-
cles such as swamps and that in some places trespassing
laws did not allow us to access boundary areas. Main
roads were also tracked. The raw GPS tracks were
loaded into DNR Garmin software (MapSource-trip and
waypoint manager), converted to KML format for inter-
mediate processing. The KML file structure allows coor-
dinates to be adjusted using a text editor and the results
of the updates could be confirmed by viewing in Google
Earth before final import into ArcMap.
We asked local elders who had resided within the sec-
tion for at least 15 years to review the map and check
our preliminary map boundaries for accuracy. We also
received input from Bo city officials. Based on the feed-
back of both the elders and the city officials, we made
further adjustments to the KML description of each sec-
tion, including adjustments to coordinates so that all
locations within the town fell into one defined section.
A final review of the boundaries was then made by all
participating parties. After our local experts had
approved the boundaries, we used DNR Garmin soft-
ware (longitude and latitude coordinates having UTM
WGS84 Zone 29 reference data) to convert the section
boundaries from the KML format into a shapefile. This
shapefile was imported into ArcGIS. In ArcCatalog, a
new polygon shapefile was created and dragged into the
ArcMap content table. ArcMap was then used to create
a digital polygon of the Bo municipal sections by tracing
the boundary lines using the editor toolbar.
Catchment area study
Patient records fromMercy Hospital and its Laboratory, a
private medical facility located on the north side of Bo in
the Kulanda Town section (Figure 1), were used for the
assessment of catchment area. Mercy Hospital Laboratory
maintains electronic records of all patients referred to it
for testing. The records contain patient demographic data,
such as age, sex, and home address (often recorded as only
the section of residence when a street address is not avail-
able), as well as the results of the various tests that were
conducted at the laboratory. These records were queried
for all Mercy Hospital patients who were referred for test-
ing to Mercy Hospital Laboratory between February 2009
andMarch 2010. When laboratory information about resi-
dential location was missing, it was filled in from the
patient’s outpatient records when available. To protect
patient privacy, no personally identifiable information,
such as patient names or addresses, was included in our
search records, and our analysis in this paper is aggregated
at the section level.
Population estimation
The first task required to make an estimation of popula-
tion in a section is to determine the number of houses
Leski et al. Health Research Policy and Systems 2012, 10:22
http://www.health-policy-systems.com/content/10/1/22
Page 195 of
10
An uman et al. International Journal of Health Geographics 2010, 9:56
http://www.ij-healthgeographics.com/content/9/1/56
in the section. Because software that automatically
marks houses by identifying rooftops from remote ima-
gery is, at present, quite expensive, we were unable to
use this specialty software and had to digitize the loca-
tion of homes manually. In ArcMap a new empty win-
dow was opened and given WGS 84 UTM Zone 29
reference data. Using the ‘Add data’ tool, a georefer-
enced satellite image was added to provide a back-
ground image for digitization. ArcCatalog was then
opened and new shapefiles were created to represent
buildings and streets/roads and given WGS84 UTM
Zone 29 reference data. These shapefiles were then
added to the ArcMap. The database table of the polygon
shapefile representing buildings was opened and a new
field added to contain the map section data within
which a building was located. Using the ArcEditor tool,
the shapefile of interest was selected and the Sketch
Tool was used to create a footprint of a particular fea-
ture, using a line to represent streets and a polygon to
represent buildings.
Once the buildings in each section were identified, an
initial physical pass was made through the streets to
note which buildings could clearly be identified as being
used for purposes other than a residence, such as barns,
sheds, and businesses. A notation was added to the map
to indicate viable residences and these were assigned
unique identifiers.
Every identified residence was visited and an adult resi-
dent asked to identify how many people lived in the
household. (The household survey was approved by the
research ethics committees of Njala University, Bo; George
Mason University, Fairfax, Virginia, USA; and the U.S.
Naval Research Laboratory, Washington, DC, USA.) The
initial visits revealed that residents would usually report
that multiple “households” were present within their
homes. For all buildings visited, the query included the
number of households living in the building and the num-
ber of individuals who were members of each household.
Two households in Kulanda Town (99.7% participation
rate) and five households in Njai Town (98.7% participa-
tion rate) declined to participate. The average household
population was determined for each section from the
households that participated. The estimated population
was calculated as this averagemultiplied by the total num-
ber of households within the section. In a similar manner
the total number of individuals per building was calculated
only from buildings in which all households participated.
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